

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 3297656 T3**

-
- (51) Int.Cl.: **A 61 K 38/37 (2006.01)** **A 61 P 7/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2020-03-09**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2020-01-08**
- (86) Europæisk ansøgning nr.: **16723776.7**
- (86) Europæisk indleveringsdag: **2016-05-20**
- (87) Den europæiske ansøgnings publiceringsdag: **2018-03-28**
- (86) International ansøgning nr.: **EP2016061443**
- (87) Internationalt publikationsnr.: **WO2016188907**
- (30) Prioritet: **2015-05-22 EP 15168930** **2016-03-31 EP 16163239**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **CSL Behring Lengnau AG, Industriestrasse 11, 2543 Lengnau BE, Schweiz**
- (72) Opfinder: **Schulte, Stefan, Bauerbacher Strasse 46, 35043 Marburg, Tyskland**
Metzner, Hubert, Im Boden 6, 35041 Marburg, Tyskland
PESTEL, Sabine, Stuempelstal 19, 35041 Marburg, Tyskland
Weimer, Thomas, Richard-Wagner-Strasse 8, 35075 Gladenbach, Tyskland
- (74) Fuldmægtig i Danmark: **Patrade A/S, Ceresbyen 75, 8000 Århus C, Danmark**
- (54) Benævnelse: **Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili**
- (56) Fremdragne publikationer:
WO-A1-2008/151817
WO-A1-2013/083858
WO-A1-2013/106787
WO-A1-2015/106052
WO-A2-2011/060242
WO-A2-2012/173873
WO-A2-2014/011819
A. YEE ET AL: "A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice", BLOOD, vol. 124, no. 3, 21 May 2014 (2014-05-21), pages 445-452, XP055225855, US ISSN: 0006-4971, DOI: 10.1182/blood-2013-11-540534

DESCRIPTION

FIELD OF THE INVENTION

[0001] The present invention relates to products and methods for improving treatment of blood coagulation disorders.

BACKGROUND OF THE INVENTION

[0002] There are various bleeding disorders caused by deficiencies of blood coagulation factors. The most common disorders are hemophilia A and B, resulting from deficiencies of blood coagulation Factor VIII (FVIII) and IX, respectively. Another known bleeding disorder is von Willebrand's disease (VWD).

[0003] In plasma FVIII exists mostly as a noncovalent complex with von Willebrand Factor (VWF), and its coagulant function is to accelerate Factor IXa dependent conversion of Factor X to Xa.

[0004] Classic hemophilia or hemophilia A is an inherited bleeding disorder. It results from a chromosome X-linked deficiency of blood coagulation FVIII, and affects almost exclusively males with an incidence of between one and two individuals per 10,000. The X-chromosome defect is transmitted by female carriers who are not themselves hemophiliacs. The clinical manifestation of hemophilia A is an increased bleeding tendency.

[0005] In severe hemophilia A patients undergoing prophylactic treatment FVIII has to be administered intravenously (i.v.) about 3 times per week due to the short plasma half-life of FVIII of about 12 to 14 hours. Each i.v. administration is cumbersome, associated with pain and entails the risk of an infection especially as this is mostly done at home by the patients themselves or by the parents of children having been diagnosed for hemophilia A.

[0006] It would thus be highly desirable to increase the half-life of FVIII so that pharmaceutical compositions containing such FVIII would have to be administered less frequently.

[0007] Several attempts have been made to prolong the half-life of non-activated FVIII either by reducing its interaction with cellular receptors (WO 03/093313 A2, WO 02/060951 A2), by covalently attaching polymers to FVIII (WO 94/15625, WO 97/11957 and US 4970300), by encapsulation of FVIII (WO 99/55306), by introduction of novel metal binding sites (WO 97/03193), by covalently attaching the A2 domain to the A3 domain either by peptidic (WO 97/40145 and WO 03/087355) or disulfide linkage (WO 02/103024A2) or by covalently attaching the A1 domain to the A2 domain (WO2006/108590).

[0008] Another approach to enhance the functional half-life of FVIII or VWF is by PEGylation of FVIII (WO 2007/126808, WO 2006/053299, WO 2004/075923) or by PEGylation of VWF (WO 2006/071801). The increased half-life of pegylated VWF would indirectly also enhance the half-life of FVIII present in plasma. Also fusion proteins of FVIII have been described (WO 2004/101740, WO2008/077616 and WO 2009/156137).

[0009] VWF, which is missing, functionally defect or only available in reduced quantity in different forms of von Willebrand disease (VWD), is a multimeric adhesive glycoprotein present in the plasma of mammals, which has multiple physiological functions. During primary hemostasis VWF acts as a mediator between specific receptors on the platelet surface and components of the extracellular matrix such as collagen. Moreover, VWF serves as a carrier and stabilizing protein for procoagulant FVIII. VWF is synthesized in endothelial cells and megakaryocytes as a 2813 amino acid precursor molecule. The amino acid sequence and the cDNA sequence of wild-type VWF are disclosed in Collins et al. 1987, Proc. Natl. Acad. Sci. USA 84:4393-4397. The precursor polypeptide, pre-pro-VWF, consists of an N-terminal 22-residue signal peptide, followed by a 741-residue pro-peptide and the 2050-residue polypeptide found in mature plasma VWF (Fischer et al., FEBS Lett. 351: 345-348, 1994). After cleavage of the signal peptide in the endoplasmatic reticulum a C-terminal disulfide bridge is formed between two monomers of VWF. During further transport through the secretory pathway 12 N-linked and 10 O-linked carbohydrate side chains are added. More important, VWF dimers are multimerized via N-terminal disulfide bridges and the propeptide of 741 amino acids length is cleaved off by the enzyme PACE/furin in the late Golgi apparatus.

[0010] Once secreted into plasma the protease ADAMTS13 can cleave high-molecular weight VWF multimers within the A1 domain of VWF. Plasma VWF therefore consists of a whole range of multimers ranging from single dimers of 500 kDa to multimers consisting of up to more than 20 dimers of a molecular weight of over 10,000 kDa. The VWF-HMWM hereby having the strongest hemostatic activity, which can be measured in ristocetin cofactor activity (VWF:RCo). The higher the ratio of VWF:RCo/VWF antigen, the higher the relative amount of high molecular weight multimers.

[0011] In plasma FVIII binds with high affinity to VWF, which protects it from premature elimination and thus, plays in addition to its role in primary hemostasis a crucial role to stabilize FVIII, regulate plasma levels of FVIII and as a consequence is also a central factor to control secondary hemostasis. The half-life of non-activated FVIII bound to VWF is about 12 to 14 hours in plasma. In von Willebrand disease type 3, where no or almost no VWF is present, the half-life of FVIII is only about 2 to 6 hours, leading to symptoms of mild to moderate hemophilia A in such patients due to decreased concentrations of FVIII. The stabilizing effect of VWF on FVIII has also been used to aid recombinant expression of FVIII in CHO cells (Kaufman et al. 1989, Mol Cell Biol 9:1233-1242).

[0012] VWF-derived polypeptides, in particular VWF fragments, have been described to stabilize FVIII in vitro and in vivo. WO 2013/106787 A1 is directed at chimeric proteins comprising certain VWF fragments and a FVIII protein. Those chimeric hetero-dimers of FVIII

and VWF-fragment do have a fixed molar ratio of VWF to FVIII of 1:1. WO 2014/198699 A2 and WO 2013/083858 A2 describe VWF fragments and their use in the treatment of hemophilia. It was found that bioavailability of FVIII may be significantly improved upon extravascular co-administration with similar molar amounts of VWF fragments. High molar excess of VWF over FVIII was said to be not desirable, and in experiments with VWF fragments co-administered s.c. with FVIII it was found that the VWF dose was not critical for FVIII bioavailability. Thus molar ratios of VWF fragments over FVIII were limited to maximally 50:1 and preferred ranges to maximally 1.5:1. WO 2011/060242 A2 discloses fusion polypeptides comprising certain VWF fragments and an antibody Fc region proposing specific molar ratios of VWF fragment over FVIII of up to 10:1. WO2013/093760 A2 describes a method for preparing a protein, comprising co-expressing FVIII or VWF polypeptides, including truncated forms of VWF, with a recombinant α -2,3-sialyltransferase. Yee et al. (2014) Blood 124(3):445-452 found that a VWF fragment containing the D'D3 domains is sufficient to stabilize Factor VIII in VWF-deficient mice. However, although a VWF D'D3-Fc fusion protein exhibited markedly prolonged survival when transfused into FVIII-deficient mice, the VWF D'D3-Fc fusion protein did not prolong the survival of co-transfused FVIII. The prior art is silent as to the benefit of exceeding certain ratios of administered VWF fragments over endogenous VWF for the purpose of prolonging the *in vivo* half-life of co-administered FVIII.

[0013] In WO 2008/151817 A1 it is shown that full length VWF can be taken up into the blood stream when administered extravascularly without any stabilizing covalent modifications and that VWF can be used to enhance the uptake of FVIII when co-administered with FVIII non-intravenously. The VWF is applied without any half-life extending modification. Any modification of VWF by use of a half-life extending moiety is neither shown nor suggested. By contrast, WO 2008/151817 A1 explicitly excludes any conjugation of VWF.

[0014] There is an ongoing need for methods increasing the half-life of FVIII and FVIII products with reduced administration frequency.

SUMMARY OF THE INVENTION

[0015] It has been found by the inventors that the *in vivo* half-life of Factor VIII can be prolonged by co-administration of a high molar excess of a truncated VWF polypeptide (polypeptide of the invention). The truncated VWF comprises a half-life extending moiety. The high molar excess is relative to the concentration of co-administered Factor VIII and, optionally, in addition relative to the concentration of endogenous VWF present in the treated subject. Without wishing to be bound to any theory, it is believed that it is important to achieve a high surplus of the administered half-life-extended truncated VWF to minimize the binding of the co-administered FVIII to the endogenous VWF which has a larger molecular structure probably leading to an increased catabolism as compared to the truncated VWF. This technical effect is achieved when the truncated VWF is not only administered in a ratio above 50 over a co-administered Factor VIII but also comprises a half-life extending moiety.

[0016] The present invention therefore relates to the following embodiments [1] to [70]:

1. [1] A polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment of a blood coagulation disorder, said treatment comprising administering to a subject having endogenous VWF the polypeptide and a Factor VIII (FVIII), wherein the polypeptide is capable of binding to said FVIII, and wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 50, wherein the polypeptide comprises a half-life extending moiety.
2. [2] The polypeptide for use according to item [1], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 100.
3. [3] The polypeptide for use according to item [1], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is at least 200.
4. [4] The polypeptide for use according to item [1], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is at least 300.
5. [5] The polypeptide for use according to item [1], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is at least 400.
6. [6] The polypeptide for use according to item [1], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is at least 500.
7. [7] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 0.5.
8. [8] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 1.
9. [9] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 2.
10. [10] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 4.
11. [11] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 5.
12. [12] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 7.
13. [13] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 10.
14. [14] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 25.
15. [15] The polypeptide for use according to any one of items [1] to [6], wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 50.
16. [16] A polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment of a blood coagulation disorder as defined in item [1], said treatment comprising administering to a subject having endogenous VWF the polypeptide and a Factor VIII (FVIII), wherein the polypeptide is capable of binding to said FVIII, and wherein the molar ratio of the polypeptide administered to the endogenous VWF is greater than 0.5.
17. [17] The polypeptide for use according to item [16], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 10.

18. [18] The polypeptide for use according to item [16], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 20.
19. [19] The polypeptide for use according to item [16], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 40.
20. [20] The polypeptide for use according to item [16], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 50.
21. [21] The polypeptide for use according to item [16], wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 100.
22. [22] The polypeptide for use according to any one of the preceding items, which binds to the FVIII with an affinity characterized by a dissociation constant K_D of less than 1 nM.
23. [23] The polypeptide for use according to item [22], wherein the K_D ranges from 1 pM to 500 pM.
24. [24] The polypeptide for use according to item [22], wherein the K_D ranges from 10 pM to 200 pM.
25. [25] The polypeptide for use according to item [22], wherein the K_D ranges from 60 pM to 100 pM.
26. [26] The polypeptide for use according to any one of the preceding items, wherein the polypeptide is administered intravenously.
27. [27] The polypeptide for use according to any one of items [1] to [25], wherein the polypeptide is administered subcutaneously.
28. [28] The polypeptide for use according to any one of items [1] to [25], wherein the polypeptide is administered intramuscularly.
29. [29] The polypeptide for use according to any one of the preceding items, wherein the truncated VWF comprises (a) amino acids 776 to 805 of SEQ ID NO:4 or (b) an amino acid sequence having a sequence identity of at least 90% to amino acids 776 to 805 of SEQ ID NO:4.
30. [30] The polypeptide for use according to any one of the preceding items, wherein the truncated VWF comprises (a) amino acids 766 to 864 of SEQ ID NO:4 or (b) an amino acid sequence having a sequence identity of at least 90% to amino acids 766 to 864 of SEQ ID NO:4.
31. [31] The polypeptide for use according to any one of the preceding items, wherein the truncated VWF comprises amino acids 764 to 1242 of SEQ ID NO:4.
32. [32] The polypeptide for use according to any one of the preceding items, wherein the truncated VWF consists of (a) amino acids 764 to 1242 of SEQ ID NO:4, (b) an amino acid sequence having a sequence identity of at least 90% to amino acids 764 to 1242 of SEQ ID NO:4, or (c) a fragment of (a) or (b).
33. [33] The polypeptide for use according to any one of the preceding items, wherein the truncated VWF lacks amino acids 1243 to 2813 of SEQ ID NO:4.
34. [34] The polypeptide for use according to any of the preceding items comprises a half-life extending moiety.
35. [35] The polypeptide for use according to item [34], wherein said half-life extending moiety is a heterologous amino acid sequence fused to the truncated VWF.
36. [36] The polypeptide for use according to item [35], wherein said heterologous amino

acid sequence comprises or consists of a polypeptide selected from the group consisting of immunoglobulin constant regions and portions thereof, e.g. the Fc fragment, transferrin and fragments thereof, the C-terminal peptide of human chorionic gonadotropin, solvated random chains with large hydrodynamic volume known as XTEN, homo-amino acid repeats (HAP), proline-alanine-serine repeats (PAS), albumin, afamin, alpha-fetoprotein, Vitamin D binding protein, polypeptides capable of binding under physiological conditions to albumin or immunoglobulin constant regions, and combinations thereof.

37. [37] The polypeptide for use according to any one of items [34], wherein said half-life-extending moiety is conjugated to the polypeptide.
38. [38] The polypeptide for use according to item [37], wherein said half-life-extending moiety is selected from the group consisting of hydroxyethyl starch (HES), polyethylene glycol (PEG), polysialic acids (PSAs), elastin-like polypeptides, heparosan polymers, hyaluronic acid and albumin binding ligands, e.g. fatty acid chains, and combinations thereof.
39. [39] The polypeptide for use according to any one of the preceding items, wherein the polypeptide is a glycoprotein comprising N-glycans, and wherein at least 75 % of said N-glycans comprise, on average, at least one sialic acid moiety.
40. [40] The polypeptide for use according to item [39], wherein at least 85 % of said N-glycans comprise, on average, at least one sialic acid moiety.
41. [41] The polypeptide for use according to items [39], wherein at least 95 % of said N-glycans comprise, on average, at least one sialic acid moiety.
42. [42] The polypeptide for use according to any one of the preceding items wherein the polypeptide comprises N-glycans, wherein less than 35%, preferably less than 34%, preferably less than 33%, preferably less than 32%, preferably less than 31%, preferably less than 30%, preferably less than 29%, preferably less than 28%, preferably less than 27% preferably less than 26%, preferably less than 25%, preferably less than 24%, preferably less than 23%, preferably less than 22%, preferably less than 21%, preferably less than 20%, preferably less than 19%, preferably less than 18%, preferably less than 17%, preferably less than 16%, preferably less than 15%, preferably less than 14%, preferably less than 13%, preferably less than 12%, preferably less than 11%, preferably less than 10%, preferably less than 9%, preferably less than 8%, preferably less than 7%, preferably less than 6% and preferably less than 5% of said N-glycans comprise, on average, two or more terminal and non-sialylated galactose residues.
43. [43] The polypeptide for use according to any one of the preceding items wherein the polypeptide comprises N-glycans, wherein less than 6%, preferably less than 5%, preferably less than 4%, preferably less than 3%, preferably less than 2%, and preferably less than 1% of said N-glycans comprise, on average, three or more terminal and non-sialylated galactose residues.
44. [44] The polypeptide for use according to any one of the preceding items, wherein the polypeptide is a dimer.
45. [45] The polypeptide for use according to item [44], wherein the two monomers forming the dimer are covalently linked to each other via one or more disulfide bridges formed by cysteine residues within the truncated VWF.

46. [46] The polypeptide for use according to item [45], wherein the cysteine residues forming the one or more disulfide bridges is/are selected from the group consisting of Cys-1099, Cys-1142, Cys-1222, Cys-1225, Cys-1227 and combinations thereof, wherein the amino acid numbering refers to SEQ ID NO:4.
47. [47] The polypeptide for use according to any one of items [44] to [46], wherein the affinity of said dimer to the FVIII is greater than the affinity of a monomeric polypeptide to said FVIII, said monomeric polypeptide having the same amino acid sequence as a monomeric subunit of the dimeric polypeptide.
48. [48] The polypeptide for use according to any one of the preceding items, wherein the mean residence time (MRT) and/or the terminal half-life of the FVIII is increased by the co-administration of the polypeptide as compared to a reference treatment, wherein said reference treatment is identical to said treatment, except that the polypeptide and the FVIII are administered in equimolar amounts in said reference treatment.
49. [49] The polypeptide for use according to item [48], wherein said increase in MRT and/or terminal half-life is at least 50%.
50. [50] The polypeptide for use according to any one of the preceding items, wherein the mean residence time (MRT) and/or terminal half-life of the FVIII is increased by the co-administration of the polypeptide as compared to a reference treatment with the FVIII alone.
51. [51] The polypeptide for use according to item [50], wherein said increase in MRT and/or terminal half-life is at least 50%.
52. [52] The polypeptide for use according to item [50], wherein said increase in MRT and/or terminal half-life is at least 100%.
53. [53] The polypeptide for use according to any one of the preceding items, wherein the clearance of the FVIII is decreased by the co-administration of the polypeptide as compared to a reference treatment with the FVIII alone.
54. [54] The polypeptide for use according to any one of the preceding items, wherein the clearance of the FVIII is decreased by the co-administration of the polypeptide as compared to a reference treatment, wherein said reference treatment is identical to said treatment, except that the polypeptide and the FVIII are administered in equimolar amounts in said reference treatment.
55. [55] The polypeptide for use according to item [53] or [54], wherein said decrease is at least 25%.
56. [56] The polypeptide for use according to item [53] or [54], wherein said decrease is at least 50%.
57. [57] The polypeptide for use according to item [53] or [54], wherein said decrease is at least 100%.
58. [58] The polypeptide for use according to any one of the preceding items, wherein the in vivo recovery of the FVIII is increased by the co-administration of the polypeptide as compared to a reference treatment with the FVIII alone.
59. [59] The polypeptide for use according to any one of the preceding items, wherein the frequency of administration of the FVIII is reduced as compared to a treatment with the FVIII alone.
60. [60] The polypeptide for use according to any one of the preceding items, wherein the

MRT and/or plasma half-life of the polypeptide is greater than that of a reference polypeptide, wherein said reference polypeptide is endogenous VWF.

61. [61] The polypeptide for use according to any one of the preceding items, wherein the MRT and/or plasma half-life of the polypeptide is greater than that of a reference polypeptide that is identical to said polypeptide except that it lacks the half-life extending moiety.
62. [62] The polypeptide for use according to item [60] or [61], wherein the MRT and/or plasma half-life of the polypeptide is at least 25 % greater than that of the reference polypeptide.
63. [63] The polypeptide for use according to item [60] or [61], wherein the MRT and/or plasma half-life of the polypeptide is at least 50 % greater than that of the reference polypeptide.
64. [64] The polypeptide for use according to item [60] or [61], wherein the MRT and/or plasma half-life of the polypeptide is at least 75 % greater than that of the reference polypeptide.
65. [65] The polypeptide for use according to item [60] or [61], wherein the MRT and/or plasma half-life of the polypeptide is at least 100 % greater than that of the reference polypeptide.
66. [66] The polypeptide for use according to any one of the preceding items, wherein the subject is a human.
67. [67] A pharmaceutical composition comprising (i) a FVIII and (ii) a polypeptide as defined in any one of items [1] to [66], wherein the molar ratio of the polypeptide to the FVIII in the composition is greater than 50.
68. [68] A pharmaceutical composition comprising (i) a FVIII and (ii) a polypeptide as defined in any one of the items [1] to [66] for use in the treatment of a blood coagulation disorder, said treatment comprising administering to a subject having endogenous VWF the polypeptide and the FVIII, wherein in addition the molar ratio of the polypeptide administered to the endogenous VWF is greater than 0.5.
69. [69] A pharmaceutical kit comprising (i) a FVIII and (ii) a polypeptide as defined in any one of items [1] to [66] for simultaneous, separate or sequential use in the treatment of a blood coagulation disorder, wherein the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 50 and the polypeptide comprises a half-life extending moiety.
70. [70] The use of a polypeptide as defined in any one of items [1] to [66] for improving the plasma half-life of Factor VIII, and/or for reducing the frequency of administration of Factor VIII.

DESCRIPTION OF THE DRAWINGS

[0017]

Fig. 1: Mean residence time, terminal half-life and clearance (mean) of D'D3-FP quantified by determining the albumin moiety in rats (Example 1).

Abbreviation: rVIII-SC: rVIII-SingleChain

Fig. 2: Mean residence time, terminal half-life and clearance (mean) of rVIII-SingleChain quantified by determining FVIII antigen in rats (Example 1).

Abbreviation: rVIII-SC: rVIII-SingleChain

Fig. 3: Mean residence time, terminal half-life and clearance (mean) of D'D3-FP quantified by determining the albumin moiety in rats (Example 2).

Abbreviation: rVIII-SC: rVIII-SingleChain

Fig. 4: Mean residence time, terminal half-life and clearance (mean) of rVIII-SingleChain quantified by determining FVIII antigen in rat (Example 2).

Abbreviation: rVIII-SC: rVIII-SingleChain

Fig. 5: Mean residence time, terminal half-life and clearance (individual animal data and mean) of D'D3-FP quantified by determining the albumin moiety in rabbits (Example 3).

Abbreviation: rVIII-SC: rVIII-SingleChain

Fig. 6: Mean residence time, terminal half-life and clearance (individual animal data and mean) of rVIII-SingleChain quantified by determining FVIII antigen in rabbits (Example 3).

Abbreviation: rVIII-SC: rVIII-SingleChain

Fig. 7: Mean residence time, terminal half-life and clearance (individual animal data and mean) of different recombinant FVIII products quantified by determining FVIII antigen in rabbits (Example 4).

Abbreviation: rVIII-SC: rVIII-SingleChain

Fig. 8: Changes of mean residence time, terminal half-life and clearance of FVIII in dependence of the molar ratio of D'D3-FP over rVIII-SingleChain (rVIII-SC given alone is defined as 1-fold change) in rats and rabbits.

Abbreviation: rVIII-SC: rVIII-SingleChain

Fig. 9: Changes of mean residence time, terminal half-life and clearance of FVIII in dependence of the molar ratio of D'D3-FP over endogenous VWF (rVIII-SC given alone is defined as 1-fold change) in rats and rabbits.

DETAILED DESCRIPTION

[0018] In a first aspect, the present invention relates to a polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment of a blood coagulation disorder, said treatment comprising administering to a subject having endogenous VWF the polypeptide and a Factor VIII (FVIII), wherein the polypeptide is capable of binding to said FVIII, and wherein

the molar ratio of the polypeptide to be administered to the FVIII to be administered is greater than 50, wherein the polypeptide comprises a half-life extending moiety.

[0019] In a second aspect, the present invention pertains to a polypeptide comprising a polypeptide comprising a truncated von Willebrand Factor (VWF), for use in the treatment of a blood coagulation disorder as defined under the first aspect, said treatment comprising administering to a subject having endogenous VWF the polypeptide and a Factor VIII (FVIII), wherein the polypeptide is capable of binding to said FVIII, and wherein in addition to the first aspect the molar ratio of the polypeptide administered to the endogenous VWF is greater than 0.5. The the polypeptide comprises a half-life extending moiety.

[0020] The polypeptide comprising a truncated von Willebrand Factor (VWF) will be referred to herein as "polypeptide of the invention". The polypeptide of the invention comprises a half-life extending moiety.

Ratios

[0021] As described in more detail below, the polypeptide of the invention may be a monomer, a dimer, or a mixture thereof. Any molar ratios according to the invention refer to a ratio of the molar concentration of the monomeric subunit of the polypeptide of the invention, whether actually present as monomer or dimer. Ratios are formed either over the molar concentration of the co-administered FVIII or over the molar concentration of the endogenous VWF monomeric subunits. Any ratios of polypeptide of the invention over FVIII in this application refer to the amount of polypeptide of the invention to be administered (in mole) divided by the amount of FVIII to be administered (in mole), unless indicated otherwise. The endogenous VWF is the VWF which is naturally present in the plasma of the animal or human being to be dosed with the polypeptide of the invention and with the co-administered FVIII. It usually consists of a range of different oligomers of approximately 2 to 40 monomeric subunits of VWF. Unless indicated otherwise, any ratios of polypeptide of the invention over endogenous VWF in this application refer to the molar plasma concentration of polypeptide of the invention immediately after administration of the polypeptide of the invention, divided by the molar plasma concentration of endogenous VWF monomeric subunits (endogeneous VWF) The molar plasma concentration of the polypeptide of the invention immediately after administration of the polypeptide of the invention is calculated assuming a dilution of the polypeptide of the invention administered directly after administration in a plasma volume of 40 mL/kg. The amount of the polypeptide of the invention immediately after administration when administered intravenously is assumed for the purposes of the invention to be identical to the amount administered.

[0022] According to one aspect of the invention the molar ratio of the polypeptide of the invention to the endogenous VWF is greater than 0.5. The concentration of endogenous VWF in the plasma of the subject to be treated can be determined by an ELISA or and activity assay, e.g. as described in the Examples. Typically, the concentration measured will be given in U/mL.

This value can be converted into a molarity as described in the following.

[0023] Normal human plasma (NHP) contains VWF in a concentration of 1 U/mL or 100% by definition. This corresponds to a protein concentration of approximately 10µg/mL (Haberichter S.L. and Montgomery R.R., Structure and function of von Willebrand factor; in: Hemostasis and Thrombosis, eds. Marder, Aird, Bennett, Schulman and White, Lippincott Williams & Wilkins 2013, pp 197-207). Based on this VWF concentration in NHP and a molecular weight of the mature VWF monomer of approximately 267,500 Da including 18-19% of glycosylation a molar plasma concentration of the VWF monomer unit of approximately 37×10^{-9} Mol/L can be calculated for NHP.

[0024] For calculation of the molar concentrations of rat or rabbit VWF subunits in normal rat or rabbit plasma, respectively, a molecular weight of the monomeric subunit comparable to human VWF was used (267,500 Da) together with an assumed comparable specific activity (100 U/mg) and the measured endogenous VWF activities in rat or rabbit plasma (refer also to examples).

[0025] The concentration of VWF in the human population varies from about 60% to about 200% of VWF concentration in NHP. In certain embodiments of the invention the concentration of endogenous VWF is defined as the concentration in NHP. In other embodiments the concentration of endogenous VWF is determined in the subject to be treated, and the dose of the polypeptide is based on this individual value.

[0026] The molar ratio of the polypeptide of the invention administered to the endogenous VWF is preferably at least 2, or at least 3, or at least 4, or at least 5, or at least 6, or at least 7, or at least 8, or at least 9, or at least 10, more preferably at least 15, or at least 20, or at least 25, or at least 30, most preferably at least 40, or at least 50, or at least 75.

[0027] The molar ratio of the polypeptide of the invention to be administered to the endogenous VWF may range from 0.5 to 1,000, or from 1 to 500, or from 2 to 400, or from 3 to 300, or from 4 to 250, or from 5 to 200, or from 6 to 150, or from 7 to 140, or from 8 to 130, or from 9 to 120, or from 10 to 110. Preferably, the molar ratio of the polypeptide of the invention administered to endogenous VWF ranges from 3 to 100, or from 4 to 90, or from 5 to 80, or from 6 to 75, or from 10 to 60.

[0028] The molar ratio of the polypeptide of the invention to be administered to FVIII to be administered is at least 50, more preferably the ratio is greater than 50, or at least 75, at least 100, or greater than 100, or at least 200, most preferably at least 300, or at least 400, or at least 500, or at least 600, or at least 700, or at least 800, or at least 900, or at least 1,000, or at least 1,100, or at least 1,200, or at least 1,300, or at least 1,400, or at least 1,500, or at least 1,600, or at least 1,700, or at least 1,800, or at least 1,900, or at least 2,000, or at least 2,500, or at least 3,000 or at least 5,000, or at least 8,000 or up to 10,000.

[0029] Preferably, the molar ratio of the polypeptide of the invention to be administered to FVIII

to be administered ranges from 60 to 2,500, or from 110 to 2,000, or from 150 to 1,500, or from 200 to 1,000.

[0030] Table 1 summarizes various embodiments of the treatment in accordance with this invention. In a given embodiment, both requirements of column 2 and 3, respectively, must be fulfilled. The herein disclosed embodiments are in accordance with the invention insofar as they concern a molar ratio of the polypeptide to be administered to the FVIII to be administered greater than 50.

Table 1:

Embodiment #	Molar ratio polypeptide of the invention : endogenous VWF	Molar ratio polypeptide of the invention : FVIII administered
1	at least 1	at least 2
2	at least 1	at least 5
3	at least 1	at least 10
4	at least 1	at least 40
5	at least 1	at least 50
6	at least 1	at least 80
7	at least 1	at least 100
6	at least 1	at least 150
7	at least 1	at least 250
8	at least 1	at least 400
9	at least 1	at least 800
10	at least 1	at least 1,000
11	at least 3	at least 2
12	at least 3	at least 5
13	at least 3	at least 10
14	at least 3	at least 40
15	at least 3	at least 50
16	at least 3	at least 80
17	at least 3	at least 100
18	at least 3	at least 150
19	at least 3	at least 250
20	at least 3	at least 400
21	at least 3	at least 800
22	at least 3	at least 1,000
23	at least 5	at least 2
24	at least 5	at least 5
25	at least 5	at least 10

Embodiment #	Molar ratio polypeptide of the invention : endogenous VWF	Molar ratio polypeptide of the invention : FVIII administered
26	at least 5	at least 40
27	at least 5	at least 50
28	at least 5	at least 80
29	at least 5	at least 100
30	at least 5	at least 150
31	at least 5	at least 250
32	at least 5	at least 400
33	at least 5	at least 800
34	at least 5	at least 1,000
35	at least 10	at least 2
36	at least 10	at least 5
37	at least 10	at least 10
38	at least 10	at least 40
39	at least 10	at least 50
40	at least 10	at least 80
41	at least 10	at least 100
42	at least 10	at least 150
43	at least 10	at least 250
44	at least 10	at least 400
45	at least 10	at least 800
46	at least 10	at least 1,000
47	at least 20	at least 2
48	at least 20	at least 5
49	at least 20	at least 10
50	at least 20	at least 40
51	at least 20	at least 50
52	at least 20	at least 80
53	at least 20	at least 100
54	at least 20	at least 150
55	at least 20	at least 250
56	at least 20	at least 400
57	at least 20	at least 800
58	at least 20	at least 1,000
59	at least 50	at least 2

Embodiment #	Molar ratio polypeptide of the invention : endogenous VWF	Molar ratio polypeptide of the invention : FVIII administered
60	at least 50	at least 5
61	at least 50	at least 10
62	at least 50	at least 40
63	at least 50	at least 50
64	at least 50	at least 80
65	at least 50	at least 100
66	at least 50	at least 150
67	at least 50	at least 250
68	at least 50	at least 400
69	at least 50	at least 800
70	at least 50	at least 1,000
71	at least 50	at least 2,000
72	at least 50	at least 4,000

[0031] Embodiments 1 to 72 shown in Table 1 can be combined with any other embodiment and aspect of the invention described herein. Further details of the treatment in accordance with the invention are described further below.

The truncated VWF

[0032] The term "von Willebrand Factor" (VWF) as used herein includes naturally occurring (native) VWF, but also variants thereof retaining at least the FVIII binding activity of naturally occurring VWF, e.g. sequence variants where one or more residues have been inserted, deleted or substituted. The FVIII binding activity is determined by a FVIII-VWF binding assay as described in Example 6.

[0033] The preferred VWF in accordance with this invention is human VWF represented by the amino acid sequence shown in SEQ ID NO:4. The cDNA encoding SEQ ID NO:4 is shown in SEQ ID NO:3.

[0034] The gene encoding human native VWF is transcribed into a 9 kb mRNA which is translated into a pre-propolypeptide of 2813 amino acids with an estimated molecular weight of 310,000 Da. The pre-propolypeptide contains an N-terminal 22 amino acids signal peptide, followed by a 741 amino acid pro-polypeptide (amino acids 23-763 of SEQ ID NO:4) and the mature subunit (amino acids 764-2813 of SEQ ID NO:4). Cleavage of the 741 amino acids propolypeptide from the N-terminus results in mature VWF consisting of 2050 amino acids.

The amino acid sequence of the human native VWF pre-propolypeptide is shown in SEQ ID NO:4. Unless indicated otherwise, the amino acid numbering of VWF residues in this application refers to SEQ ID NO:4, even if the VWF molecule does not comprise all residues of SEQ ID NO:4.

[0035] The propolypeptide of native VWF comprises multiple domains. Different domain annotations can be found in the literature (see, e.g. Zhou et al. (2012) Blood 120(2): 449-458). The following domain annotation of native pre-propolypeptide of VWF is applied in this application:

D1-D2-D'-D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-CK

With reference to SEQ ID NO:4, the D' domain consists of amino acids 764-865; and the D3 domain consists of amino acids 866-1242.

[0036] The feature "truncated" means that the polypeptide does not comprise the entire amino acid sequence of mature VWF (amino acids 764-2813 of SEQ ID NO:4). Typically, the truncated VWF does not comprise all amino acids 764-2813 of SEQ ID NO:4 but only a fragment thereof. A truncated VWF may also be referred to as a VWF fragment, or in the plural as VWF fragments.

[0037] The truncated VWF is capable of binding to a Factor VIII. Preferably, the truncated VWF is capable of binding to the mature form of human native Factor VIII. In another embodiment, the truncated VWF is capable of binding to the single-chain Factor VIII consisting of the amino acid sequence SEQ ID NO:5. Binding of the truncated VWF to Factor VIII can be determined by a FVIII-VWF binding assay as described in Example 6.

[0038] The truncated VWF of the present invention preferably comprises or consists of an amino acid sequence having a sequence identity of at least 90% to amino acids 776 to 805 of SEQ ID NO:4 and is capable of binding to FVIII. In preferred embodiments the truncated VWF comprises or consists of an amino acid sequence having a sequence identity of at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to amino acids 776 to 805 of SEQ ID NO:4 and is capable of binding to FVIII. Most preferably, the truncated VWF comprises or consists of amino acids 776 to 805 of SEQ ID NO:4. Unless indicated otherwise herein, sequence identities are determined over the entire length of the reference sequence (e.g. amino acids 776 to 805 of SEQ ID NO:4).

[0039] The truncated VWF of the present invention preferably comprises or consists of an amino acid sequence having a sequence identity of at least 90% to amino acids 766 to 864 of SEQ ID NO:4 and is capable of binding to FVIII. In preferred embodiments the truncated VWF comprises or consists of an amino acid sequence having a sequence identity of at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to amino acids 766 to 864 of SEQ ID NO:4 and is capable of binding to FVIII. Most preferably, the truncated VWF comprises or consists of amino acids 766 to 864 of SEQ ID NO:4.

[0040] In another preferred embodiment, the truncated VWF consists of (a) an amino acid

sequence having a sequence identity of at least 90% to amino acids 764 to 1242 of SEQ ID NO:4, or (b) a fragment thereof, provided that the truncated VWF is still capable of binding to FVIII. More preferably, the truncated VWF consists of (a) an amino acid sequence having a sequence identity of at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to amino acids 764 to 1242 of SEQ ID NO:4, or (b) a fragment thereof, provided that the truncated VWF is still capable of binding to FVIII. Most preferably, the truncated VWF consists of (a) amino acids 764 to 1242 of SEQ ID NO:4, or (b) a fragment thereof, provided that the truncated VWF is still capable of binding to FVIII.

[0041] As described in more detail below, the polypeptide may be prepared by a method which uses cells comprising a nucleic acid encoding the polypeptide comprising the truncated VWF. The nucleic acid is introduced into suitable host cells by techniques that are known *per se*.

[0042] In a preferred embodiment, the nucleic acid in the host cell encodes (a) an amino acid sequence having a sequence identity of at least 90% to amino acids 1 to 1242 of SEQ ID NO:4, or (b) a fragment thereof, provided that the truncated mature VWF is still capable of binding to FVIII. More preferably, the nucleic acid encodes (a) an amino acid sequence having a sequence identity of at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to amino acids 1 to 1242 of SEQ ID NO:4, or (b) a fragment thereof, provided that the truncated VWF is still capable of binding to FVIII. Most preferably, the nucleic acid encodes (a) amino acids 1 to 1242 of SEQ ID NO:4, or (b) a fragment thereof, provided that the truncated VWF is still capable of binding to FVIII. Especially if the polypeptide in accordance with this invention is a dimer, the nucleic acid will comprise a sequence encoding amino acids 1 to 763 of VWF (e.g. SEQ ID NO:4), even if the truncated VWF in the polypeptide does not comprise amino acids 1 to 763 of VWF (e.g. SEQ ID NO:4).

[0043] In other embodiments the truncated VWF comprises or consists of one of the following amino acid sequences, each referring to SEQ ID NO:4:

776-805; 766-805; 764-805; 776-810; 766-810; 764-810; 776-815; 766-815; 764-815; 776-820; 766-820; 764-820; 776-825; 766-825; 764-825; 776-830; 766-830; 764-830; 776-835; 766-835; 764-835; 776-840; 766-840; 764-840; 776-845; 766-845; 764-845; 776-850; 766-850; 764-850; 776-855; 766-855; 764-855; 776-860; 766-860; 764-860; 776-864; 766-864; 764-864; 776-865; 766-865; 764-865; 776-870; 766-870; 764-870; 776-875; 766-875; 764-875; 776-880; 766-880; 764-880; 776-885; 766-885; 764-885; 776-890; 766-890; 764-890; 776-895; 766-895; 764-895; 776-900; 766-900; 764-900; 776-905; 766-905; 764-905; 776-910; 766-910; 764-910; 776-915; 766-915; 764-915; 776-920; 766-920; 764-920; 776-925; 766-925; 764-925; 776-930; 766-930; 764-930; 776-935; 766-935; 764-935; 776-940; 766-940; 764-940; 776-945; 766-945; 764-945; 776-950; 766-950; 764-950; 776-955; 766-955; 764-955; 776-960; 766-960; 764-960; 776-965; 766-965; 764-965; 776-970; 766-970; 764-970; 776-975; 766-975; 764-975; 776-980; 766-980; 764-980; 776-985; 766-985; 764-985; 776-990; 766-990; 764-990; 776-995; 766-995; 764-995; 776-1000; 766-1000; 764-1000; 776-1005; 766-1005; 764-1005; 776-1010; 766-1010; 764-1010; 776-1015; 766-1015; 764-1015; 776-1020; 766-1020; 764-1020; 776-1025; 766-1025; 764-1025; 776-1030; 766-1030; 764-1030; 776-1035; 766-1035; 764-1035; 776-1040; 766-1040; 764-1040; 776-1045; 766-

1045; 764-1045; 776-1050; 766-1050; 764-1050; 776-1055; 766-1055; 764-1055; 776-1060; 766-1060; 764-1060; 776-1065; 766-1065; 764-1065; 776-1070; 766-1070; 764-1070; 776-1075; 766-1075; 764-1075; 776-1080; 766-1080; 764-1080; 776-1085; 766-1085; 764-1085; 776-1090; 766-1090; 764-1090; 776-1095; 766-1095; 764-1095; 776-1100; 766-1100; 764-1100; 776-1105; 766-1105; 764-1105; 776-1110; 766-1110; 764-1110; 776-1115; 766-1115; 764-1115; 776-1120; 766-1120; 764-1120; 776-1125; 766-1125; 764-1125; 776-1130; 766-1130; 764-1130; 776-1135; 766-1135; 764-1135; 776-1140; 766-1140; 764-1140; 776-1145; 766-1145; 764-1145; 776-1150; 766-1150; 764-1150; 776-1155; 766-1155; 764-1155; 776-1160; 766-1160; 764-1160; 776-1165; 766-1165; 764-1165; 776-1170; 766-1170; 764-1170; 776-1175; 766-1175; 764-1175; 776-1180; 766-1180; 764-1180; 776-1185; 766-1185; 764-1185; 776-1190; 766-1190; 764-1190; 776-1195; 766-1195; 764-1195; 776-1200; 766-1200; 764-1200; 776-1205; 766-1205; 764-1205; 776-1210; 766-1210; 764-1210; 776-1215; 766-1215; 764-1215; 776-1220; 766-1220; 764-1220; 776-1225; 766-1225; 764-1225; 776-1230; 766-1230; 764-1230; 776-1235; 766-1235; 764-1235; 776-1240; 766-1240; 764-1240; 776-1242; 766-1242; 764-1242; 764-1464; 764-1250; 764-1041; 764-828; 764-865; 764-1045; 764-1035; 764-1128; 764-1198; 764-1268; 764-1261; 764-1264; 764-1459; 764-1463; 764-1464; 764-1683; 764-1873; 764-1482; 764-1479; 764-1672; and 764-1874.

[0044] In certain embodiments the truncated VWF has an internal deletion relative to mature wild type VWF. For example, the A1, A2, A3, D4, C1, C2, C3, C4, C5, C6 domains or combinations thereof may be deleted, and the D' domain, the D3 domain and the CK domain is retained. In further embodiments the truncated VWF does not comprise the binding sites for platelet glycoprotein Iba (GPIba), collagen and/or integrin $\alpha\text{IIb}\beta\text{III}$ (RGDS sequence within the C1 domain). In other embodiments, the truncated VWF does not comprise the cleavage site (Tyr1605-Met1606) for ADAMTS13 which is located at the central A2 domain of VWF. In yet another embodiment, the truncated VWF does not comprise the binding sites for GPIba, and/or does not comprise the binding site for collagen, and/or does not comprise the binding site for integrin $\alpha\text{IIb}\beta\text{III}$, and/or it does not comprise the cleavage site (Tyr1605-Met1606) for ADAMTS13 which is located at the central A2 domain of VWF.

[0045] In other embodiments the truncated VWF comprises or consists of an amino acid sequence that has a sequence identity of at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, to one of the amino acid sequences recited in the preceding paragraph, provided that the truncated VWF is capable of binding to FVIII.

[0046] A polypeptide of the invention is termed a "dimer" in the present invention if two monomers of polypeptide of the invention are linked covalently. Preferably the two monomeric subunits are covalently linked via at least one disulfide bridge, e.g. by one, two, three or four disulfide bridges. The cysteine residues forming the at least one disulfide bridge are preferably located within the truncated VWF portion of the polypeptide of the invention. In one embodiment, these cysteine residues are Cys-1099, Cys-1142, Cys-1222, Cys-1225, or Cys-1227 or combinations thereof.

[0047] If the polypeptide of the invention is a dimer, the truncated VWF preferably comprises or consists of two polypeptides each with an amino acid sequence having a sequence identity of at least 90% to amino acids 764 to 1099, amino acids 764 to 1142, amino acids 764 to 1222, amino acids 764 to 1225, or amino acids 764 to 1227 of SEQ ID NO:4 and is capable of binding to FVIII. In preferred embodiments the truncated VWF comprises or consists of an amino acid sequence having a sequence identity of at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to amino acids 764 to 1099, amino acids 764 to 1142, amino acids 764 to 1222, amino acids 764 to 1225, or amino acids 764 to 1227 of SEQ ID NO:4 and is capable of binding to FVIII. Most preferably, the truncated VWF comprises or consists of amino acids 764 to 1099, amino acids 764 to 1142, amino acids 764 to 1222, amino acids 764 to 1225, or amino acids 764 to 1227 of SEQ ID NO:4.

[0048] The truncated VWF may be any one of the VWF fragments disclosed in WO 2013/106787 A1, WO 2014/198699 A2, WO 2011/060242 A2 or WO 2013/093760 A2.

[0049] The term "endogenous VWF" as used herein refers to monomeric subunits of VWF, independent of its degree of di- or oligomerization. For example in the determination of ratios according to the present invention a ratio formed by a certain number of molecules of a polypeptide of the invention divided by 1,000 molecules of decameric multimers of VWF would be the same as a ratio formed by the same number of molecules of polypeptides of the invention divided by 2,000 pentameric multimers of VWF.

Half-life extending moiety

[0050] In addition to the truncated VWF, the polypeptide of the invention further comprise a half-life extending moiety. The half-life-extending moiety may be a heterologous amino acid sequence fused to the truncated VWF. Alternatively, the half-life-extending moiety may be chemically conjugated to the polypeptide comprising the truncated VWF by a covalent bond different from a peptide bond.

[0051] In certain embodiments of the invention, the half-life of the polypeptide of the invention is extended by chemical modification, e.g. attachment of a half-life extending moiety such as polyethylene glycol (PEGylation), glycosylated PEG, hydroxyl ethyl starch (HESylation), polysialic acids, elastin-like polypeptides, heparosan polymers or hyaluronic acid. In another embodiment, the polypeptide of the invention is conjugated to a HLEP such as albumin via a chemical linker. The principle of this conjugation technology has been described in an exemplary manner by Conjuchem LLC (see, e.g., US patent No. 7,256,253).

[0052] In other embodiments, the half-life-extending moiety is a half-life enhancing protein (HLEP). Preferably, the HLEP is an albumin or a fragment thereof. The N-terminus of the albumin may be fused to the C-terminus of the truncated VWF. Alternatively, the C-terminus of the albumin may be fused to the N-terminus of the truncated VWF. One or more HLEPs may be fused to the N- or C-terminal part of VWF provided that they do not to interfere with or

abolish the binding capability of the truncated VWF to FVIII.

[0053] In one embodiment the polypeptide has the following structure:



Wherein tVWF is the truncated VWF, L1 is a chemical bond or a linker sequence, and H is a HLEP.

[0054] L1 may be a chemical bond or a linker sequence consisting of one or more amino acids, e.g. of 1 to 50, 1 to 30, 1 to 20, 1 to 15, 1 to 10, 1 to 5 or 1 to 3 (e.g. 1, 2 or 3) amino acids and which may be equal or different from each other. Usually, the linker sequences are not present at the corresponding position in the wild-type VWF. Examples of suitable amino acids present in L1 include Gly and Ser. The linker should be non-immunogenic and may be a non-cleavable or cleavable linker. Non-cleavable linkers may be comprised of alternating glycine and serine residues as exemplified in WO2007/090584. In another embodiment of the invention the peptidic linker between the truncated VWF moiety and the albumin moiety consists of peptide sequences, which serve as natural interdomain linkers in human proteins. Preferably such peptide sequences in their natural environment are located close to the protein surface and are accessible to the immune system so that one can assume a natural tolerance against this sequence. Examples are given in WO2007/090584. Cleavable linker sequences are described, e.g., in WO 2013/120939 A1.

[0055] Preferred HLEP sequences are described infra. Likewise encompassed by the invention are fusions to the exact "N-terminal amino acid" or to the exact "C-terminal amino acid" of the respective HLEP, or fusions to the "N-terminal part" or "C-terminal part" of the respective HLEP, which includes N-terminal deletions of one or more amino acids of the HLEP. The polypeptide may comprise more than one HLEP sequence, e.g. two or three HLEP sequences. These multiple HLEP sequences may be fused to the C-terminal part of VWF in tandem, e.g. as successive repeats.

Half-life enhancing polypeptides (HLEPs)

[0056] Preferably, the half-life extending moiety is a half-life extending polypeptide (HLEP), more preferably HLEP is selected from albumin or fragments thereof, immunoglobulin constant region and portions thereof, e.g. the Fc fragment, solvated random chains with large hydrodynamic volume (e.g. XTEN (Schellenberger et al. 2009; Nature Biotechnol. 27:1186-1190), homo-amino acid repeats (HAP) or proline-alanine-serine repeats (PAS), afamin, alpha-fetoprotein, Vitamin D binding protein, transferrin or variants thereof, carboxyl-terminal peptide (CTP) of human chorionic gonadotropin- β subunit, polypeptides or lipids capable of binding under physiological conditions to albumin or immunoglobulin constant region.

[0057] A "half-life enhancing polypeptide" as used herein is preferably selected from the group

consisting of albumin, a member of the albumin-family, the constant region of immunoglobulin G and fragments thereof, region and polypeptides capable of binding under physiological conditions to albumin, to members of the albumin family as well as to portions of an immunoglobulin constant region. It may be a full-length half-life-enhancing protein described herein (e.g. albumin, a member of the albumin-family or the constant region of immunoglobulin G) or one or more fragments thereof that are capable of stabilizing or prolonging the therapeutic activity or the biological activity of the coagulation factor. Such fragments may be of 10 or more amino acids in length or may include at least about 15, at least about 20, at least about 25, at least about 30, at least about 50, at least about 100, or more contiguous amino acids from the HLEP sequence or may include part or all of specific domains of the respective HLEP, as long as the HLEP fragment provides a functional half-life extension of at least 25% compared to the respective polypeptide without the HLEP.

[0058] The HLEP portion of the polypeptide of the invention may be a variant of a wild type HLEP. The term "variants" includes insertions, deletions and substitutions, either conservative or non-conservative, where such changes do not substantially alter the FVIII-binding activity of the truncated VWF.

[0059] In particular, the proposed VWF HLEP fusion constructs of the invention may include naturally occurring polymorphic variants of HLEPs and fragments of HLEPs. The HLEP may be derived from any vertebrate, especially any mammal, for example human, monkey, cow, sheep, or pig. Non-mammalian HLEPs include, but are not limited to, hen and salmon.

Albumin as HLEP

[0060] The terms, "human serum albumin" (HSA) and "human albumin" (HA) and "albumin" (ALB) are used interchangeably in this application. The terms "albumin" and "serum albumin" are broader, and encompass human serum albumin (and fragments and variants thereof) as well as albumin from other species (and fragments and variants thereof).

[0061] As used herein, "albumin" refers collectively to albumin polypeptide or amino acid sequence, or an albumin fragment or variant, having one or more functional activities (e.g., biological activities) of albumin. In particular, "albumin" refers to human albumin or fragments thereof, especially the mature form of human albumin as shown in SEQ ID NO:6 herein or albumin from other vertebrates or fragments thereof, or analogs or variants of these molecules or fragments thereof.

[0062] In particular, the proposed polypeptides of the invention may include naturally occurring polymorphic variants of human albumin and fragments of human albumin. Generally speaking, an albumin fragment or variant will be at least 10, preferably at least 40, most preferably more than 70 amino acids long.

[0063] Preferred embodiments of the invention include albumin variants used as a HLEP of the

polypeptide of the invention with enhanced binding to the FcRn receptor. Such albumin variants may lead to a longer plasma half-life of a truncated VWF albumin variant fusion protein as compared to a truncated VWF fusion with a wild-type albumin.

[0064] The albumin portion of the polypeptides of the invention may comprise at least one subdomain or domain of HA or conservative modifications thereof.

Immunoglobulins as HLEPs

[0065] Immunoglobulin G (IgG) constant regions (Fc) are known in the art to increase the half-life of therapeutic proteins (Dumont J A et al. 2006. BioDrugs 20:151-160). The IgG constant region of the heavy chain consists of 3 domains (CH1-CH3) and a hinge region. The immunoglobulin sequence may be derived from any mammal, or from subclasses IgG1, IgG2, IgG3 or IgG4, respectively. IgG and IgG fragments without an antigen-binding domain may also be used as HLEPs. The therapeutic polypeptide portion is connected to the IgG or the IgG fragments preferably via the hinge region of the antibody or a peptidic linker, which may even be cleavable. Several patents and patent applications describe the fusion of therapeutic proteins to immunoglobulin constant regions to enhance the therapeutic protein's in vivo half-lives. US 2004/0087778 and WO 2005/001025 describe fusion proteins of Fc domains or at least portions of immunoglobulin constant regions with biologically active peptides that increase the half-life of the peptide, which otherwise would be quickly eliminated in vivo. Fc-IFN- β fusion proteins were described that achieved enhanced biological activity, prolonged circulating half-life and greater solubility (WO 2006/000448). Fc-EPO proteins with a prolonged serum half-life and increased in vivo potency were disclosed (WO 2005/063808) as well as Fc fusions with G-CSF (WO 2003/076567), glucagon-like peptide-1 (WO 2005/000892), clotting factors (WO 2004/101740) and interleukin-10 (U.S. Pat. No. 6,403,077), all with half-life enhancing properties.

[0066] Various HLEPs which can be used in accordance with this invention are described in detail in WO 2013/120939 A1.

N-Glycans and Sialylation of the polypeptide of the invention

[0067] The polypeptide of the invention preferably comprises N-glycans, and at least 75%, preferably at least 85%, more preferably at least 90% of said N-glycans comprise, on average, at least one sialic acid moiety. In preferred embodiments, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, of said N-glycans comprise, on average, at least one sialic acid moiety. The inventors found that polypeptides comprising highly sialylated VWF fragments not only have a prolonged half-life themselves, but are also capable to extend the half-life of co-administered FVIII. In other words, administration of the polypeptide of the invention leads to an extended half-life and/or to

a reduced clearance of co-administered FVIII.

[0068] The polypeptide of the invention preferably comprises N-glycans, and at least 50% of the sialyl groups of the N-glycans of the glycoproteins are α -2,6-linked sialyl groups. In general, terminal sialyl groups can be attached to the galactose groups via a α -2,3- or via a α -2,6-linkage. Typically, N-glycans of the polypeptide of the invention comprise more α -2,6-linked sialyl groups than α -2,3-linked sialyl groups. Preferably, at least 60%, or at least 70%, or at least 80%, or at least 90% of the sialyl groups of the N-glycans are α -2,6-linked sialyl groups. These embodiments can be obtained by, e.g., co-expressing human α -2,6-sialyltransferase in mammalian cells.

[0069] In one embodiment, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, of the N-glycans of the polypeptide of the invention comprise at least one sialic acid group. In another embodiment, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, of the N-glycans of the polypeptide of the invention comprise at least one sialic acid group.

[0070] In another embodiment, less than 15%, less than 12%, less than 10%, or less than 8%, or less than 6%, or less than 5%, or less than 4%, or less than 3%, or less than 2% or even less than 1% of the N-glycans of the polypeptide of the invention are asialo-N-glycans, i.e. they are N-glycans lacking a sialic acid group. In another embodiment, less than 15%, less than 12%, less than 10%, or less than 8%, or less than 6%, or less than 5%, or less than 4%, or less than 3%, or less than 2% or even less than 1% of the N-glycans of the polypeptide of the invention are asialo-N-glycans, i.e. they do not have a sialic acid group.

[0071] Other embodiments of the invention comprise a truncated von Willebrand Factor (VWF), wherein said truncated VWF is capable of binding to a Factor VIII (FVIII), and wherein said glycoprotein comprises N-glycans, wherein less than 35%, preferably less than 34%, preferably less than 33%, preferably less than 32%, preferably less than 31%, preferably less than 30%, preferably less than 29%, preferably less than 28%, preferably less than 27%, preferably less than 26%, preferably less than 25%, preferably less than 24%, preferably less than 23%, preferably less than 22%, preferably less than 21%, preferably less than 20%, preferably less than 19%, preferably less than 18%, preferably less than 17%, preferably less than 16%, preferably less than 15%, preferably less than 14%, preferably less than 13%, preferably less than 12%, preferably less than 11%, preferably less than 10%, preferably less than 9%, preferably less than 8%, preferably less than 7%, preferably less than 6% and preferably less than 5% of said N-glycans comprise, on average, two or more terminal and non-sialylated galactose residues.

[0072] Still other embodiments of the invention comprise a truncated von Willebrand Factor (VWF), wherein said truncated VWF is capable of binding to a Factor VIII (FVIII), and wherein said truncated VWF comprises N-glycans, wherein less than 6%, preferably less than 5%, preferably less than 4%, preferably less than 3%, preferably less than 2%, and preferably less than 1% of said N-glycans comprise, on average, three or more terminal and non-sialylated

galactose residues.

[0073] The above-described embodiments can be combined with each other. Any percentages of N-glycans mentioned above, or any indications of the degree of sialylation, are to be understood as average percentages or degrees, i.e. they refer to a population of molecules, not to a single molecule. It is clear that the glycosylation or sialylation of the individual glycoprotein molecules within a population of glycoproteins will show some heterogeneity.

Dimers

[0074] It has further been found that the polypeptides of this invention have a high proportion of dimers. The polypeptide of the invention is therefore preferably present as dimer. In one embodiment, at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95% or about 100% of the polypeptides are present as dimers. In another embodiment, the ratio dimer : monomer of the polypeptide of the invention is at least 1.5, preferably at least 2, more preferably at least 2.5 or at least 3. Most preferably all polypeptides of the invention are present as dimers. The use of dimers is favorable, as the dimer has an improved affinity to Factor VIII as compared to the monomer. The dimer content, and the ratio of dimer to monomer of the polypeptide of the invention can be determined as described in Example 1.

[0075] In one embodiment, the affinity of the polypeptide of the invention to Factor VIII is greater than that of human native VWF to the same Factor VIII molecule. The factor VIII affinity may refer to human native Factor VIII, or to the Factor VIII molecule characterized by SEQ ID NO:5.

[0076] It has been found that preparations of the polypeptide of this invention with a high proportion of dimers do have an increased affinity to Factor VIII. Such increased affinity to Factor VIII does lead to an enhanced stabilization of Factor VIII by the polypeptides of the present invention. Alternatively to or in combination with an increased dimer proportion also polypeptides in accordance with the invention with mutations within the Factor VIII binding domain which do increase the affinity to Factor VIII are preferred embodiments of the invention. Suitable mutations are disclosed, e.g., in WO 2013/120939 A1.

Preparation of the polypeptide

[0077] The nucleic acid encoding the polypeptide of the invention can be prepared according to methods known in the art. Based on the cDNA sequence of VWF (SEQ ID NO:3), recombinant DNA encoding the above-mentioned truncated VWF constructs or polypeptides of the invention can be designed and generated.

[0078] Even if the polypeptide which is secreted by the host cells does not comprise amino acids 1 to 763 of VWF, it is preferred that the nucleic acid (e.g. the DNA) encoding the intracellular precursor of the polypeptide comprises a nucleotide sequence encoding an amino acid sequence having a sequence identity of at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to amino acids 23 to 763 or preferably to amino acids 1 to 763 of SEQ ID NO:4. Most preferably, the nucleic acid (e.g. the DNA) encoding the intracellular precursor of the polypeptide comprises a nucleotide sequence encoding amino acids 23 to 763 of SEQ ID NO:4, or amino acids 1 to 763 of SEQ ID NO:4.

[0079] Constructs in which the DNA contains the entire open reading frame inserted in the correct orientation into an expression plasmid may be used for protein expression. Typical expression vectors contain promoters that direct the synthesis of large amounts of mRNA corresponding to the inserted nucleic acid in the plasmid-bearing cells. They may also include an origin of replication sequence allowing for their autonomous replication within the host organism, and sequences that increase the efficiency with which the synthesized mRNA is translated. Stable long-term vectors may be maintained as freely replicating entities by using regulatory elements of, for example, viruses (e.g., the OriP sequences from the Epstein Barr Virus genome). Cell lines may also be produced that have integrated the vector into the genomic DNA, and in this manner the gene product is produced on a continuous basis.

[0080] Typically, the cells to be provided are obtained by introducing the nucleic acid encoding a polypeptide of the invention into mammalian host cells.

[0081] Any host cell susceptible to cell culture, and to expression of glycoproteins, may be utilized in accordance with the present invention. In certain embodiments, a host cell is mammalian. Nonlimiting examples of mammalian cells that may be used in accordance with the present invention include BALB/c mouse myeloma line (NSO/ 1, ECACC No: 85110503); human retinoblasts (PER.C6 (CruCell, Leiden, The Netherlands)); monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36:59, 1977); baby hamster kidney cells (BHK, ATCC CCL10); Chinese hamster ovary cells +/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216, 1980); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243 251, 1980); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1 587); human cervical carcinoma cells (HeLa, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (HepG2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals NY. Acad. Sci., 383:44-68, 1982); MRC 5 cells; PS4 cells; human amniocyte cells (CAP); and a human hepatoma line (Hep G2). Preferably, the cell line is a rodent cell line, especially a hamster cell line such as CHO or BHK.

[0082] Methods suitable for introducing nucleic acids sufficient to achieve expression of a glycoprotein of interest into mammalian host cells are known in the art. See, for example, Gething et al., Nature, 293:620-625, 1981; Mantei et al., Nature, 281:40-46, 1979; Levinson et

al. EP 117,060; and EP 117,058. For mammalian cells, common methods of introducing genetic material into mammalian cells include the calcium phosphate precipitation method of Graham and van der Erb (Virology, 52:456-457, 1978) or the lipofectamine™ (Gibco BRL) Method of Hawley-Nelson (Focus 15:73, 1993). General aspects of mammalian cell host system transformations have been described by Axel in US. Pat. No. 4,399,216. For various techniques for introducing genetic material into mammalian cells, see Keown et al., Methods in Enzymology, 1989, Keown et al., Methods in Enzymology, 185:527-537, 1990, and Mansour et al., Nature, 336:348-352, 1988.

[0083] The cells are cultured under conditions that allow expression of the polypeptide. The polypeptide can be recovered and purified using methods that are known to the skilled artisan.

Terminal half-life, MRT and Clearance

[0084] Another aspect of the invention is the use of a polypeptide as defined hereinabove for increasing the terminal half-life or mean residence time (MRT) or reducing the clearance of Factor VIII. For evaluation of the pharmacokinetic data a linear pharmacokinetics model (compound elimination via the central compartment) was applied. Accordingly, any pharmacokinetic parameters used herein are based on a linear pharmacokinetics model (compound elimination via the central compartment), unless indicated otherwise.

[0085] The "half-life" $T_{1/2}(t)$ at a certain time t is the time it takes to halve the plasma concentration $C(t)$ that is present at time t , i.e. $C[t + T_{1/2}(t)] = C(t)/2$. The "terminal half-life" is the limit of $T_{1/2}(t)$ when t tends to infinity.

[0086] The terminal half-life of administered FVIII is increased by at least 25%, preferably by at least 50%, more preferably by at least 75%, more preferably by at least 100%, most preferably by at least 150%, if an effective amount of the polypeptide of the present invention is co-administered, relative to administration of the FVIII alone. Another aspect of the invention is the use of a polypeptide as defined hereinabove for increasing the terminal half-life of Factor VIII.

[0087] The term "MRT", as used herein, means the average time a drug molecule (e.g. the polypeptide of the invention or a FVIII) resides in the body. In a linear pharmacokinetic system with constant clearance MRT can be calculated as the area under the first moment curve (AUMC) divided by the area under the plasma concentration-time curve (AUC). The first moment curve is time multiplied by plasma concentration at that time.

[0088] The MRT of administered FVIII is increased by at least 25%, preferably by at least 50%, more preferably by at least 75%, more preferably by at least 100%, most preferably by at least 150%, if an effective amount of the polypeptide of the present invention is co-administered, relative to administration of the FVIII alone. Another aspect of the invention is the use of a polypeptide as defined hereinabove for increasing the terminal half-life or mean residence time (MRT) or reducing the clearance of Factor VIII.

[0089] The term "clearance", as used herein, refers to the rate at which plasma is cleared of drug. Specifically, it is the current elimination rate of a drug divided by its current plasma concentration. In a linear pharmacokinetic system after a single intravenous administration the clearance can be calculated as the ratio of dose over the area under the plasma concentration-time curve (AUC), provided the clearance is constant. The lower the clearance the longer it takes until the plasma is cleared of the drug.

[0090] The clearance of administered FVIII is reduced by at least 10%, preferably by at least 25%, more preferably by at least 50%, more preferably by at least 60%, most preferably by at least 70%, if an effective amount of the polypeptide of the present invention is co-administered, relative to administration of the FVIII alone.

[0091] The invention further relates to a method of increasing the MRT or half-life, or to a method of reducing the clearance of Factor VIII *in vivo*, comprising administering to a subject an effective amount of a polypeptide as defined hereinabove.

[0092] The term "in vivo recovery of FVIII", as used herein, is defined as the percentage of FVIII, which is in the circulation extrapolated to $t=0$ in relation to the total amount of FVIII administered. As a basis for calculation of the expected FVIII concentration in the circulation a plasma volume of 40 mL per kg is assumed in general.

[0093] The invention further relates to the use of a polypeptide as defined hereinabove, e.g. but not limited to embodiments [01] to [72] detailed in Table 1 above, for increasing the in vivo recovery of FVIII. The in vivo recovery of FVIII is increased by at least 5%, preferably by at least 10%, more preferably by at least 15%, 18%, 20%, 25%, even more preferably by at least 26%, 27%, 28%, 29%, or 30%, most preferably by more than 35% or even more than 40% relative to the FVIII recovery without administration of the polypeptide.

[0094] A further aspect of this invention is a method of treating a blood coagulation disorder, comprising administering to a patient in need thereof an effective amount of a polypeptide as defined hereinabove.

[0095] A further aspect is the use of a polypeptide as defined hereinabove, e.g. by any of but not limited to embodiments [01] to [72] in Table 1 above, for reducing the frequency of administration of FVIII in a treatment of hemophilia A. The frequency of intravenous or subcutaneous administration of FVIII may be reduced to twice per week. Alternatively, the frequency of intravenous or subcutaneous administration of FVIII may be reduced to once per week, or even lower, e.g. to once per 10 days or once per 14 days. The FVIII may be administered twice weekly, every 5 days, once weekly, every 10 days, every two weeks, every three weeks, every four weeks or once a month, or in any range between any two of the foregoing values, for example from every four days to every month, from every 10 days to every two weeks, or from two to three times a week, etc.

[0096] Another aspect is the use of a polypeptide as defined hereinabove for reducing the dose of FVIII to be administered in a treatment of hemophilia A.

Treatment of coagulation disorder

[0097] The polypeptides of the invention are useful for treating coagulation disorders including hemophilia A. The term "hemophilia A" refers to a deficiency in functional coagulation FVIII, which is usually inherited.

[0098] Treatment of a disease encompasses the treatment of patients already diagnosed as having any form of the disease at any clinical stage or manifestation; the delay of the onset or evolution or aggravation or deterioration of the symptoms or signs of the disease; and/or preventing and/or reducing the severity of the disease.

[0099] A "subject" or "patient" to whom a polypeptide of the invention is administered preferably is a human. In certain aspects, the human is a pediatric patient. In other aspects, the human is an adult patient.

[0100] Compositions comprising a polypeptide of the invention and, optionally FVIII, are described herein. The compositions typically are supplied as part of a sterile, pharmaceutical composition that includes a pharmaceutically acceptable carrier. This composition can be in any suitable form (depending upon the desired method of administering it to a patient).

[0101] The term "Factor VIII" and "FVIII" are used interchangeably herein and encompass both plasma derived FVIII and recombinant FVIII. Recombinant FVIII encompasses without limitation full-length FVIII as well as two-chain B-domain deleted or truncated variants as well as single-chain B-domain deleted or truncated variants for example those described in WO 2004/067566 and other FVIII variants with mutations outside the B-domain but having the biological activity of FVIII.

[0102] The polypeptide of the invention can be administered to a patient by a variety of routes such as orally, transdermally, subcutaneously, intranasally, intravenously, intraperitoneally, intramuscularly, topically or locally. The most suitable route for administration in any given case will depend on the particular polypeptide, the subject, and the nature and severity of the disease and the physical condition of the subject. Typically, a polypeptide of the invention will be administered intravenously.

[0103] The polypeptide and the FVIII are preferably administered intravenously or subcutaneously.

[0104] In a first embodiment, both the polypeptide and the FVIII are administered intravenously. In a second embodiment, both the polypeptide and the FVIII are administered subcutaneously.

[0105] In another embodiment, the FVIII is administered intravenously, and the polypeptide is administered via a different route. In further embodiments, the polypeptide is administered subcutaneously, and the FVIII is administered via a different route. For example, the polypeptide may be administered subcutaneously, and the FVIII may be administered intravenously.

[0106] In further embodiments, the FVIII is administered subcutaneously, and the polypeptide is administered via a different route. In further embodiments, the polypeptide is administered intravenously, and the FVIII is administered via a different route. For example, the polypeptide may be administered intravenously, and the FVIII may be administered subcutaneously.

[0107] Determination of the total number of doses, and length of treatment with a polypeptide of the invention is well within the capabilities of those skilled in the art. The dosage of the polypeptide of the invention to be administered depends on the concentrations of the FVIII to be administered, the concentration of endogenous VWF in the patient to be treated, or both. An effective dosage based on the ratios defined by the inventors of this application can be determined by the skilled person, taking into account the molecular weight of the polypeptide of the invention. Typical dosages for FVIII may range from about 20 U/kg body weight to about 100 U/kg body weight.

[0108] In accordance with this invention, the patient being treated with the polypeptide of the invention is also treated with blood coagulation Factor VIII. The polypeptide of the invention and the Factor VIII may be administered simultaneously or in a sequential fashion both modes of administration being encompassed by the term "combination therapy" and "co-administration". The polypeptide of the invention and the Factor VIII may be administered as a mixture, i.e. within the same composition, or separately, i.e. as separate compositions.

[0109] The concentration of Factor VIII in the composition used is typically in the range of 10-10,000 IU/mL. In different embodiments, the concentration of FVIII in the compositions of the invention is in the range of 10-8,000 IU/mL, or 10-5,000 IU/mL, or 20-3,000 IU/mL, or 50-1,500 IU/mL, or 3,000 IU/mL, or 2,500 IU/mL, or 2,000 IU/mL, or 1,500 IU/mL, or 1,200 IU/mL, or 1,000 IU/mL, or 800 IU/mL, or 750 IU/mL, or 600 IU/mL, or 500 IU/mL, or 400 IU/mL, or 300 IU/mL, or 250 IU/mL, or 200 IU/mL, or 150 IU/mL, or 125 IU/mL, or 100 IU/mL, or 62.5 IU/mL, or 50 IU/mL, provided the requirements regarding the ratio with respect to the VWF polypeptide of the invention as defined herein are fulfilled.

[0110] "International Unit," or "IU," is a unit of measurement of the blood coagulation activity (potency) of FVIII as measured by a FVIII activity assay such as a one stage clotting assay or a chromogenic substrate FVIII activity assay using a standard calibrated against an international standard preparation calibrated in "IU". One stage clotting assays are known to the art, such as that described in N Lee, Martin L, et al., An Effect of Predilution on Potency Assays of FVIII Concentrates, Thrombosis Research (Pergamon Press Ltd.) 30, 511 519 (1983). Principle of the one stage assay: The test is executed as a modified version of the activated Partial

Thromboplastin Time (aPTT)-assay: Incubation of plasma with phospholipids and a surface activator leads to the activation of factors of the intrinsic coagulation system. Addition of calcium ions triggers the coagulation cascade. The time to formation of a measurable fibrin clot is determined. The assay is executed in the presence of Factor VIII deficient plasma. The coagulation capability of the deficient plasma is restored by Coagulation Factor VIII included in the sample to be tested. The shortening of coagulation time is proportional to the amount of Factor VIII present in the sample. The activity of Coagulation Factor VIII is quantified by direct comparison to a standard preparation with a known activity of Factor VIII in International Units.

[0111] Another standard assay is a chromogenic substrate assay. Chromogenic substrate assays may be purchased commercially, such as the coamatic FVIII test kit (Chromogenix-Instrumentation Laboratory SpA V. le Monza 338 - 20128 Milano, Italy). Principle of the chromogenic assay: In the presence of calcium and phospholipid, Factor X is activated by Factor IXa to Factor Xa. This reaction is stimulated by Factor VIIIa as cofactor. FVIIIa is formed by low amounts of thrombin in the reaction mixture from FVIII in the sample to be measured. When using the optimum concentrations of Ca^{2+} , phospholipid and Factor IXa and an excess quantity of Factor X, activation of Factor X is proportional to the potency of Factor VIII. Activated Factor X releases the chromophore pNA from the chromogenic substrate S-2765. The release of pNA, measured at 405 nm, is therefore proportional to the amount of FXa formed, and, therefore, also to the Factor VIII activity of the sample.

Pharmaceutical compositions

[0112] Therapeutic formulations of the polypeptide of the invention suitable in the methods described herein can be prepared for storage as lyophilized formulations or aqueous solutions by mixing the polypeptide having the desired degree of purity with optional pharmaceutically-acceptable carriers, excipients or stabilizers typically employed in the art (all of which are referred to herein as "carriers"), i.e., buffering agents, stabilizing agents, preservatives, isotonicifiers, non-ionic detergents, antioxidants, and other miscellaneous additives. See, Remington's Pharmaceutical Sciences, 16th edition (Osol, ed. 1980). Such additives must be nontoxic to the recipients at the dosages and concentrations employed.

[0113] Buffering agents help to maintain the pH in the range which approximates physiological conditions. They can present at concentration ranging from about 2 mM to about 50 mM. Suitable buffering agents include both organic and inorganic acids and salts thereof such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g., gluconic acid-sodium glyconate mixture, gluconic acid-sodium hydroxide mixture, gluconic

acid-potassium gluconate mixture, etc.), oxalate buffer (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture, etc.) and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, etc.). Additionally, phosphate buffers, histidine buffers and trimethylamine salts such as Tris can be used.

[0114] Preservatives can be added to retard microbial growth, and can be added in amounts ranging from 0.2%- 1% (w/v). Suitable preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalconium halides (e.g., chloride, bromide, and iodide), hexamethonium chloride, and alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, and 3-pentanol. Isotonicifiers sometimes known as "stabilizers" can be added to ensure isotonicity of liquid compositions and include polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol. Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the therapeutic agent or helps to prevent denaturation or adherence to the container wall. Typical stabilizers can be polyhydric sugar alcohols (enumerated above); amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc., organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, glycerol and the like, including cyclitols such as inositol; polyethylene glycol; amino acid polymers; sulfur containing reducing agents, such as urea, glutathione, thiocetic acid, sodium thioglycolate, thioglycerol, α -monothioglycerol and sodium thio sulfate; low molecular weight polypeptides (e.g., peptides of 10 residues or fewer); proteins such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins; hydrophylic polymers, such as polyvinylpyrrolidone monosaccharides, such as xylose, mannose, fructose, glucose; disaccharides such as lactose, maltose, sucrose and trisaccharides such as raffinose; and polysaccharides such as dextran. Stabilizers can be present in the range from 0.1 to 10,000 weights per part of weight active protein.

[0115] Non-ionic surfactants or detergents (also known as "wetting agents") can be added to help solubilize the therapeutic agent as well as to protect the therapeutic protein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stressed without causing denaturation of the protein. Suitable non-ionic surfactants include polysorbates (20, 80, etc.), polyoxamers (184, 188 etc.), Pluronic polyols, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.). Non-ionic surfactants can be present in a range of about 0.05 mg/ml to about 1.0 mg/ml, or in a range of about 0.07 mg/ml to about 0.2 mg/ml.

[0116] Additional miscellaneous excipients include bulking agents (e.g., starch), chelating agents (e.g., EDTA), antioxidants (e.g., ascorbic acid, methionine, vitamin E), and cosolvents.

[0117] The formulation herein can also contain a second therapeutic agent in addition to a

polypeptide of the invention. Examples of suitable second therapeutic agents are provided below.

[0118] The dosing schedule can vary from once a month to daily depending on a number of clinical factors, including the type of disease, severity of disease, and the patient's sensitivity to the polypeptide of the invention. In specific embodiments, a polypeptide of the invention is administered, twice weekly, every 5 days, once weekly, every 10 days, every two weeks, every three weeks, every four weeks or once a month, or in any range between any two of the foregoing values, for example from every four weeks to every month, from every 10 days to every two weeks, or from two to three times a week, etc.

[0119] The dosage of a polypeptide of the invention to be administered will vary according to the particular polypeptide, the subject, and the nature and severity of the disease, the physical condition of the subject, the therapeutic regimen (e.g., whether a second therapeutic agent is used), and the selected route of administration; the appropriate dosage can be readily determined by a person skilled in the art.

[0120] It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a polypeptide of the invention will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the age and condition of the particular subject being treated, and that a physician will ultimately determine appropriate dosages to be used. This dosage can be repeated as often as appropriate. If side effects develop the amount and/or frequency of the dosage can be altered or reduced, in accordance with normal clinical practice.

[0121] The nucleotide and amino acid sequences shown in the sequence listing are summarized in the Table 2.

Table 2:

SEQ ID NO:	Remarks
1	DNA sequence encoding a polypeptide comprising acids 1 to 1242 of human VWF, a glycine/serine linker and human albumin; nucleotide positions (nt):
	nt 1-6: EcoRI restriction enzyme cleavage site
	nt 32 - 3757: coding sequence for VWF amino acids 1 to 1242
	nt 3758 - 3850: coding sequence for glycine/serine linker
	nt 3851 - 5608: coding sequence for human albumin
	nt 5609 - 5616: NotI restriction enzyme cleavage site
2	Amino acid sequence encoded by SEQ ID NO:1 (mature form): amino acid positions (aa):
	aa 1 - 479: VWF D'D3 region (VWF amino acids 764 - 1242)
	aa 480 - 510: glycine/serine linker

SEQ ID NO:	Remarks
	aa 511 - 1095: human albumin
3	DNA sequence encoding the pre-pro form of human native VWF
4	Amino acid sequence encoded by SEQ ID NO:3
5	Amino acid sequence of a single chain Factor VIII molecule
6	Amino acid sequence of mature human serum albumin
7	Amino acid sequence of D'D3-His8
	aa 1 - 479: VWF D'D3 region (VWF amino acids 764 - 1242)
	aa 480 - 511: glycine/serine linker
	aa 512 - 519: polyhistidine tag
8	Amino acid sequence of D'D3-CTP
	aa 1 - 479: VWF D'D3 region (VWF amino acids 764 - 1242)
	aa 480 - 511: glycine/serine linker
	aa 512 - 576: C-terminal peptide of human chorionic gonadotropin- β subunit
	aa 577 - 584: polyhistidine tag

[0122] The following Examples illustrate the invention by way of example.

EXAMPLES

Aim

[0123] We aimed at investigating the impact of the ratio of a polypeptide comprising a truncated VWF and a half-life-extending moiety ("polypeptide of the invention") to FVIII and endogenous VWF, respectively, on pharmacokinetics (PK) of the fragment and FVIII.

An overview of the experiments is given in the following table.

Table 3:

Ex. #.	Animal	polypeptide of the invention dose	FVIII dose	Dose ratio polypeptide of the invention : FVIII	Dose ratio polypeptide of the invention : endogenous VWF
1	rat	Increasing (D'D3-FP)	constant	increasing	increasing
2	rat	Increasing (D'D3-FP)	increasing	constant	increasing

Ex. #.	Animal	polypeptide of the invention dose	FVIII dose	Dose ratio polypeptide of the invention : FVIII	Dose ratio polypeptide of the invention : endogenous VWF
3	rabbit	Increasing (D'D3-FP)	constant	increasing	increasing
4	rabbit	Single dose with different recombinant FVIII products			
5	rat	D'D3 without half-life extending moiety and D'D3-CTP at a fixed ratio			

[0124] In the pharmacokinetic examples, different molar ratios were calculated. Therefore, the following assumptions were made:

- The drugs are diluted in 40 mL plasma per kg body weight after their administration
- Molecular weight of the polypeptide of the invention used: D'D3-FP molecular weight of monomeric subunit (including glycosylation): 127,000 Da (HLEM = human albumin)
- Molecular weight of FVIII used: rVIII-SingleChain molecular weight (with glycosylation): 180,000 Da and specific activity: 11,000 IU/mg
- Molecular weight of albumin as part of the D'D3-FP: 66,000 Da
- Same molar FVIII activity of the recombinant FVIII products was used (rVIII-SingleChain, Advate®, NovoEight®), calculating for identical molar ratios when administered at same activity doses
- Endogenous human, rat or rabbit VWF monomer molecular weight (with 18-19% glycosylation): 267,500 Da
- Endogenous rat or rabbit VWF is assumed to have the same specific activity as human VWF, i.e. one U/mL (or 100% of the norm) is assumed to be 10 µg/mL (published human concentration relating to one U/mL or 100 % of the norm)
- Endogenous VWF activity in rat plasma measured as 0.946±0.181 U/mL and calculated to $35.36 \cdot 10^{-9}$ mol/L from 12 CD rats using the INNOVANCE® VWF Ac kit (Siemens Healthcare Diagnostics GmbH, Eschborn, Germany) calibrated against standard human plasma (calibrated against the respective WHO standard, Siemens Healthcare Diagnostics GmbH)
- Endogenous VWF activity in rabbit plasma measured as 0.242±0.056 U/mL and calculated to $9.05 \cdot 10^{-9}$ mol/L from 5 rabbits from example 3 using the INNOVANCE® VWF Ac kit (Siemens Healthcare Diagnostics GmbH, Eschborn, Germany) calibrated against standard human plasma (calibrated against the respective WHO standard, Siemens Healthcare Diagnostics GmbH).

Example 1: Prolongation of pharmacokinetics of FVIII by co-administration of rVIII-SingleChain (constant dose) and increasing D'D3-FP doses in the rat

Material and Methods**Generation of D'D3 albumin fusion protein (D'D3-FP):**

[0125] The expression cassette for D'D3-FP consisting of cDNA encoding VWF amino acids 1 to 1242, a glycine/serine linker and the cDNA of human albumin was prepared by custom gene synthesis (Eurofins Genomics, Ebersberg, Germany). Through flanking restriction sites (EcoRI, NotI) the expression cassette was excised from the cloning vector supplied and inserted into a pIRESneo3 vector (BD Biosciences, Franklin Lakes, NJ, USA) linearized with EcoRI and NotI. The resulting expression plasmid contained nucleotide sequences encoding the VWF propeptide, D' and D3 (VWF amino acids 1 to 1242 of SEQ ID NO:4) fused to the albumin coding sequence through a short linker coding sequence under CMV promoter control. The nucleotide sequence of the coding sequence is displayed as SEQ ID NO:1, the amino acid sequence of the mature D'D3-FP is shown as SEQ ID NO:2.

[0126] A similar approach was used to generate an expression plasmid for a His-tagged D'D3 protein (D'D3 and His8 linked by a glycine/serine linker) and a D'D3 fusion protein to the C-terminal peptide of human chorionic gonadotropin- β subunit, also linked via a glycine/serine linker and tagged by 8 histidines at the C-terminus of the fusion protein. The amino acid sequence of the mature D'D3-His8 is shown as SEQ ID NO: 7 and the amino acid sequence of the mature D'D3-CTP is shown as SEQ ID NO: 8.

[0127] The expression plasmids as described above were grown up in XL10 Gold (Agilent Technologies) and purified using standard protocols (Qiagen, Hilden, Germany).

[0128] CHO K1 cells were transfected using the Lipofectamine 2000 reagent (Invitrogen) and grown up in serum-free medium (CD-CHO, Invitrogen) in the presence of 500-1000 μ g/ml Geneticin. An expression plasmid encoding PACE/furin (pFu-797) as described in WO2007/144173 was cotransfected to maximize propeptide cleavage efficacy. Single cell derived clones were grown up and selected according to their D'D3-FP expression yield as quantified by an albumin specific enzyme immunoassay (see below). The cell line finally selected for D'D3-FP fermentation was called T2050-CL3.

[0129] Production of D'D3-FP was carried out in bioreactors applying a fermentation process in perfusion mode. The fermentation process for the production of D'D3-containing polypeptides started with the thaw of cell line T2050-CL3 followed by cell expansion in shake flasks and finally a fermentation process in perfusion mode using the Sartorius BioStat B-DCU 5 L bioreactor and the BioStat STR 50L single-use bioreactors. The BioSeps 10L or 200L (Applikon), respectively, were used as cell retention devices. Cell culture media were either PowerCHO3 (Lonza BES1204) with 8 mM L-glutamine and 1 μ M CuSO₄ or ProCHO5 (Lonza BES1072) with 10 mM L-glutamine and 1 μ M CuSO₄.

[0130] The seed trains in shake flasks were performed at 37°C, 7.5% CO₂ at a shaker speed of 160 rpm.

[0131] The 5L bioreactor was inoculated with a target VCD of 2.5×10^5 cells/mL. The cells were cultivated in PowerCHO3 with 8 mM L-glutamine and 1 μ M CuSO₄ at a temperature of +37.0°C, a pH of 7.00, and at 30 % oxygen saturation. A temperature shift to +34.0 °C (evaluated range +31°C to +35°C) was performed after initial harvests from the bioreactor run at +37°C had been taken. The pH was controlled using CO₂ sparged as acid and NaHCO₃ as base. The overlay air flow rate was set to 0.5 L/min. A ring sparger was used as a sparging unit. The agitation rate was 150 rpm with a 2fold pitch blade impeller in down pull mode.

[0132] The 50L bioreactor was inoculated with a target VCD of 3.0×10^5 cells/mL. The cells were cultivated in ProCHO5 medium with 10 mM L-glutamine and 1 μ M CuSO₄ at a temperature of +37.0°C, a pH of 6.90, and at 30 % oxygen saturation. A temperature shift to +34.0 °C was performed after the initial one or two harvests. PH control as above, the overlay air flow rate was set to 2 L/min. A micro sparger was used as a sparging unit. The agitation rate was 90 rpm with a 2fold pitch blade impeller in down pull mode.

[0133] The perfusion was initiated when the VCD in the bioreactor was $\geq 1.0 \times 10^6$ cells/mL. The perfusion rate was set to 1.0 volume/volume/day. The BioSep was operated in back flush mode with 5 (10) minutes runtime and 10 seconds back flush at a power input of 7 (30) W (numbers in brackets refer to the 50L bioreactor). The perfusate and the bleed were filtered inline and collected in bags over 48 hours at +2 to +8°C. The VCD was controlled by active bleeding using a turbidity probe using glucose consumption as parameter with a target of 2 g/L glucose. Harvest and bleed were filtered inline, the harvest system consisting of a disposable filter and disposable bag was changed every second day.

[0134] To prepare material for the PK analyses described below D'D3 albumin fusion protein harvests were purified by affinity and size exclusion chromatography.. Briefly, the cell-free harvest from the bioreactor was concentrated 30-fold using a TFF system (e.g. Pall Centramate 500 S) with a 30 kD membrane (e.g. Pall Centramate OS030T12). That concentrate was spiked with NaCl and EDTA to a final concentration of 0.75 M NaCl and 5 mM EDTA and loaded overnight on a CaptureSelect Human Albumin column (Life Technologies) which was pre-equilibrated with 20 mM Tris buffer pH 7.4. After washing the column with equilibration buffer D'D3-FP was eluted with elution buffer (20 mM Tris, 2 M MgCl₂, pH 7.4). The eluate was then 10-fold concentrated and dialyzed against 50 mM Tris, 150 mM NaCl, pH 7.4 using Ultra Centrifugal Filters with a 30 kD cut-off (e.g. Amicon. UFC903024). To separate the D'D3-FP dimer from the monomer portion that material was loaded on a Superdex 200 pg column (GE Healthcare Code: 17-1069-01) pre-equilibrated with 50 mM Tris, 150 mM NaCl, pH 7.4 and the peak fractions containing the D'D3-FP dimer were pooled. The area under the curve for the dimer and monomer peak fractions were used to calculate dimer to monomer ratio. Dimer preparations of D'D3-FP were used for the pharmacokinetic experiments in

Examples 1-4.

[0135] His-tagged D'D3 proteins were purified by Ni-chelate affinity and size exclusion chromatography. Briefly, TFF concentrated cell-free bioreactor harvest (see above for details) was loaded on a preequilibrated (20mM sodium phosphate / 500 mM NaCl, pH 7.4) Ni-Sepharose column (HisTrap™, GE Healthcare) over night. After washing the column with 20mM sodium phosphate / 500 mM NaCl / 30 mM Imidazol, pH 7.4 the protein was eluted with 20mM sodium phosphate + 500 mM NaCl + 500 mM Imidazol, pH 7.4. The eluate was then concentrated and dialysed (TBS, pH7.4) using an Amicon Ultra Centrifugal Filter (see above). The final product was then loaded onto a SEC column (see above), the peak fractions containing the dimer were pooled and concentrated to about 7 mg/mL OD₂₈₀₋₃₂₀.

Animals:

[0136] Female Crl:CD (Sprague Dawley) rats in a weight range of 240-300 g were bred at Charles River Laboratories (Sulzfeld, Germany). In house, the animals were kept at standard housing conditions, i.e. at 21-22°C under a 12 h/12 h light-darkness cycle. Animals were fed ad libitum with standard rat diet (Ssniff-Versuchsdäten, Soest, Germany). Tap water was supplied ad libitum. Animal husbandry and study procedures complied with the German Animal Welfare law and European Union regulations. The group size was n=6, divided in 2 cohorts. Thus, n=3 animals per time-point were used.

Laboratory evaluations:

[0137] The test articles were administered i.v. by a single injection into the lateral tail vein at a total volume of 3 mL/kg. D'D3-FP preparations were applied at dose levels from 50 to 10,000 µg/kg based on human albumin values, and co-administered with 200 IU/kg rVIII-SingleChain (rVIII-SingleChain, chromogenic activity) after incubating for approximately 30 minutes at +37°C. Animals receiving only rVIII-SingleChain served as control (Table 4). This led to administered molar ratios of D'D3-FP (calculated as monomer) over rVIII-SingleChain ranging from 7.5 to 1500 as well as a molar ratio of D'D3-FP over endogenous rat VWF (both as monomers to adjust for FVIII binding sites) from 0.54 to 107.1.

[0138] Blood samples were taken retroorbitally under short term anaesthesia at 5 min, 3, 8, 24, 32, 48, 56 and 72 h after intravenous bolus injection using an alternating sampling scheme. The PK profile was taken from two cohorts of rats per group. Blood samples were anticoagulated using sodium citrate (2 parts sodium citrate 3.13% + 8 parts blood), processed to plasma and stored at -20°C for the determination of FVIII antigen and/or albumin.

[0139] D'D3-FP exposure was determined by measurement of the albumin part of the construct using a human albumin ELISA. Accordingly, any amount or dose of D'D3-FP is

indicated as the amount or dose of albumin. Other D'D3-containing polypeptides were detected with a D'D3 specific Elisa. FVIII:Ag plasma levels were detected with the FVIII Asserachrom ELISA testkit from Stago, S.A.S., France.

[0140] D'D3-albumin fusions were measured in plasma samples in an Elisa with a commercial polyclonal antibody preparation. For capture and detection the same antibodies were used, except that the detection antibodies were POD labelled. Briefly, each well of a 96-well plate (Nunc Immuno-Plate Maxisorp, product number 449824) was coated with 100 µL of coating solution (goat anti-human Albumin-IgG, Cat. No. A80-129A, Bethyl Laboratories, diluted to 2 µg/mL in 50 mM coating buffer (Carbonate-Bicarbonate Capsules, Sigma product No.: C-3041)) and incubated at +21°C for 2-20 hours. The coating procedure was followed by 3 wash steps using wash buffer (phosphate buffered saline with tween 20, Sigma product No.: P3563). Subsequent blocking was performed for 1.5 h at +21°C, with blocking solution (Candor Bioscience, Cat.No. 110500) followed by another 3 wash steps. Subsequently 100 µl of each sample were applied to the plate and incubated for 1 h at +37°C. As standards the respective injection solutions of the substances tested were diluted with sample buffer (Low Cross Buffer, Candor Bioscience, Cat. No. 100500) to concentrations from 50 ng/mL to 0.78 ng/mL in 2 step decrements. The citrated plasma samples, taken from the animals were also diluted with sample buffer at least 1:30, sample buffer was also applied as blank. After another four washing steps, 100 µL of detection solution (POD labelled anti human albumin-IgG, Cat. No. A80-129P, Bethyl Laboratories, diluted 1:40000 in blocking solution solution) was applied to each well for 45 min at +37°C. After another four washing steps, 100 µL per well of chromogenic substrate (TMB, Siemens Healthcare product OUVF, OUVG) was applied for 20 min, followed by addition of another 100 µl stop solution (OSFA, Siemens Healthcare) per well. The plates were measured in a plate reader at 450/650nm.

[0141] D'D3-containing polypeptides without albumin were measured in plasma samples with an anti-D'D3 sandwich ELISA with proprietary anti-D'D3 antibodies. Briefly, each well of a 96-well plate (Nunc Immuno-Plate Maxisorp, product number 449824) was coated with 100 µL of coating solution (D'D3 capture antibody diluted to 1 µg/mL in 50 mM coating buffer (Carbonate-Bicarbonate Capsules, Sigma product No.: C-3041)) and incubated at +21°C for 16 hours. The coating procedure was followed by 3 wash steps using wash buffer (Tris buffer saline with tween 20, Sigma product No.: T9039). Blocking was performed for 1.5 h at +21°C, with blocking solution (Candor Bioscience, Cat. No. 110500), followed by another 3 wash steps. Subsequently 100 µl each of each sample were applied to the plate and incubated for 1.5 h at +21°C. As standards the respective injection solutions of the substances tested were diluted with sample buffer (Tris buffer saline with tween 20, Sigma product No.: T9039) to concentrations from 70 ng/mL to 1.1 ng/mL in 2 step decrements. The citrated plasma samples were also diluted with sample buffer at least 1:30, sample buffer was also applied as blank. After another three washing steps, 100 µL of detection solution (POD labelled anti D'D3 detection antibody (proprietary research grade preparation), diluted to 0.2 µg/mL in sample buffer) was applied to each well and incubated for 1 h at +21°C. After another three washing steps, 100µL per well of chromogenic substrate (TMB, Siemens Healthcare product No.: OUVF, OUVG) was applied for 30 min, followed by another 100 µl stop solution (OSFA,

Siemens Healthcare) per well. The plates were measured in a plate reader at 450/650nm.

[0142] Estimation of mean residence time (MRT), clearance (CL) and terminal half-life ($t_{1/2}$) was done by non-compartmental methods.

Table 4: Treatment groups

No.	Treatment	D'D3-FP dose [mg albumin/kg]	FVIII dose [IU FVIII:C/kg]	Molar ratio D'D3-FP *: rVIII-SC	Molar ratio D'D3- FP* over rat VWF**
1	rVIII-SC	-	200	-	-
3	D'D3-FP & rVIII-SC	0.05	200	7.5	0.54
4	D'D3-FP & rVIII-SC	0.10	200	15	1.07
5	D'D3-FP & rVIII-SC	0.20	200	30	2.14
6	D'D3-FP & rVIII-SC	0.50	200	75	5.36
7	D'D3-FP & rVIII-SC	1.00	200	150	10.7
8	D'D3-FP & rVIII-SC	2.00	200	300	21.4
9	D'D3-FP & rVIII-SC	5.00	200	750	53.6
10	D'D3-FP & rVIII-SC	10.00	200	1500	107.1

FVIII:C = chromogenic FVIII activity; rVIII-SC = rVIII-SingleChain
 * D'D3-FP calculated as monomer
 ** D'D3-FP calculated as monomer over endogenous VWF monomer to compare same numbers of FVIII binding sites. For calculation of the endogenous rat VWF the same specific activity as human VWF was assumed, i.e. one U/mL (or 100% of the norm) is assumed to be 10 µg/mL (measured rat plasma concentration 0.946 U/mL)

Results

[0143] D'D3-FP was quantified by determining the albumin component, followed by calculation of the D'D3-FP concentration, and all measured data (up to 72 h p.a.) were well above the detection limit of the assay. The ELISA used specifically detected human albumin. Mean residence time (MRT) and clearance of D'D3-FP were not affected by the given dose in a range from 0.05 to 10 mg/kg i.v. (Fig. 1 and Table 5).

[0144] The exposure of the co-administered FVIII (200 IU/kg chromogenic FVIII activity), quantified as FVIII:Ag via ELISA, was prolonged in the presence of D'D3-FP (Fig. 2 and Table 5). Thus, in the rVIII-SingleChain group, FVIII:Ag reached the detection limit of 117 mIU/mL at 24-32h p.a., while the D'D3-FP co-treated groups had dose-dependently increased plasma concentrations and did not reach the detection limit up to 72h p.a. in the groups co-treated with 5 and 10 mg/kg.

[0145] Already the lowest dose of 0.05 mg/kg i.v. of D'D3-FP increased MRT and terminal half-life and slightly reduced clearance of rVIII-SingleChain. Up to 0.2 mg/kg only minor changes were seen on MRT, terminal half-life and clearance, and from 0.5 to 10 mg/kg a dose-dependent increase was seen for MRT and terminal half-life or decrease for clearance. It is thus concluded that in this experimental setting an about 75-fold excess of D'D3-FP (the 0.5 mg/kg dose) over rVIII-SingleChain is needed to relevantly prolong FVIII half-life.

[0146] It is assumed that at lower doses of D'D3-FP, the endogenous rat VWF competes with D'D3-FP for binding to the co-administered FVIII more relevantly than at higher doses, thereby explaining the dose-dependence of D'D3-FP dose on FVIII PK.

[0147] Calculation of increases of MRT and terminal half-life and decreases of clearance as compared to rVIII-SingleChain given alone is presented in Table 5. Co-administration of rVIII-SingleChain with 0.05-0.2 mg/kg D'D3-FP reduced clearance and prolonged MRT and terminal half-life by less than a factor of 2. Starting from 0.5 mg/kg (molar ratio D'D3-FP over rVIII-SingleChain = 75; molar ratio over endogenous rat VWF = 5.36), a dose-dependent reduction of clearance and increase of MRT and terminal half-life can be seen. Even at a dose of 10 mg/kg D'D3-FP (molar ratio D'D3-FP over rVIII-SingleChain = 1500; molar ratio over endogenous rat VWF = 107.1), a further change over the lower dose was seen, suggesting that the plateau of the effect was not yet reached.

Table 5: Pharmacokinetic parameters of D'D3-FP and FVIII:Ag after co-administration of rVIII-SingleChain and D'D3-FP in rats (non-compartmental analysis) Dose D'D3-FP 0.05 to 10 mg/kg, dose rVIII-SingleChain 200 IU/kg

No.	Treatment*	C _{max} , extrap.	Clearance	MRT	Half-life, terminal
		µg/mL (D'D3-FP ^c) IU/mL (FVIII:Ag)	mL/kg/h	h	h
D'D3-FP					
3	D'D3-FP (0.05) & rVIII-SC	1.27	1.00	56.6	40.2
4	D'D3-FP (0.1) & rVIII-SC	2.33	1.09	59.5	42.4
5	D'D3-FP (0.2) & rVIII-SC	5.15	1.07	55.4	39.7
6	D'D3-FP (0.5) &	9.47	1.11	64.1	45.5

No.	Treatment*	C _{max} , extrap.	Clearance	MRT	Half-life, terminal
		µg/mL (D'D3-FP ^c) IU/mL (FVIII:Ag)	mL/kg/h	h	h
D'D3-FP					
	rVIII-SC				
7	D'D3-FP (1) & rVIII-SC	23.80	1.29	47.7	34.0
8	D'D3-FP (2) & rVIII-SC	36.24	1.22	56.4	39.3
9	D'D3-FP (5) & rVIII-SC	115.17	1.28	46.8	33.8
10	D'D3-FP (10) & rVIII-SC	221.84	1.25	54.0	38.6
FVIII:Ag					
1	rVIII-SC	3.36	8.25	7.4	5.2
3	D'D3-FP (0.05) & rVIII-SC	4.41	4.93 (1.7fold ^a)	10.5 (1.4fold ^b)	7.1 (1.4fold ^b)
4	D'D3-FP (0.1) & rVIII-SC	4.52	4.72 (1.7fold ^a)	10.8 (1.5fold ^b)	7.7 (1.5fold ^b)
5	D'D3-FP (0.2) & rVIII-SC	4.35	4.72 (1.7fold ^a)	11.9 (1.6fold ^b)	8.4 (1.6fold ^b)
6	D'D3-FP (0.5) & rVIII-SC	3.93	3.78 (2.2fold ^a)	15.1 (2.0fold ^b)	10.5 (2.0fold ^b)
7	D'D3-FP (1) & rVIII-SC	4.28	2.83 (2.9fold ^a)	16.7 (2.3fold ^b)	11.0 (2.1fold ^b)
8	D'D3-FP (2) & rVIII-SC	4.62	2.18 (3.8fold ^a)	19.9 (2.7fold ^b)	13.9 (2.7fold ^b)
9	D'D3-FP (5) & rVIII-SC	4.82	1.85 (4.5fold ^a)	25.8 (3.5fold ^b)	17.6 (3.4fold ^b)
10	D'D3-FP (10) & rVIII-SC	4.63	1.68 (4.9fold ^a)	29.6 (4.0fold ^b)	20.3 (3.9fold ^b)
rVIII-SC = rVIII-SingleChain					
^a fold decrease over data from rVIII-SingleChain given alone					
^b fold increase over data from rVIII-SingleChain given alone					
^c determination of albumin in µg/mL					

Example 2: Prolongation of pharmacokinetics of FVIII by co-administration of rVIII-

SingleChain and D'D3-FP at different doses (constant in D'D3-FP : rVIII-SingleChain ratio) in the rat

Material and Methods

[0148] Animals: Female Crl:CD (Sprague Dawley) rats in a weight range of 220-270 g were bred at Charles River Laboratories (Sulzfeld, Germany). In house, the animals were kept at standard housing conditions, i.e. at 21-22°C under a 12 h/12 h light-darkness cycle. Animals were fed ad libitum with standard rat diet (Ssniff-Versuchsdäten, Soest, Germany). Tap water was supplied ad libitum. Animal husbandry and study procedures complied with the German Animal Welfare law and European Union regulations.

[0149] The group size was n=6, divided in 2 cohorts. Thus, n=3 animals per time-point were used.

[0150] Laboratory evaluations: The test articles were administered i.v. by a single injection into the lateral tail vein at a total volume of 4.5 mL/kg. D'D3-FP preparations were applied at dose levels from 1 to 10 mg/kg based on human albumin values, and co-administered with 100 to 1000 IU/kg rVIII-SingleChain (rVIII-SingleChain, chromogenic activity) at constant D'D3-FP to rVIII-SingleChain ratios after incubating for approximately 30 minutes at +37°C. Animals receiving only rVIII-SingleChain served as control (Table 6).

[0151] Blood samples were taken retro-orbitally under short term anaesthesia at 5 min, 3, 8, 24, 32, 48, 56 and 72 h after intravenous bolus injection using an alternating sampling scheme. The PK profile was taken from two cohorts of rats per group. Blood samples were anticoagulated using sodium citrate (2 parts sodium citrate 3.13% + 8 parts blood), processed to plasma and stored at -20°C for the determination of FVIII antigen and/or albumin.

[0152] D'D3-FP exposure was determined by measurement of the albumin part of the construct using a human albumin ELISA. Accordingly, any amount or dose of D'D3-FP is indicated as the amount or dose of albumin. FVIII:Ag plasma levels were detected with the FVIII Asserachrom ELISA testkit from Stago, S.A.S., France.

[0153] Estimation of mean residence time (MRT), clearance (CL) and terminal half-life ($t_{1/2}$) was done by non-compartmental methods.

Table 6: Treatment groups

No	Treatment	D'D3-FP dose [mg albumin/kg]	FVIII dose [IU FVIII:C/kg]	Molar ratio D'D3-FP* over rVIII-SC	Molar ratio D'D3-FP* over rat VWF **
1	rVIII-SC (100)	-	100	-	-
2	D'D3-FP (1) &	1	100	300	10.7

No	Treatment	D'D3-FP dose [mg albumin/kg]	FVIII dose [IU FVIII:C/kg]	Molar ratio D'D3-FP* over rVIII-SC	Molar ratio D'D3-FP* over rat VWF **
	rVIII-SC (100)				
3	rVIII-SC (300)	-	300	-	-
4	D'D3-FP (3) & rVIII-SC (300)	3	300	300	32.1
5	rVIII-SC (1000)	-	1000	-	-
6	D'D3-FP (10) & rVIII-SC (1000)	10	1000	300	107.1

FVIII:C = chromogenic FVIII activity; rVIII-SC = rVIII-SingleChain

* D'D3-FP calculated as monomer

** D'D3-FP calculated as monomer over endogenous VWF monomer to compare same numbers of FVIII binding sites. For calculation of the endogenous rat VWF the same specific activity as human VWF was assumed, i.e. one U/mL (or 100% of the norm) is assumed to be 10 µg/mL (measured rat plasma concentration 0.946 U/mL)

Results

[0154] D'D3-FP was quantified via its albumin component, and all measured data (up to 72 h p.a.) were well above the detection limit of the assay. Mean residence time (MRT) and clearance of D'D3-FP were not affected by the given dose in the range from 1 to 10 mg/kg i.v. (Fig. 3 and Table 7, compare Fig. 1 and Table 5).

[0155] The exposure of the co-administered FVIII (100 to 1000 IU/kg chromogenic FVIII activity), quantified as FVIII:Ag via ELISA, was prolonged in the presence of D'D3-FP (Fig. 4 and Table 7). With the dose-dependency of FVIII exposure, the low dose rVIII-SingleChain group reached the FVIII:Ag detection limit of 117 mIU/mL already at 24h p.a., while higher doses reached the detection limit later, and longest profiles were observed with co-treatment with D'D3-FP, especially both high dose D'D3-FP co-treated groups did not reach the detection limit up to 72h p.a.

[0156] Pharmacokinetic characteristics of FVIII were not affected by the FVIII dose. As stated before, D'D3-FP pharmacokinetics were also not affected by the D'D3-FP dose.

Table 7: Pharmacokinetic parameters of D'D3-FP and FVIII:Ag after co-administration of rVIII-SingleChain and D'D3-FP in rats (non-compartmental analysis) Dose D'D3-FP 1 to 10 mg/kg, dose rVIII-SingleChain 100 to 1000 IU/kg, constant D'D3-FP to rVIII-SingleChain ratio.

Treatment*	C _{max} , extrap.	Clearance	MRT	Half-life, terminal
	µg/mL (D'D3-FP ^c) IU/mL (FVIII:Ag)	mL/kg/h	h	h
D'D3-FP				
D'D3-FP (1 mg/kg) & rVIII-SC (100 IU/kg)	18.0	1.26	67.1	48.0
D'D3-FP (3 mg/kg) & rVIII-SC (300 IU/kg)	67.3	1.22	52.8	37.7
D'D3-FP (10 mg/kg) & rVIII-SC (1000 IU/kg)	234.6	1.09	58.4	42.3
FVIII:Ag				
rVIII-SC (100 IU/kg)	1.50	9.99	6.4	4.5
D'D3-FP (1 mg/kg) & rVIII-SC (100 IU/kg)	2.03	3.42 (2.9fold ^a)	15.7 (2.5fold ^b)	10.8 (2.4fold ^b)
rVIII-SC (300 IU/kg)	5.45	8.78	7.9	5.8
D'D3-FP (3 mg/kg) & rVIII-SC (300 IU/kg)	6.04	2.41 (3.6fold ^a)	23.0 (2.9fold ^b)	15.7 (2.7fold ^b)
rVIII-SC (1000 IU/kg)	19.03	12.42	6.8	5.2
D'D3-FP (10 mg/kg) & rVIII-SC (1000 IU/kg)	24.46	1.64 (7.6fold ^a)	30.2 (4.4fold ^b)	20.5 (3.9fold ^b)
rVIII-SC = rVIII-SingleChain ^a fold decrease over data from rVIII-SingleChain given alone ^b fold increase over data from rVIII-SingleChain given alone ^c determination of albumin in µg/mL				

Example 3: Prolongation of pharmacokinetics of FVIII by co-administration of rVIII-SingleChain (constant dose) and increasing D'D3-FP doses in the rabbit

Material and Methods

[0157] Animals: Female CHB rabbits in a weight range of 2.2-2.8 kg (Bauer, Neuental, Germany) were housed one per cage in wire-steel cages at standard housing conditions, i.e. at 21-23°C and 50% relative humidity under a 12 h/12 h light-darkness cycle. The animals were provided tap water ad libitum and fed rabbit pellets (Deukanin®, Deutsche Tiernahrung Cremer GmbH & Co. KG, Dusseldorf, Germany). Animal husbandry and study procedures complied with the German Animal Welfare law and European Union regulations.

[0158] Laboratory evaluations: The test articles were administered i.v. by a single injection into the lateral ear vein, with a group size of n=3 animals per group. D'D3-FP preparations were applied at a dose level of 0.5 to 3 mg/kg based on human albumin values, and co-administered with 150 IU/kg rVIII-SingleChain (rVIII-SingleChain, chromogenic activity) after incubating for approximately 30 minutes at +37°C. Animals receiving only rVIII-SingleChain served as control (Table 8).

[0159] Blood samples were taken from the ear artery at pre-dose, 5 and 30 min, 1, 2, 4, 6, 8, 24, 32, 48, 72 and 96 h (rVIII-SingleChain) or pre-dose, 5 min, 1, 4, 8, 24, 32, 48, 72, 96, 120, 144 and 168 h (rVIII-SingleChain co-treated with D'D3-FP) after intravenous bolus injection. Blood samples were anticoagulated using sodium citrate (2 parts sodium citrate 3.13% + 8 parts blood), processed to plasma and stored at -20°C for the determination of FVIII antigen and/or D'D3-FP. D'D3-FP exposure was determined by measurement of the albumin part of the construct using a human albumin-specific ELISA. Accordingly, any amount or dose of D'D3-FP is indicated as the amount or dose of albumin. FVIII:Ag plasma levels were detected by ELISA (Asserachrom Stago, S.A.S., France).

[0160] Estimation of mean residence time (MRT), clearance (CL) and terminal half-life ($t_{1/2}$) was done by non-compartmental methods.

Table 8: Treatment groups

Treatment*	D'D3-FP dose [mg albumin/kg]	FVIII dose [IU FVIII:C/kg]	Volume [mL/kg]	Molar ratio D'D3-FP* over rVIII-SC	Molar ratio D'D3-FP* over rabbit VWF**
rVIII-SC	-	150	0.434	-	-
D'D3-FP & rVIII-SC	0.5	150	0.519	100	20.9
D'D3-FP & rVIII-SC	1.5	150	0.688	300	62.8
D'D3-FP & rVIII-SC	3.0	150	0.943	600	125.6

FVIII:C = chromogenic FVIII activity; rVIII-SC = rVIII-SingleChain

* D'D3-FP calculated as monomer

** D'D3-FP calculated as monomer over endogenous VWF monomer to compare same numbers of FVIII binding sites. For calculation of the endogenous rabbit VWF the same specific activity as human VWF was assumed, i.e. one U/mL (or 100% of

the norm) is assumed to be 10 µg/mL (measured rabbit plasma concentration 0.242 U/mL)

Results

[0161] In general, results in rats and rabbits are very comparable. The following observations were made in detail:

D'D3-FP was quantified via its albumin component; and measurements were well above the detection limit of the assay up to the measured 168 h p.a. The increase in dose in the range from 0.5 to 3 mg/kg did not affect MRT and clearance (Fig. 5) or terminal half-life (Table 9).

[0162] The exposure of the co-administered FVIII (150 IU/kg chromogenic FVIII activity), quantified as FVIII:Ag via ELISA, was relevantly prolonged in the presence of D'D3-FP (Fig. 6). In the rabbit, plasma levels of FVIII:Ag could be measured maximally up to 48 h p.a. when rVIII-SingleChain was given alone (detection limit of 117 mIU/mL), and maximally up to the last time-point of 168 h p.a. after co-treatment with 3 mg/kg D'D3-FP. Like in the rat, this prolongation of PK was dose-dependent.

Table 9: Pharmacokinetic parameters of D'D3-FP and FVIII:Ag after co-administration of rVIII-SingleChain and D'D3-FP in rabbits (non-compartmental analysis) Dose D'D3-FP 0.5-3 mg/kg, dose rVIII-SingleChain 150 IU/kg

Treatment*	C _{max} , extrap.	Clearance	MRT	Half-life, terminal
	µg/mL (D'D3-FP ^c) IU/mL (FVIII:Ag)	m L/kg/h	h	h
D'D3-FP				
D'D3-FP (0.5 mg/kg) & rVIII-SC	7.0	0.516	181	126
D'D3-FP (1.5 mg/kg) & rVIII-SC	22.0	0.638	154	107
D'D3-FP (3 mg/kg) & rVIII-SC	48.2	0.493	150	104
FVIII:Ag				
rVIII-SC	2.51	3.71	23.2	17.3
D'D3-FP (0.5 mg/kg) & rVIII-SC	2.59	1.79 (2.1fold ^a)	33.0 (1.4fold ^b)	21.2 (1.2fold ^b)
D'D3-FP (1.5 mg/kg) & rVIII-SC	2.84	1.37 (2.7fold ^a)	47.3 (2.0fold ^b)	32.6 (1.9fold ^b)
D'D3-FP (3 mg/kg) & rVIII-SC	2.38	0.98 (3.8fold ^a)	64.2 (2.8fold ^b)	43.9 (2.5fold ^b)

FVIII:Ag
rVIII-SC = rVIII-SingleChain ^a fold decrease over data from rVIII-SingleChain given alone ^b fold increase over data from rVIII-SingleChain given alone ^c determination of albumin in µg/mL

[0163] Calculation of increases of clearance, MRT and terminal half-life of FVIII:Ag is presented in Table 9. The lowest co-administered dose of 0.5 mg/kg (molar ratio D'D3-FP over rVIII-SingleChain = 100) already relevantly prolong FVIII:Ag exposure. The increase in D'D3-FP dose to 3 mg/kg (molar ratio D'D3-FP over rVIII-SingleChain = 600) led to an at least 2.5fold prolongation of FVIII:Ag MRT and terminal half-life and a 2.5 fold reduction of clearance of FVIII:Ag.

Example 4: Prolongation of pharmacokinetics of FVIII by co-administration of different recombinant FVIII products with D'D3-FP in the rabbit

Material and Methods

[0164] Animals: Female CHB rabbits in a weight range of 2.2-2.8 kg (Bauer, Neuental, Germany) were housed one per cage in wire-steel cages at standard housing conditions, i.e. at 21-23°C and 50% relative humidity under a 12 h/12 h light-darkness cycle. The animals were provided tap water ad libitum and fed rabbit pellets (Deukanin®, Deutsche Tiernahrung Cremer GmbH & Co. KG, Düsseldorf, Germany). Animal husbandry and study procedures complied with the German Animal Welfare law and European Union regulations.

[0165] Laboratory evaluations: The test articles were administered i.v. by a single injection into the lateral ear vein, with a group size of n=3 animals per group. D'D3-FP preparations were applied at a dose level of 1.5 mg/kg based on human albumin values, and co-administered with 150 IU/kg rVIII-SingleChain (rVIII-SingleChain, dosed according to measured chromogenic activity), 150 IU/kg Advate® (recombinant full length FVIII, dosed according to label) or 150 IU/kg NovoEight® (recombinant B-domain-deleted FVIII, dosed according to label) after incubating for approximately 30 minutes at +37°C. Animals receiving only 150 IU/kg rVIII-SingleChain, Advate® or NovoEight® served as control (Table 10).

[0166] Blood samples were taken from the ear artery at pre-dose, 5 and 30 min, 1, 2, 4, 6, 8, 24, 32, 48, 72 and 96 h (recombinant FVIII products alone) or pre-dose, 5 min, 1, 4, 8, 24, 32, 48, 72, 96, 120, 144 and 168 h (recombinant FVIII products co-treated with D'D3-FP) after intravenous bolus injection. Blood samples were anticoagulated using sodium citrate (2 parts sodium citrate 3.13% + 8 parts blood), processed to plasma and stored at -20°C for the

determination of FVIII antigen and/or D'D3-FP. D'D3-FP exposure was determined by measurement of the albumin part of the construct using a human albumin ELISA. Accordingly, any amount or dose of D'D3-FP is indicated as the amount or dose of albumin. FVIII:Ag plasma levels were detected by ELISA (Asserachrom Stago, S.A.S., France).

[0167] Estimation of mean residence time (MRT), clearance (CL) and terminal half-life ($t_{1/2}$) was done by non-compartmental methods.

Table 10: Treatment groups

Treatment*	D'D3-FP dose [mg albumin/kg]	FVIII dose [IU/kg]	Volume [mL/kg]	Molar ratio D'D3-FP* over rFVIII	Molar ratio D'D3-FP* over rabbit VWF**
rVIII-SC	-	150	0.434	-	-
Advate®	-	150	1.920	-	-
NovoEight®	-	150	1.536	-	-
D'D3-FP & rVIII-SC	1.5	150	0.688	300	62.8
D'D3-FP & Advate®	1.5	150	2.174	300	62.8
D'D3-FP & NovoEight®	1.5	150	1.790	300	62.8

rFVIII = recombinant factor VIII; rVIII-SC = rVIII-SingleChain

* D'D3-FP calculated as monomer

** D'D3-FP calculated as monomer over endogenous VWF monomer to compare same numbers of FVIII binding sites. For calculation of the endogenous rabbit VWF the same specific activity as human VWF was assumed, i.e. one U/mL (or 100% of the norm) is assumed to be 10 µg/mL (measured rabbit plasma concentration 0.242 U/mL)

Assumption: same specific activity of all products, thus calculating for identical molar ratios

Results

[0168] In general, results between the different recombinant FVIII products are very comparable. The following observations regarding the prolongation of FVIII in plasma due to co-administration of D'D3-FP were made in detail:

The exposure of the co-administered FVIII (150 IU/kg chromogenic FVIII activity), quantified as FVIII:Ag via ELISA, was relevantly prolonged in the presence of D'D3-FP (Fig. 7). Plasma levels of FVIII:Ag could be measured maximally up to 32 h p.a. (Advate®) or 48 h p.a. (rVIII-SingleChain and NovoEight®) when the recombinant FVIII products were given alone (detection limit of 117 mIU/mL), and maximally up to the last time-point of 96 h p.a. (Advate®) or 120 h p.a. (rVIII-SingleChain and NovoEight®) after co-treatment with D'D3-FP.

Table 11: Pharmacokinetic parameters of D'D3-FP and FVIII:Ag after co-administration of different rFVIII products and D'D3-FP in rabbits (non-compartmental analysis) Dose D'D3-FP 1.5 mg/kg, dose rFVIII 150 IU/kg

Treatment*	Cmax, extrap.	Clearance	MRT	Half-life, terminal
	µg/ml (D-D3-FP ^c) IU/mL (FVIII:Ag)	mL/kg/h	h	h
D'D3-FP				
D'D3-FP & rVIII-SC	22.0	0.638	154	107
D'D3-FP & Advate®	22.2	0.615	126	86
D'D3-FP & NovoEight®	20.2	0.643	137	94
FVIII:Ag				
rVIII-SC	2.51	3.71	23.2	17.3
Advate®	1.52	9.93	17.8	13.4
NovoEight®	2.48	4.42	23.0	18.5
D'D3-FP & rVIII-SC	2.84	1.37 (2.7fold ^a)	47.3 (2.0fold ^b)	32.6 (1.9fold ^b)
D'D3-FP & Advate®	1.34	3.82 (2.6fold ^a)	57.5 (3.2fold ^b)	40.5 (3.0fold ^b)
D'D3-FP & NovoEight®	2.22	1.88 (2.4fold ^a)	44.1 (1.9fold ^b)	31.1 (1.7fold ^b)
rVIII-SC = rVIII-SingleChain				
^a fold decrease over data from each rFVIII product given alone				
^b fold increase over data from each rFVIII product given alone				
^c determination of albumin in µg/mL				

[0169] Calculation of decreases of clearance, as well as increases in MRT and terminal half-life of FVIII:Ag is presented in Table 11. Decreases in clearance were very comparable for all three products, i.e. between 2.4fold to 2.7fold changes. Based on the difference in t_{1/2} and MRT of the three recombinant FVIII products alone, the relative increase in MRT and t_{1/2} showed higher variability and ranged from 3.0-3.2fold for Advate®, which has the shortest pharmacokinetics when given alone to 1.7-2.0 fold for rVIII-SingleChain and NovoEight®, which showed roughly comparable pharmacokinetics when given alone. Taken together and with major sight on relative decreases in clearance, the prolongation of pharmacokinetics of the three recombinant FVIII products was very comparable.

Example 5: Prolongation of pharmacokinetics of FVIII by co-administration of rVIII-

SingleChain with D'D3-His8 as well as D'D3-CTP fusion protein in the rat**Material and Methods**

[0170] Animals: Female Crl:CD (Sprague Dawley) rats in a weight range of about 230-300 g were bred at Charles River Laboratories (Sulzfeld, Germany). In house, the animals were kept at standard housing conditions, i.e. at 21-22°C under a 12 h/12 h light-darkness cycle. Animals were fed ad libitum with standard rat diet (Ssniff-Versuchsdäten, Soest, Germany). Tap water was supplied ad libitum. Animal husbandry and study procedures complied with the German Animal Welfare law and European Union regulations.

[0171] The group size was n=6, divided in 2 cohorts. Thus, n=3 animals per time-point were used.

[0172] Laboratory evaluations: The test articles were administered i.v. by a single injection into the lateral tail vein at a total volume of 3.0 mL/kg. D'D3 comprising proteins were applied at a dose level of 1 mg/kg based on OD values and co-administered with 200 IU/kg rVIII-SingleChain (rVIII-SingleChain, chromogenic activity) after incubating for approximately 30 minutes at +37°C. This leads to the D'D3 comprising protein ratios over rVIII-SingleChain of 78 and over endogenous VWF of 5.6 (Table 12); animals receiving only rVIII-SingleChain served as control.

[0173] Blood samples were taken retro-orbitally under short term anaesthesia at 5 min, 3, 8, 24, 32, 48, 56 and 72 h after intravenous bolus injection using an alternating sampling scheme. The PK profile was taken from two cohorts of rats per group. Blood samples were anticoagulated using sodium citrate (2 parts sodium citrate 3.13% + 8 parts blood), processed to plasma and stored at -20°C for the determination of FVIII antigen and/or D'D3 fusion protein.

[0174] D'D3-His8 and D'D3-CTP fusion protein exposure was determined by an ELISA method using D'D3-FP as a standard (see above). FVIII:Ag plasma levels were detected with the FVIII Asserachrom ELISA testkit from Stago, S.A.S., France.

[0175] Estimation of mean residence time (MRT), clearance (CL) and terminal half-life ($t_{1/2}$) was done by one-compartmental methods.

Table 12: Treatment groups

No	Treatment	D'D3-His8 and D'D3-CTP protein dose [mg/kg]*	FVIII dose [IU FVIII:C/kg]	Molar ratio D'D3-His8 and D'D3-CTP protein** over rVIII-SC	Molar ratio D'D3-His8 and D'D3-CTP protein** over rat VWF***
1	rVIII-SC	-	200	-	-

No	Treatment	D'D3-His8 and D'D3-CTP protein dose [mg/kg]*	FVIII dose [IU FVIII:C/kg]	Molar ratio D'D3-His8 and D'D3-CTP protein** over rVIII-SC	Molar ratio D'D3-His8 and D'D3-CTP protein** over rat VWF***
2	D'D3-His8 & rVIII-SC	1	200	78	5.6
4	D'D3-CTP & rVIII-SC	1	200	78	5.6

FVIII:C = chromogenic FVIII activity; rVIII-SC = rVIII-SingleChain
 * D'D3-His8 and D'D3-CTP protein dose based on OD
 ** D'D3-His8 and D'D3-CTP protein dose corrected by molecular weight
 *** D'D3-His8 and D'D3-CTP calculated as monomer over endogenous VWF monomer to compare same numbers of FVIII binding sites. For calculation of the endogenous rat VWF the same specific activity as human VWF was assumed, i.e. one U/mL (or 100% of the norm) is assumed to be 10 µg/mL (measured rat plasma concentration 0.946 U/mL)

Results

[0176] All measured data (up to 72 h p.a.) were well above the detection limit of the assay. MRT, t_{1/2} and clearance suggest that D'D3-CTP had a longer half-life and mean residence time as well as reduced clearance compared to D'D3-8His but even D'D3-8His showed slightly longer MRT and half-life as well as reduced clearance (Table 13).

[0177] The pharmacokinetic parameters of the co-administered FVIII (200 IU/kg chromogenic FVIII activity), quantified as FVIII:Ag via ELISA, were improved in the presence of both D'D3 proteins (Table 13). The difference in exposure of the D'D3 comprising proteins translates to the difference in FVIII:Ag exposure, i.e., D'D3-CTP led to a longer FVIII:Ag exposure than D'D3-8His.

Table 13: Pharmacokinetic parameters of D'D3 comprising proteins and FVIII:Ag after co-administration of rVIII-SingleChain and D'D3 proteins in rats (non-compartmental analysis). Dose D'D3 comprising protein 1 mg/kg, dose rVIII-SingleChain 200 IU/kg.

Treatment*	C _{max} , extrap.	Clearance	MRT	Half-life, terminal
	µg/mL (D'D3 fusion protein ^c) IU/mL (FVIII:Ag)	mL/kg/h	h	h
D'D3 fusion protein				
D'D3-His8 & rVIII-SC	31.6	6.80	10.3	7.2
D'D3-CTP & rVIII-SC	19.7	2.43	34.9	26.9

Treatment*	C _{max} , extrap.	Clearance	MRT	Half-life, terminal
	µg/mL (D'D3 fusion protein ^c) IU/mL (FVIII:Ag)	mL/kg/h	h	h
D'D3 fusion protein				
FVIII:Ag				
rVIII-SC	3.02	6.45	10.3	7.1
D'D3-His8 & rVIII-SC	3.84	4.61 (1.4fold ^a)	11.3 (1.1fold ^b)	7.8 (1.1fold ^b)
D'D3-CTP & rVIII-SC	3.35	3.58 (1.8fold ^a)	16.7 (1.6fold ^b)	11.6 (1.6fold ^b)
rVIII-SC = rVIII-SingleChain ^a fold decrease over data from rVIII-SingleChain given alone ^b fold increase over data from rVIII-SingleChain given alone ^c determination based on OD				

Conclusion from PK study results

[0178] These studies demonstrated that co-administration of D'D3-FP with FVIII products prolonged FVIII:Ag plasma MRT and half-life and decreased FVIII:Ag clearance independent of whether the FVIII molecule does contain the B domain is B-domain deleted or is present as a single- or two-chain product. This prolongation solely was dependent on the ratio of D'D3-FP over co-administered FVIII as well as over endogenous VWF.

[0179] Effects in the rat tend to be stronger than in the rabbit, when the increase in terminal half-life and MRT or reduction of clearance is depicted over the molar ratio of D'D3-FP over administered rVIII-Single-Chain (Fig. 8) as well as over endogenous VWF (Fig. 9). Regarding the molar ratio over rVIII-SingleChain, in the rat ≤30-fold ratios lead to smaller than twofold changes, while more favourable effects can be achieved at >50fold ratios, and equal to or more than 2.7 fold improvement can be achieved starting at about 300 fold ratios. Even higher ratios above 750 or preferably 1000 or more preferably 1250 or even more preferably 1500 lead to a still higher improvement of terminal half-life and MRT or reduction of clearance.

[0180] Regarding ratios over endogenous VWF, species-specific differences are larger, suggesting that a 2 fold improvement may-be achieved in the rat (and in humans assuming similar endogenous VWF levels as in rats) at about ratios ≥5 and in the rabbit at about >60. 3fold improvements were achieved in the rat at ratios of about >50.

[0181] Surprisingly it could be shown that D'D3-His8 having no half-life extending moiety also prolonged FVIII pharmacokinetic parameters slightly when administered at a ratio of 78 over co-administered FVIII and/or a ratio of 5.6 over endogenous VWF. Even better prolongation of FVIII half-life and mean residence time and reduced clearance was obtained at these ratios with a D'D3-CTP fusion protein which comprises the C-terminal peptide of human chorionic gonadotropin- β subunit as a half-life extending moiety instead of the albumin comprised in D'D3-FP.

[0182] Since in the rat and the rabbit (in contrast to human haemophilia A patients) human administered and endogenous FVIII compete with D'D3-FP and VWF binding sites, it may be expected that the effect on FVIII in the human haemophilia A patient is even stronger.

Example 6: Determination of FVIII affinity to VWF fragment dimer and monomer

[0183] A VWF fragment (1-1242) albumin fusion (D'D3-FP) was expressed in a bioreactor; after purification as described above and isolation of monomer and dimer, the affinity of FVIII to these preparations was assessed through surface plasmon resonance via a Biacore instrument (T200, GE Healthcare).

[0184] An anti-albumin antibody (MA1-20124, Thermo Scientific) was covalently coupled via its N-terminus to an activated CM 3 chip by NHS (N-Hydroxysuccinimide) and EDC (Ethanolamine hydrochloride), both contained in the amine coupling kit (BR1000-50) from GE Healthcare. For immobilization 3 $\mu\text{g/mL}$ of the antibody were diluted in sodium acetate buffer (10 mM, pH 5.0) and the antibody solution was flown over the chip for 7 min. at a flow rate of 10 $\mu\text{L/min}$. After the immobilization procedure non-coupled dextran filaments were saturated by flowing ethanolamine solution (1 M, pH 8.3) over the chip for 5 min (at a flow rate of 10 $\mu\text{L/min}$). The aim of saturating the flow cell was to minimize unspecific binding of the analytes to the chip. A reference flow cell was set up by saturating an empty flow cell with ethanolamine by using the same procedure as above.

[0185] Dimeric and monomeric D'D3-FP proteins, respectively, were immobilized to the covalently coupled anti-albumin antibody by a flow of the D'D3-FP proteins (5 $\mu\text{g/mL}$) over the chip for 3 min (flow rate of 10 $\mu\text{L/min}$). The captured mass of dimeric D'D3-FP was 335 RU and for monomeric D'D3-FP 147 RU, assuming one binding site both on the monomer and on the dimer D'D3-FP for FVIII.

[0186] To create binding curves for FVIII, each D'D3-FP protein preparation was diluted in running buffer (HBS-P+: 0.1 M HEPES, 1.5 M NaCl and 0.5% v/v Surfactant P20, pH 7.4; product code BR100671, GE Healthcare) to concentrations of 0.25 nM, 0.5 nM, 1 nM, 3nM and 4 nM. By performing a single cycle kinetic, samples with ascending concentrations of each dilution were flown over the chip for 2 min (flow rate 30 $\mu\text{L/min}$.), followed by a dissociation time of 10 min. with running buffer HBS-P+. All measurements were performed twice. The temperature for the measuring procedure was adjusted to +25°C.

[0187] Binding parameters were calculated using BiaEvaluation Software. The curve fitting methods were based on Langmuir equations. The input data for calculations were the molar mass of the analyte FVIII (rVIII-SingleChain), other parameters like max. RU and slopes were automatically extracted out of the fitted association and dissociation curves. The outputs of BiaEvaluation Software are the association rate constants and the dissociation rate constants, from which the affinity constants were calculated. The results are shown in Table 12.

Table 12: FVIII affinity data for D'D3-FP dimer and monomer

D'D3-FP preparation	ka [1/Ms]	kd [1/s]	KD [M]
D'D3-FP Dimer	2,33E+07	1,37E-03	5,90E-11
D'D3-FP Monomer	4,41 E+07	3,96E-03	8,99E-11

[0188] The association rate constant was slightly increased for rVIII-SingleChain to the monomeric D'D3-FP, while the dissociation rate constant of rVIII-SingleChain to D'D3-FP dimer was three times slower than to the monomer. The quotient of the dissociation rate constant and the association rate constant indicates the affinity of rVIII-SingleChain to D'D3-FP. The dimeric D'D3-FP hence shows an increased affinity to FVIII compared to the D'D3-FP monomer.

SEQUENCE LISTING

[0189]

<110> CSL Behring Recombinant Facility AG

<120> Truncated von Willebrand factor polypeptides for treating hemophilia

<130> A222

<150> EP 15168930.4

<151> 2015-05-22

<150> EP 16163239.3

<151> 2016-03-31

<160> 8

<170> PatentIn version 3.5

<210> 1

<211> 5616

<212> DNA

<213> Artificial Sequence

<220>

<223> DNA encoding construct VWF fragment - G/S linker - albumin

<220>

<221> misc_feature

<222> (1)..(6)

<223> EcoRI restriction enzyme cleavage site

<220>

<221> misc_feature

<222> (32)..(3757)

<223> coding sequence for VWF amino acids 1 to 1242

<220>

<221> misc_feature

<222> (3758)..(3850)

<223> coding sequence for glycine/serine linker

<220>

<221> misc_feature

<222> (3851)..(5608)

<223> coding sequence for human albumin

<220>

<221> misc_feature

<222> (5609)..(5616)

<223> NotI restriction enzyme cleavage site

<400> 1

gaattccgc agccctcatt tgcaggggaa gatgattcct gccagatttg ccggggtgct	60
gcttgctctg gccctcattt tgccagggaac ctttgtgca gaaggaactc gcggcaggtc	120
atccacggcc cgatgcagcc ttctcggaag tgacttcgtc aacacctttg atgggagcat	180
gtacagcttt gcgggatact gcagttacct cctggcaggg ggctgccaga aacgtcctt	240
ctcgattatt ggggacttcc agaattggcaa gagagtgagc ctctccgtgt atctgggga	300
atttttgac atccatttgt ttgtcaatgg taccgtgaca cagggggacc aaagagtctc	360
catgccctat gctccaaag ggctgtatct agaaactgag gctgggtact acaagctgtc	420
cggtgaggcc tatggctttg tggccaggat cgatggcagc ggcaacttcc aagtctgtct	480
gtcagacaga tacttcaaca agacctgcgg gctgtgtggc aactttaaca tctttgctga	540
agatgacttt atgaccaag aagggaacct gacctggac ccttatgact ttgccaactc	600
atgggctctg agcagtggag aacagtgggt tgaacgggca tctctccca gcagctcatg	660

caacatctcc tctggggaaa tgcagaaggg cctgtgggag cagtgccagc ttctgaagag 720
 cacctcgggtg ttgtcccgt gccaccctct ggtggacccc gagcctttg tggccctgtg 780
 tgagaagact ttgtgtgagt gtgtggggg gctggagtg cctgccctg ccctcctgga 840
 gtacgcccgg acctgtccc aggagggaaat ggtgtgtac ggctggaccg accacagcgc 900
 gtgcagccca gtgtgccctg ctggtatgga gtataggcag tgtgtgtccc ctgcccag 960
 gacctgccag agcctgcaca tcaatgaaat gtgtcaggag cgatgcgtg atggctgcag 1020
 ctgccctgag ggacagctcc tggatgaagg cctctcgtg gagagcaccg agtgtccctg 1080
 cgtgcattcc ggaaagcgt accctcccg cacctccctc tctcgagact gcaacacctg 1140
 cattgccga aacagccagt ggalctgcag caatgaagaa tgtccagggg agtgcctgt 1200
 cacaggtcaa tcacactca agagcttga caacagatac ttacactca gtgggatctg 1260
 ccagtacctg ctggccggg attgccagga ccactcctc tccattgtca ttgagactgt 1320
 ccagtgtgt gatgaccgc acgtgtgtg caccgctcc gtcaccgtc ggctgcctg 1380
 cctgcacaac agccttgtga aactgaagca tggggcagga gttccatgg atggccagga 1440
 cgtccagctc cccctcctga aaggtagct ccgatccag catacagtga cggcctcgt 1500
 gcgcctcagc tacggggagg acctgcagat ggactgggat ggccgcggga ggctgtgtgt 1560
 gaagctgtcc cccgtctatg ccgggaagac ctgcggcctg tgtgggaatt acaatggcaa 1620
 ccagggcgac gacttcctta cccctctgg gctggcggag ccccggtgg aggactcgg 1680
 gaacgcctgg aagctgcacg gggactgcca ggacctgcag aagcagcaca gcgatccctg 1740
 cgcctcaac ccgcgcatga ccaggtctc cgaggaggcg tgcgcgtcc tgacgtccc 1800
 cacattcgag gcctgccatc gtgccgtcag cccgtgccc tacctgcgga actgcgcta 1860
 cgacgtgtgc tctgtctgg acggccgcga gtgcctgtgc ggcgcctgg ccagctatgc 1920
 cgcggcctgc gcggggagag gcgtgcgct cgcgtggcg gagccaggcc gctgtgagct 1980
 gaactgccg aaaggccag tgaacctga gtgcgggacc cctgcaacc tgacctgccg 2040
 ctctctct taccggatg aggaatgcaa tgaggcctgc ctggagggt gctctgccc 2100
 ccagggtc tacatggatg agagggggga ctgcgtgcc aaggccagt gccctgta 2160
 ctatgacgt gagatctcc agccagaaga catctctca gaccatcaca ccatgtgcta 2220
 ctgtaggat ggcttcatgc actgtacat gattggagtc ccggaagct tgcgtcctga 2280
 cgtgtcctc agcagtcctc tctctatcg cagcaaaagg agcctatct gtcggcccc 2340
 catggtcaag ctggtgtgc ccgtgacaa cctgcgggt gaagggtcg agtgtacaa 2400
 aacgtgccag aactatgacc tggagtgcag gagcatggg tgtgtctg gctgcctctg 2460

cccccgggc atggtccggc atgagaacag atgtgtggcc ctggaaaggt gtcctgctt 2520
 ccatcagggc aaggagtatg cccctggaga aacagtgaag attggctgca acacttgtgt 2580
 ctgtcgggac cggaagtga actgcacaga ccatgttgt gatgccacgt gctccacgat 2640
 cggcatggcc cactacctca ccttcgacgg gctcaaatac ctgttccccg gggagtgcc 2700
 gtacgttctg gtgcaggatt actgcggcag taacctggg accttcgga tcctagtggg 2760
 gaataagggg tgcagccacc cctcagtga atgcaagaaa cgggtcacca tcctggtgga 2820
 gggaggagag attgagctgt ttgacgggga ggtgaatgtg aagaggccca tgaaggatga 2880
 gactcacttt gaggtggtgg agtctggccg gtacatcatt ctgctgctgg gcaaagccct 2940
 ctccgtggtc tgggaccgcc acctgagcat ctccgtggtc ctgaagcaga cataccagga 3000
 gaaagtgtgt ggcctgtgtg ggaatttga tggcatccag aacaatgacc tcaccagcag 3060
 caacctcaa gtggaggaag acctgtgga ctttgggaac tcctggaaag tgagctcgca 3120
 gtgtgctgac accagaaaag tgccctgga ctcatccct gccacctgcc ataacaacat 3180
 catgaagcag acgatggtg attcctctg tagaatcctt accagtgaag tcctccagga 3240
 ctgcaacaag ctggtggacc ccgagccata tctggatgtc tgcatttacg acacctgtc 3300
 ctgtgagtcc attggggact gcgcctgctt ctgcgacacc attgtgcct atgccacgt 3360
 gtgtgcccag catggcaagg tggtagctg gaggacggcc acattgtgcc cccagagctg 3420
 cgaggagagg aatctccggg agaacgggta tgagtgtgag tggcgctata acagctgtgc 3480
 acctgcctgt caagtcacgt gtcagcacc tgagccactg gcctgccctg tgcagtgtgt 3540
 ggagggctgc catgccact gccctccagg gaaaatcctg gatgagcttt tcagacctg 3600
 cgttgacct gaagactgtc cagtgtgtga ggtggctggc cggcgtttg cctcaggaaa 3660
 gaaagtcacc ttgaatcca gtgacctga gcactgccag atttgccact gtgatgtgt 3720
 caacctcacc tgtgaagcct gccaggagcc gggaggctcg agcgggggat ctggcgggtc 3780
 tggaggctct ggagggtcgg gaggtctg aggtctggg ggalctggcg ggtctggagg 3840
 gtcgggatcc gatgcacaca agagttaggt tgctcatcgg tttaaagatt tgggagaaga 3900
 aaatttcaa gccttggtgt tgattgcctt tgctcagtat cttcagcagt gtccattga 3960
 agatcatgta aaattagtga atgaagtaac tgaattgca aaaacatgtg ttgctgatga 4020
 gtcagctgaa aatttgaca aatcactca taccctttt ggagacaaat tatgcacagt 4080
 tgcaactctt cgtgaaacct atggtgaaat ggctgactgc tgtgcaaac aagaacctga 4140
 gagaaatgaa tgctcttgc aacacaaaga tgacaacca aacctcccc gattggtgag 4200
 accagaggtt gatctatct gactcctt tcatgcaat caagagacat tttaaaaa 4260

atacttatat gaaattgcc a gaagacatcc ttacttttat gccccggaac tccttttctt 4320
 tgctaaaagg tataaagctg cttttacaga atgttgccaa gctgctgata aagctgcctg 4380
 cctgttgcca aagctcgatg aacttcggga tgaagggaag gcttcgtctg ccaaacagag 4440
 actcaagtg gccagctcc aaaaatttg agaaagagct ttcaaagcat gggcagtagc 4500
 tcgcctgagc cagagatttc ccaaagctga gtttcagaa gttccaagt tagtgacaga 4560
 tcttaccaaa gtccacacgg aatgctgcca tggagatctg ctggaatgtg ctgatgacag 4620
 ggccgacctt gccaaagtata tctgtgaaaa tcaagattcg atctccagta aactgaagga 4680
 atgctgtgaa aaacctctgt tggaaaaatc ccactgcatt gccgaagtgg aaaatgatga 4740
 gatgcctgct gacttcctt cattagctgc tgattttgtt gaaagtaagg atgtttgcaa 4800
 aaactatgct gaggcaaagg atgtcttctt gggcatgtt ttgatgaat atgcaagaag 4860
 gcatcctgat tactctgtcg tgctgctgt gagacttgcc aagacatatg aaaccactct 4920
 agagaagtgc tgtgccgtg cagatcctca tgaatgctat gccaaagtgt tcgatgaatt 4980
 taaacctctt gtggaagagc ctcaagaatt aatcaacaa aattgtgagc ttttgagca 5040
 gcttgagag tacaaattcc agaatgcgt attagttcgt tacaccaaga aagtacccca 5100
 agtgtcaact ccaactcttg tagaggctc aagaaacctt gaaaaagtgg gcagcaaagt 5160
 ttgtaaocat cctgaagcaa aaagaatgcc ctgtgcagaa gactatctat ccgtggctct 5220
 gaaccagtta tgtgtgttc atgagaaaac gccagtaagt gacagagtca ccaaagtctg 5280
 cacagaatcc ttgggaaca ggcgaccatg ctttcagct ctggaagtgc atgaaacata 5340
 cgttccaaa gagtttaatg ctgaaacatt caccttccat gcagatatat gcacacttc 5400
 tgagaaggag agacaaatca agaaacaaac tgcactgtt gagctcgtga aacacaagcc 5460
 caaggcaaca aaagagcaac tgaaagctgt tatggatgat ttgcagctt ttgtagagaa 5520
 gtgctgcaag gctgacgata aggagacctg cttgcccag gagggtaaaa aactgttgc 5580
 tgcaagtcaa gctgccttag gcttataggc ggccgc 5616

<210> 2

<211> 1095

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide encoded by SEQ ID NO:1

<220>

<221> MISC_FEATURE

<222> (1)..(479)

<223> VWF D'D3 region (VWF amino acids 764 - 1242)

<220>

<221> MISC_FEATURE

<222> (480)..(510)

<223> glycine/serine linker

<220>

<221> MISC_FEATURE

<222> (511)..(1095)

<223> human albumin

<400> 2

Ser Leu Ser Cys Arg Pro Pro Met Val Lys Leu Val Cys Pro Ala Asp
1 5 10 15

Asn Leu Arg Ala Glu Gly Leu Glu Cys Thr Lys Thr Cys Gln Asn Tyr
20 25 30

Asp Leu Glu Cys Met Ser Met Gly Cys Val Ser Gly Cys Leu Cys Pro
35 40 45

Pro Gly Met Val Arg His Glu Asn Arg Cys Val Ala Leu Glu Arg Cys
50 55 60

Pro Cys Phe His Gln Gly Lys Glu Tyr Ala Pro Gly Glu Thr Val Lys
65 70 75 80

Ile Gly Cys Asn Thr Cys Val Cys Arg Asp Arg Lys Trp Asn Cys Thr
85 90 95

Asp His Val Cys Asp Ala Thr Cys Ser Thr Ile Gly Met Ala His Tyr

100 105 110

Leu Thr Phe Asp Gly Leu Lys Tyr Leu Phe Pro Gly Glu Cys Gln Tyr
115 120 125

Val Leu Val Gln Asp Tyr Cys Gly Ser Asn Pro Gly Thr Phe Arg Ile
130 135 140

Leu Val Gly Asn Lys Gly Cys Ser His Pro Ser Val Lys Cys Lys Lys
145 150 155 160

Arg Val Thr Ile Leu Val Glu Gly Gly Glu Ile Glu Leu Phe Asp Gly
 165 170 175

Glu Val Asn Val Lys Arg Pro Met Lys Asp Glu Thr His Phe Glu Val
 180 185 190

Val Glu Ser Gly Arg Tyr Ile Ile Leu Leu Leu Gly Lys Ala Leu Ser
 195 200 205

Val Val Trp Asp Arg His Leu Ser Ile Ser Val Val Leu Lys Gln Thr
 210 215 220

Tyr Gln Glu Lys Val Cys Gly Leu Cys Gly Asn Phe Asp Gly Ile Gln
 225 230 235 240

Asn Asn Asp Leu Thr Ser Ser Asn Leu Gln Val Glu Glu Asp Pro Val
 245 250 255

Asp Phe Gly Asn Ser Trp Lys Val Ser Ser Gln Cys Ala Asp Thr Arg
 260 265 270

Lys Val Pro Leu Asp Ser Ser Pro Ala Thr Cys His Asn Asn Ile Met
 275 280 285

Lys Gln Thr Met Val Asp Ser Ser Cys Arg Ile Leu Thr Ser Asp Val
 290 295 300

Phe Gln Asp Cys Asn Lys Leu Val Asp Pro Glu Pro Tyr Leu Asp Val
 305 310 315 320

Cys Ile Tyr Asp Thr Cys Ser Cys Glu Ser Ile Gly Asp Cys Ala Cys
 325 330 335

Phe Cys Asp Thr Ile Ala Ala Tyr Ala His Val Cys Ala Gln His Gly
 340 345 350

Lys Val Val Thr Trp Arg Thr Ala Thr Leu Cys Pro Gln Ser Cys Glu
 355 360 365

Glu Arg Asn Leu Arg Glu Asn Gly Tyr Glu Cys Glu Trp Arg Tyr Asn
 370 375 380

Ser Cys Ala Pro Ala Cys Gln Val Thr Cys Gln His Pro Glu Pro Leu
 385 390 395 400

Ala Cys Pro Val Gln Cys Val Glu Gly Cys His Ala His Cys Pro Pro
 405 410 415

Gly Lys Ile Leu Asp Glu Leu Leu Gln Thr Cys Val Asp Pro Glu Asp
 420 425 430

Cys Pro Val Cys Glu Val Ala Gly Arg Arg Phe Ala Ser Gly Lys Lys
 435 440 445

Val Thr Leu Asn Pro Ser Asp Pro Glu His Cys Gln Ile Cys His Cys
 450 455 460

Asp Val Val Asn Leu Thr Cys Glu Ala Cys Gln Glu Pro Gly Gly Ser
 465 470 475 480

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
 485 490 495

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Ser Asp Ala
 500 505 510

His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn
 515 520 525

Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys
 530 535 540

Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala
 545 550 555 560

Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu
 565 570 575

His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu
 580 585 590

Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg
 595 600 605

Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg
 610 615 620

Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn
 625 630 635 640

Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His
645 650 655

Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys
660 665 670

Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu
675 680 685

Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala
690 695 700

Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala
705 710 715 720

Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala
725 730 735

Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His
740 745 750

Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala
755 760 765

Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys
770 775 780

Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile
785 790 795 800

Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala
805 810 815

Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala
820 825 830

Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His
835 840 845

Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu
850 855 860

Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr
865 870 875 880

Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln Asp

Ala Lys Val Thr Asp Glu Thr Lys Thr Leu Val Glu Glu Thr Gln Asn

885

890

895

Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys

900

905

910

Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val

915

920

925

Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly

930

935

940

Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu

945

950

955

960

Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu Lys

965

970

975

Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val

980

985

990

Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val

995

1000

1005

Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile

1010

1015

1020

Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala

1025

1030

1035

Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln

1040

1045

1050

Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys

1055

1060

1065

Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys

1070

1075

1080

Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu

1085

1090

1095

<210> 3

<211> 8442

<212> DNA

<213> Homo Sapiens

<400> 3

atgattcctg ccagatttgc cgggggtgctg ctgtctctgg cccatctttt gccagggacc 60
 ctttgtgcag aaggaactcg cggcagggtca tccacggccc gatgcagcct ttcggaagt 120
 gacttcgtca acacctttga tgggagcatg tacagctttg cgggatactg cagttacctc 180
 ctggcagggg gctgccagaa acgctccttc tcgattattg gggacttcca gaatggcaag 240
 agagtgcgcc tctccgtgta tcttggggaa tttttgaca tccatttgtt tgtcaatggt 300
 accgtgacac aggggggacca aagagtctcc atgccctatg cctccaaagg gctgtatcta 360
 gaaactgagg ctgggtacta caagctgtcc ggtgaggcct atggccttgt ggccaggatc 420
 gatggcagcg gcaacttca agtctctgctg tcagacagat acttcaacaa gacctgcggg 480
 ctgtgtggca acttaacat ctttctgaa gatgacttta tgaccaaga agggaccttg 540
 acctcggacc ctatgactt tgccaactca tgggctctga gcagtggaga acagtgtgtg 600
 gaacgggcat ctctccag cagctcatgc aacatctct ctggggaaat gcagaagggc 660
 ctgtgggagc agtgccagct tctgaagagc acctcgggtg ttgcccgctg ccaccctctg 720
 gtggaccccg agccttttgt ggccctgtgt gagaagactt tgtgtgagtg tgctgggggg 780
 ctggagtgcg cctgccctgc cctctggag tacgcccga cctgtgccca ggagggaatg 840
 gtgtgtacg gctggaccga ccacagcgcg tgcagcccag tgtgccctgc tggatggag 900
 tataggcagt gtgtgtcccc ttgcgccagg acctgccaga gctgcacat caatgaaatg 960
 tgtcaggagc gatgcgtgga tggctgcagc tgccctgagg gacagctcct ggaatgaaggc 1020
 ctctcgttg agagcaccga gtgtccctgc gtgcattccg gaaagcgcta ccctcccggc 1080
 acctccctct ctgagactg caacacctgc atttgccgaa acagccagtg gatctgcagc 1140
 aatgaagaat gtccagggga gtgcctgtc acaggtcaat cacactcaa gagctttgac 1200
 aacagatact tcacctcag tgggatctgc cagtacctgc tggcccgga ttgccaggac 1260
 cactcctct ccatgtcat tgagactgtc cagtgtgctg atgaccgga cgctgtgtgc 1320
 acccgctccg tcaccgtccg gctgcctggc ctgcacaaca gccttgtgaa actgaagcat 1380
 ggggcaggag ttgccatgga tggccaggac gtccagctcc ccctctgaa aggtgacctc 1440
 cgcattccagc atacagtac ggctccgtg cgctcagct acggggagga cctgcagatg 1500
 gactgggatg gccgcgggag gctgtgtgtg aagctgtccc ccgtctatgc cgggaagacc 1560
 tgcggcctgt gtgggaatta caatggcaac cagggcgacg acttcttac ccctctggg 1620
 ctggcggagc cccgggtgga ggactcggg aacgcctgga agctgcacgg ggactgccag 1680
 aaactacaga agagagagag caactactac aaactacaga agagagagag caactatata 1740

gaccctgcaga agcagcaccag cgaacccctgc gccctcaacc cgcgcctgac caggtctcc 1740
 gaggaggcgt gcgcggctct gacgtccccc acattcgagg cctgccatcg tgccgtcagc 1800
 ccgtgcctt accctgcgaa ctgccgtac gacgtgtgt cctgctcgga cggccgcgag 1860
 tgctgtgctg gcgcccctggc cagctatgcc gcggcctgcg cggggagagg cgtgcgcgtc 1920
 gcgtggcgcg agccaggccg ctgtgagctg aactgcccga aaggccaggt gtacctgcag 1980
 tgcgggaccc cctgcaacct gacctgccgc tctctctctt acccgatga ggaatgcaat 2040
 gaggcctgcc tggagggctg cttctgcccc ccagggtctt acatggatga gaggggggac 2100
 tgctgcccc aggccagtg cccctgttac tatgacggtg agatcttcca gccagaagac 2160
 atcttctcag accatcacac catgtgtctac tgtgaggatg gcttcatgca ctgtaccatg 2220
 agtggagtcc ccggaagctt gctgcctgac gctgtctca gcagtcccct gtctcatgc 2280
 agcaaaagga gcctatctg tcggccccc atggtcaagc tgggtgttcc cgctgacaac 2340
 ctgcgggctg aagggtctga gtgtacaaa acgtgccaga actatgacct ggagtgcag 2400
 agcatgggct gtgtctctgg ctgcctctgc cccccggga tggccggca tgagaacaga 2460
 tgtgtggccc tggaaagggt tccctgttc catcagggca aggagtatgc ccctggagaa 2520
 acagtgaaga ttggctgcaa cacttgtgtc tgcgggacc ggaagtggaa ctgcacagac 2580
 catgtgtgtg atgccacgtg ctccacgac gccatggccc actacctcac ctgcacggg 2640
 ctcaaatacc tgtccccgg ggagtgccag tacgttctgg tgcaggatta ctgcggcagt 2700
 aacctggga ctttggat cctagtggg aataagggt gcagccacc ctcatgaaa 2760
 tgcaagaaac gggtcacat cctggtggag ggaggagaga ttgagctgtt tgacggggag 2820
 gtgaatgtga agaggcccat gaaggatgag actcacttg agtggtgga gtctggccgg 2880
 tacatcattc tctgtctgg caaagccctc tccgtgtct gggaccgcca cctgagcatc 2940
 tccgtgttcc tgaagcagac ataccaggag aaagtgtgt gcctgtgtgg gaatttgat 3000
 ggcatccaga acaatgacct caccagcagc aacctcaag tggaggaaga ccctgtggac 3060
 ttgggaact cctggaaagt gagctgcag tgtgtgaca ccagaaaagt gcctctggac 3120
 tcatcccctg ccacctgcca taacaacatc atgaagcaga cgatggtgga ttctctctgt 3180
 agaatccta ccagtacgt ctccaggac tgcaacaagc tggtggaacc cgagccatat 3240
 ctggaagtct gcattacga cacctgtcc tgtgagtcca ttggggactg cgcctgttc 3300
 tgcgacacca ttgtgccta tgcacagtg tgtcccagc atggcaagg ggtgacctg 3360
 aggacggcca cattgtccc ccagagctgc gaggagagga atctccggga gaacgggtat 3420
 gagtgtgagt ggcgtataa cagctgtgca cctgcctgtc aagtcacgt tcagaccct 3480

gagccactgg cctgccctgt gcagtgtgtg gagggctgcc atgccactg ccctccaggg 3540
 aaaatcctgg atgagctttt gcagacctgc gttgacctg aagactgtcc agtgtgtgag 3600
 gtggctggcc ggcgttttgc ctacaggaaag aaagtcacct tgaatcccag tgacctgag 3660
 cactgccaga ttgccactg tgatgtgtgc aacctcacct gtgaagcctg ccaggagccg 3720
 ggaggcctgg tggtgctcc cacagatgcc ccggtgagcc ccaccactct gtatgtggag 3780
 gacatctcgg aaccgccgtt gcacgatttc tactgcagca ggctactgga cctggcttc 3840
 ctgtggatg gctcctccag gctgtccgag gctgagtttg aagtgtgaa ggcctttgtg 3900
 gtggacatga tggagcggct gcgcactcc cagaagtggg tccgcgtggc cgtggtggag 3960
 taccacgacg gctccacgc ctacatcggg ctcaaggacc ggaagcgacc gtcagagctg 4020
 cggcgcattg ccagccaggt gaagtatcg ggcagccagg tggcctccac cagcgaggtc 4080
 ttgaaataca cactgttoca aatcttcagc aagatcgacc gccctgaagc ctcccgcatc 4140
 gccctgctcc tgatggccag ccaggagccc caacggatgt cccggaactt tgtccgctac 4200
 gtccagggcc tgaagaagaa gaaggtcatt gtgatcccg tgggcattgg gccccatgcc 4260
 aacctcaagc agatccgct catcgagaag caggccccctg agaacaaggc ctctgtgctg 4320
 agcagtgtgg atgagctgga gcagcaaagg gacgagatcg ttagctacct ctgtgacctt 4380
 gccctgaag cccctctcc tactctgcc ccccatgga cacaagtcac tgtgggcccg 4440
 gggctcttg gggtttcgac cctggggccc aagaggaact ccatggttct ggatgtggcg 4500
 ttctctctgg aaggatcga caaaattggt gaagccgact tcaacaggag caaggagtc 4560
 atggaggagg tgattcagcg gatggatgtg ggccaggaca gcatccacgt cacggtgctg 4620
 cagtactcct acatggtgac cgtggagtac cccttcagcg aggcacagtc caaaggggac 4680
 atctgcagc gggtcgaga gatccgctac cagggcggca acaggacca cactgggctg 4740
 gccctgcgtt acctcttga ccacagcttc ttggtcagcc agggtgaccg ggagcaggcg 4800
 cccaacctgg tctacatggt caccggaaat cctgcctctg atgagatcaa gaggtgcct 4860
 ggagacatcc aggtggtgcc cattggagtg ggcctaatg ccaacgtgca ggagctggag 4920
 aggattggct ggcccaatgc ccctalcct atccaggact ttgagacgct cccccgagag 4980
 gctctgacc tgggtctgca gaggtgctgc tccggagagg ggctgcagat cccaccctc 5040
 tcccctgcac ctgactgcag ccagccccctg gacgtgatcc ttctctgga tggctctcc 5100
 agtttcccag cttctatatt tgatgaaatg aagagtttcg ccaaggcttt catttcaaaa 5160
 gccaatatg ggctctgtct cactcaggtg tcagtgtctc agtatggaag catcaccacc 5220
 attgacgtgc catggaacgt ggtccggag aaagcccatt tgctgagcct tgtggacgtc 5280

atgcagcggg agggaggccc cagccaaatc ggggatgcct tgggctttgc tgtgcgatac 5340
 ttgacttcag aaatgcatgg ggcgcgcccc ggagcctcaa aggcggtggt catcctggtc 5400
 acggacgtct ctgtggattc agtggatgca gcagctgatg ccgccaggtc caacagagtg 5460
 acagtgttcc ctattggaat tggagatgcg tacgatgcag ccagctacg gatcttggca 5520
 ggcccagcag ggcactccaa cgtggtgaag ctccagcgaa tcgaagacct ccctaccatg 5580
 gtcaccttgg gcaattcctt cctccacaaa ctgtgctctg gatttgttag gatttgcag 5640
 gatgaggatg ggaatgagaa gaggcccggg gacgtctgga ccttgccaga ccagtgccac 5700
 accgtgactt gccagccaga tggccagacc ttgtgaaga gtcacgggt caactgtgac 5760
 cgggggctga ggccttcgtg ccctaacagc cagtcacctg ttaaagtga agagacctgt 5820
 ggctgccgt ggacctgcc ctgctgtgc acaggcagct cactcggca catcgtgacc 5880
 ttgatgggc agaattcaa gctgactggc agctgttctt atgtctatt taaaacaag 5940
 gagcaggacc tggaggtgat tctcataat ggtgcctgca gccctggagc aaggcagggc 6000
 tgcataaat ccacgaggt gaagcacagt gccctcctcg tcgagctgca cagtacatg 6060
 gaggtagcgg tgaatgggag actggtctct gttccttacg tgggtggga catggaagtc 6120
 aacgtttatg gtccatcat gcatgaggtc agattcaatc accttggta catcttaca 6180
 ttactccac aaaacaatga gtccaactg cagctcagcc ccaagacttt tgctcaaag 6240
 acgtatggtc tgtgtgggat ctgtgatgag aacggagcca atgacttcat gctgagggat 6300
 ggacagtc caacagactg gaaaacactt gttcaggaat ggactgtgca gcggccaggg 6360
 cagacgtgcc agccatcct ggaggagcag tgtctgtcc ccgacagtc cactgccag 6420
 gtctctctt taccactgtt tctgaatgc cacaaggctc tggctccagc cacattctat 6480
 gccatctgcc agcaggacag ttgccaccag gagcaagtgt gtgaggtgat cgcctctat 6540
 gccacctct gtcggaccaa cggggtctgc gttgactgga ggacacctga ttctgtgt 6600
 atgcatgcc caccatctct ggtttataac cactgtgagc atggctgtcc ccggcactgt 6660
 gatggcaacg tgagctcctg tggggacct cctccgaag gctgtttctg cctccagat 6720
 aaagtcatgt tgaaggcag ctgtgtccct gaagaggcct gcactcagtg cattggtgag 6780
 gatggagtcc agcaccagtt cctggaagcc tgggtcccgg accaccagcc ctgtcagatc 6840
 tgcacatgcc tcagcgggcg gaaggtcaac tgcacaacgc agccctgcc cacggccaaa 6900
 gctcccacgt gtggcctgtg tgaagtagcc cgcctccgc agaatgcaga ccagtgtgc 6960
 cccgagtatg agtgtgtgtg tgaccagtg agctgtgacc tgccccagt gcctcactgt 7020

----- 7080

gaacgiggcc tccagcccac acigaccaac cctggcgagi gcagacccaa cttaccctgc 7080
 gcctgcagga aggaggagtg caaaagagtg tccccaccct cctgcccccc gcaccgttg 7140
 cccacccttc ggaagacca gtgtgtgat gagtatgagt gtgctgcaa ctgtgtcaac 7200
 tccacagtga gctgtcccct tgggtacttg gcctcaaccg ccaccaatga ctgtggctgt 7260
 accacaacca cctgccttcc cgacaagggtg tgtgtccacc gaagcaccat ctaccctgtg 7320
 ggccagttct gggaggaggg ctgcgatgtg tgcacctgca ccgacatgga ggatgccgtg 7380
 atgggcctcc gcgtggccca gtgtcccag aagccctgtg aggacagctg tcggtcgggc 7440
 ttacttacg ttctgcatga aggcgagtg tgtggaaggt gcctgccatc tgctgtgag 7500
 gtggtgactg gctcaccgcg gggggactcc cagtcttctt ggaagagtgt cggctcccag 7560
 tgggcctccc cggagaacct ctgcctcatc aatgagtgtg tccgagtga ggaggaggtc 7620
 ttatacaac aaaggaacgt ctctgcccc cagctggagg tccctgtctg cccctcgggc 7680
 tttagctga gctgtaagac ctacgctgc tgcccaagct gtcgtgtga gcgcatggag 7740
 gcctgcatgc tcaatggcac tgtcattggg ccgggaaga ctgtgatgat cgatgtgtgc 7800
 acgacctgcc gctgcatggt gcagggtggg gtcctctctg gattcaagct ggagtgcagg 7860
 aagaccacct gcaacccctg cccctgggt tacaaggaag aaaataacac aggtgaatgt 7920
 tgtgggagat gtttgcctac ggctgcacc attcagctaa gaggaggaca gatcatgaca 7980
 ctgaagcgtg atgagacgct ccaggatggc tgtgatactc acttctgcaa ggtcaatgag 8040
 agaggagagt acttctggga gaagagggc acaggctgcc cacccttga tgaacacaag 8100
 tgtctggctg agggaggtaa aattatgaaa attccaggca cctgctgtga cacatgtgag 8160
 gagcctgagt gcaacgacat cactgccagg ctgcagtatg tcaagggtgg aagctgtaag 8220
 tctgaagtag aggtggatat ccactactgc cagggcaa atgtccagcaa agccatgtac 8280
 tccattgaca tcaacgatgt gcaggaccag tgctcctgct gctctccgac acggacggag 8340
 cccatgcagg tggccctgca ctgcaccaat ggctctgttg tgtaccatga ggttctcaat 8400
 gccatggagt gcaaatgctc cccaggaag tgcagcaagt ga 8442

<210> 4

<211> 2813

<212> PRT

<213> Homo sapiens

<400> 4

Met Ile Pro Ala Arg Phe Ala Gly Val Leu Leu Ala Leu Ala Leu Ile
 1 5 10 15

Leu Pro Gly Thr Leu Cys Ala Glu Gly Thr Arg Gly Arg Ser Ser Thr
 20 25 30

Ala Arg Cys Ser Leu Phe Gly Ser Asp Phe Val Asn Thr Phe Asp Gly
 35 40 45

Ser Met Tyr Ser Phe Ala Gly Tyr Cys Ser Tyr Leu Leu Ala Gly Gly
 50 55 60

Cys Gln Lys Arg Ser Phe Ser Ile Ile Gly Asp Phe Gln Asn Gly Lys
 65 70 75 80

Arg Val Ser Leu Ser Val Tyr Leu Gly Glu Phe Phe Asp Ile His Leu
 85 90 95

Phe Val Asn Gly Thr Val Thr Gln Gly Asp Gln Arg Val Ser Met Pro
 100 105 110

Tyr Ala Ser Lys Gly Leu Tyr Leu Glu Thr Glu Ala Gly Tyr Tyr Lys
 115 120 125

Leu Ser Gly Glu Ala Tyr Gly Phe Val Ala Arg Ile Asp Gly Ser Gly
 130 135 140

Asn Phe Gln Val Leu Leu Ser Asp Arg Tyr Phe Asn Lys Thr Cys Gly
 145 150 155 160

Leu Cys Gly Asn Phe Asn Ile Phe Ala Glu Asp Asp Phe Met Thr Gln
 165 170 175

Glu Gly Thr Leu Thr Ser Asp Pro Tyr Asp Phe Ala Asn Ser Trp Ala
 180 185 190

Leu Ser Ser Gly Glu Gln Trp Cys Glu Arg Ala Ser Pro Pro Ser Ser
 195 200 205

Ser Cys Asn Ile Ser Ser Gly Glu Met Gln Lys Gly Leu Trp Glu Gln
 210 215 220

Cys Gln Leu Leu Lys Ser Thr Ser Val Phe Ala Arg Cys His Pro Leu
 225 230 235 240

Val Asp Pro Glu Pro Phe Val Ala Leu Cys Glu Lys Thr Leu Cys Glu
 245 250 255

Cys Ala Gly Gly Leu Glu Cys Ala Cys Pro Ala Leu Leu Glu Tyr Ala
 260 265 270

Arg Thr Cys Ala Gln Glu Gly Met Val Leu Tyr Gly Trp Thr Asp His
 275 280 285

Ser Ala Cys Ser Pro Val Cys Pro Ala Gly Met Glu Tyr Arg Gln Cys
 290 295 300

Val Ser Pro Cys Ala Arg Thr Cys Gln Ser Leu His Ile Asn Glu Met
 305 310 315 320

Cys Gln Glu Arg Cys Val Asp Gly Cys Ser Cys Pro Glu Gly Gln Leu
 325 330 335

Leu Asp Glu Gly Leu Cys Val Glu Ser Thr Glu Cys Pro Cys Val His
 340 345 350

Ser Gly Lys Arg Tyr Pro Pro Gly Thr Ser Leu Ser Arg Asp Cys Asn
 355 360 365

Thr Cys Ile Cys Arg Asn Ser Gln Trp Ile Cys Ser Asn Glu Glu Cys
 370 375 380

Pro Gly Glu Cys Leu Val Thr Gly Gln Ser His Phe Lys Ser Phe Asp
 385 390 395 400

Asn Arg Tyr Phe Thr Phe Ser Gly Ile Cys Gln Tyr Leu Leu Ala Arg
 405 410 415

Asp Cys Gln Asp His Ser Phe Ser Ile Val Ile Glu Thr Val Gln Cys
 420 425 430

Ala Asp Asp Arg Asp Ala Val Cys Thr Arg Ser Val Thr Val Arg Leu
 435 440 445

Pro Gly Leu His Asn Ser Leu Val Lys Leu Lys His Gly Ala Gly Val
 450 455 460

Ala Met Asp Gly Gln Asp Ile Gln Leu Pro Leu Leu Lys Gly Asp Leu
 465 470 475 480

Arg Ile Gln His Thr Val Thr Ala Ser Val Arg Leu Ser Tyr Gly Glu
 485 490 495

Asp Leu Gln Met Asp Trp Asp Gly Arg Gly Arg Leu Leu Val Lys Leu
 500 505 510

Ser Pro Val Tyr Ala Gly Lys Thr Cys Gly Leu Cys Gly Asn Tyr Asn
 515 520 525

Gly Asn Gln Gly Asp Asp Phe Leu Thr Pro Ser Gly Leu Ala Glu Pro
 530 535 540

Arg Val Glu Asp Phe Gly Asn Ala Trp Lys Leu His Gly Asp Cys Gln
 545 550 555 560

Asp Leu Gln Lys Gln His Ser Asp Pro Cys Ala Leu Asn Pro Arg Met
 565 570 575

Thr Arg Phe Ser Glu Glu Ala Cys Ala Val Leu Thr Ser Pro Thr Phe
 580 585 590

Glu Ala Cys His Arg Ala Val Ser Pro Leu Pro Tyr Leu Arg Asn Cys
 595 600 605

Arg Tyr Asp Val Cys Ser Cys Ser Asp Gly Arg Glu Cys Leu Cys Gly
 610 615 620

Ala Leu Ala Ser Tyr Ala Ala Ala Cys Ala Gly Arg Gly Val Arg Val
 625 630 635 640

Ala Trp Arg Glu Pro Gly Arg Cys Glu Leu Asn Cys Pro Lys Gly Gln
 645 650 655

Val Tyr Leu Gln Cys Gly Thr Pro Cys Asn Leu Thr Cys Arg Ser Leu
 660 665 670

Ser Tyr Pro Asp Glu Glu Cys Asn Glu Ala Cys Leu Glu Gly Cys Phe
 675 680 685

Cys Pro Pro Gly Leu Tyr Met Asp Glu Arg Gly Asp Cys Val Pro Lys
 690 695 700

Ala Gln Cys Pro Cys Tyr Tyr Asp Gly Glu Ile Phe Gln Pro Glu Asp
 705 710 715 720

Ile Phe Ser Asp His His Thr Met Cys Tyr Cys Glu Asp Gly Phe Met
 725 730 735

His Cys Thr Met Ser Gly Val Pro Gly Ser Leu Leu Pro Asp Ala Val
 740 745 750

Leu Ser Ser Pro Leu Ser His Arg Ser Lys Arg Ser Leu Ser Cys Arg
 755 760 765

Pro Pro Met Val Lys Leu Val Cys Pro Ala Asp Asn Leu Arg Ala Glu
 770 775 780

Gly Leu Glu Cys Thr Lys Thr Cys Gln Asn Tyr Asp Leu Glu Cys Met
 785 790 795 800

Ser Met Gly Cys Val Ser Gly Cys Leu Cys Pro Pro Gly Met Val Arg
 805 810 815

His Glu Asn Arg Cys Val Ala Leu Glu Arg Cys Pro Cys Phe His Gln
 820 825 830

Gly Lys Glu Tyr Ala Pro Gly Glu Thr Val Lys Ile Gly Cys Asn Thr
 835 840 845

Cys Val Cys Arg Asp Arg Lys Trp Asn Cys Thr Asp His Val Cys Asp
 850 855 860

Ala Thr Cys Ser Thr Ile Gly Met Ala His Tyr Leu Thr Phe Asp Gly
 865 870 875 880

Leu Lys Tyr Leu Phe Pro Gly Glu Cys Gln Tyr Val Leu Val Gln Asp
 885 890 895

Tyr Cys Gly Ser Asn Pro Gly Thr Phe Arg Ile Leu Val Gly Asn Lys
 900 905 910

Gly Cys Ser His Pro Ser Val Lys Cys Lys Lys Arg Val Thr Ile Leu
 915 920 925

Val Glu Gly Gly Glu Ile Glu Leu Phe Asp Gly Glu Val Asn Val Lys
 930 935 940

Arg Pro Met Lys Asp Glu Thr His Phe Glu Val Val Glu Ser Gly Arg

945 950 955 960

Tyr Ile Ile Leu Leu Leu Gly Lys Ala Leu Ser Val Val Trp Asp Arg
 965 970 975

His Leu Ser Ile Ser Val Val Leu Lys Gln Thr Tyr Gln Glu Lys Val
 980 985 990

Cys Gly Leu Cys Gly Asn Phe Asp Gly Ile Gln Asn Asn Asp Leu Thr
 995 1000 1005

Ser Ser Asn Leu Gln Val Glu Glu Asp Pro Val Asp Phe Gly Asn
 1010 1015 1020

Ser Trp Lys Val Ser Ser Gln Cys Ala Asp Thr Arg Lys Val Pro
 1025 1030 1035

Leu Asp Ser Ser Pro Ala Thr Cys His Asn Asn Ile Met Lys Gln
 1040 1045 1050

Thr Met Val Asp Ser Ser Cys Arg Ile Leu Thr Ser Asp Val Phe
 1055 1060 1065

Gln Asp Cys Asn Lys Leu Val Asp Pro Glu Pro Tyr Leu Asp Val
 1070 1075 1080

Cys Ile Tyr Asp Thr Cys Ser Cys Glu Ser Ile Gly Asp Cys Ala
 1085 1090 1095

Cys Phe Cys Asp Thr Ile Ala Ala Tyr Ala His Val Cys Ala Gln
 1100 1105 1110

His Gly Lys Val Val Thr Trp Arg Thr Ala Thr Leu Cys Pro Gln
 1115 1120 1125

Ser Cys Glu Glu Arg Asn Leu Arg Glu Asn Gly Tyr Glu Cys Glu
 1130 1135 1140

Trp Arg Tyr Asn Ser Cys Ala Pro Ala Cys Gln Val Thr Cys Gln
 1145 1150 1155

His Pro Glu Pro Leu Ala Cys Pro Val Gln Cys Val Glu Gly Cys
 1160 1165 1170

His Ala His Cys Pro Pro Gly Lys Ile Leu Asp Glu Leu Leu Gln
 1175 1180 1185

Thr Cys Val Asp Pro Glu Asp Cys Pro Val Cys Glu Val Ala Gly
 1190 1195 1200

Arg Arg Phe Ala Ser Gly Lys Lys Val Thr Leu Asn Pro Ser Asp
1205 1210 1215

Pro Glu His Cys Gln Ile Cys His Cys Asp Val Val Asn Leu Thr
1220 1225 1230

Cys Glu Ala Cys Gln Glu Pro Gly Gly Leu Val Val Pro Pro Thr
1235 1240 1245

Asp Ala Pro Val Ser Pro Thr Thr Leu Tyr Val Glu Asp Ile Ser
1250 1255 1260

Glu Pro Pro Leu His Asp Phe Tyr Cys Ser Arg Leu Leu Asp Leu
1265 1270 1275

Val Phe Leu Leu Asp Gly Ser Ser Arg Leu Ser Glu Ala Glu Phe
1280 1285 1290

Glu Val Leu Lys Ala Phe Val Val Asp Met Met Glu Arg Leu Arg
1295 1300 1305

Ile Ser Gln Lys Trp Val Arg Val Ala Val Val Glu Tyr His Asp
1310 1315 1320

Gly Ser His Ala Tyr Ile Gly Leu Lys Asp Arg Lys Arg Pro Ser
1325 1330 1335

Glu Leu Arg Arg Ile Ala Ser Gln Val Lys Tyr Ala Gly Ser Gln
1340 1345 1350

Val Ala Ser Thr Ser Glu Val Leu Lys Tyr Thr Leu Phe Gln Ile
1355 1360 1365

Phe Ser Lys Ile Asp Arg Pro Glu Ala Ser Arg Ile Thr Leu Leu
1370 1375 1380

Leu Met Ala Ser Gln Glu Pro Gln Arg Met Ser Arg Asn Phe Val
1385 1390 1395

Arg Tyr Val Gln Gly Leu Lys Lys Lys Lys Val Ile Val Ile Pro
1400 1405 1410

Val Gly Ile Gly Pro His Ala Asn Leu Lys Gln Ile Arg Leu Ile
1415 1420 1425

Glu Lys Gln Ala Pro Glu Asn Lys Ala Phe Val Leu Ser Ser Val
 1430 1435 1440

Asp Glu Leu Glu Gln Gln Arg Asp Glu Ile Val Ser Tyr Leu Cys
 1445 1450 1455

Asp Leu Ala Pro Glu Ala Pro Pro Pro Thr Leu Pro Pro Asp Met
 1460 1465 1470

Ala Gln Val Thr Val Gly Pro Gly Leu Leu Gly Val Ser Thr Leu
 1475 1480 1485

Gly Pro Lys Arg Asn Ser Met Val Leu Asp Val Ala Phe Val Leu
 1490 1495 1500

Glu Gly Ser Asp Lys Ile Gly Glu Ala Asp Phe Asn Arg Ser Lys
 1505 1510 1515

Glu Phe Met Glu Glu Val Ile Gln Arg Met Asp Val Gly Gln Asp
 1520 1525 1530

Ser Ile His Val Thr Val Leu Gln Tyr Ser Tyr Met Val Thr Val
 1535 1540 1545

Glu Tyr Pro Phe Ser Glu Ala Gln Ser Lys Gly Asp Ile Leu Gln
 1550 1555 1560

Arg Val Arg Glu Ile Arg Tyr Gln Gly Gly Asn Arg Thr Asn Thr
 1565 1570 1575

Gly Leu Ala Leu Arg Tyr Leu Ser Asp His Ser Phe Leu Val Ser
 1580 1585 1590

Gln Gly Asp Arg Glu Gln Ala Pro Asn Leu Val Tyr Met Val Thr
 1595 1600 1605

Gly Asn Pro Ala Ser Asp Glu Ile Lys Arg Leu Pro Gly Asp Ile
 1610 1615 1620

Gln Val Val Pro Ile Gly Val Gly Pro Asn Ala Asn Val Gln Glu
 1625 1630 1635

Leu Glu Arg Ile Gly Trp Pro Asn Ala Pro Ile Leu Ile Gln Asp
 1640 1645 1650

Phe Glu Thr Leu Pro Arg Glu Ala Pro Asp Leu Val Leu Gln Arg
 1655 1660 1665

Cys Cys Ser Gly Glu Gly Leu Gln Ile Pro Thr Leu Ser Pro Ala
 1670 1675 1680

Pro Asp Cys Ser Gln Pro Leu Asp Val Ile Leu Leu Leu Asp Gly
 1685 1690 1695

Ser Ser Ser Phe Pro Ala Ser Tyr Phe Asp Glu Met Lys Ser Phe
 1700 1705 1710

Ala Lys Ala Phe Ile Ser Lys Ala Asn Ile Gly Pro Arg Leu Thr
 1715 1720 1725

Gln Val Ser Val Leu Gln Tyr Gly Ser Ile Thr Thr Ile Asp Val
 1730 1735 1740

Pro Trp Asn Val Val Pro Glu Lys Ala His Leu Leu Ser Leu Val
 1745 1750 1755

Asp Val Met Gln Arg Glu Gly Gly Pro Ser Gln Ile Gly Asp Ala
 1760 1765 1770

Leu Gly Phe Ala Val Arg Tyr Leu Thr Ser Glu Met His Gly Ala
 1775 1780 1785

Arg Pro Gly Ala Ser Lys Ala Val Val Ile Leu Val Thr Asp Val
 1790 1795 1800

Ser Val Asp Ser Val Asp Ala Ala Ala Asp Ala Ala Arg Ser Asn
 1805 1810 1815

Arg Val Thr Val Phe Pro Ile Gly Ile Gly Asp Arg Tyr Asp Ala
 1820 1825 1830

Ala Gln Leu Arg Ile Leu Ala Gly Pro Ala Gly Asp Ser Asn Val
 1835 1840 1845

Val Lys Leu Gln Arg Ile Glu Asp Leu Pro Thr Met Val Thr Leu
 1850 1855 1860

Gly Asn Ser Phe Leu His Lys Leu Cys Ser Gly Phe Val Arg Ile
 1865 1870 1875

Cys Met Asp Glu Asp Gly Asn Glu Lys Arg Pro Gly Asp Val Trp
1880 1885 1890

Thr Leu Pro Asp Gln Cys His Thr Val Thr Cys Gln Pro Asp Gly
1895 1900 1905

Gln Thr Leu Leu Lys Ser His Arg Val Asn Cys Asp Arg Gly Leu
1910 1915 1920

Arg Pro Ser Cys Pro Asn Ser Gln Ser Pro Val Lys Val Glu Glu
1925 1930 1935

Thr Cys Gly Cys Arg Trp Thr Cys Pro Cys Val Cys Thr Gly Ser
1940 1945 1950

Ser Thr Arg His Ile Val Thr Phe Asp Gly Gln Asn Phe Lys Leu
1955 1960 1965

Thr Gly Ser Cys Ser Tyr Val Leu Phe Gln Asn Lys Glu Gln Asp
1970 1975 1980

Leu Glu Val Ile Leu His Asn Gly Ala Cys Ser Pro Gly Ala Arg
1985 1990 1995

Gln Gly Cys Met Lys Ser Ile Glu Val Lys His Ser Ala Leu Ser
2000 2005 2010

Val Glu Leu His Ser Asp Met Glu Val Thr Val Asn Gly Arg Leu
2015 2020 2025

Val Ser Val Pro Tyr Val Gly Gly Asn Met Glu Val Asn Val Tyr
2030 2035 2040

Gly Ala Ile Met His Glu Val Arg Phe Asn His Leu Gly His Ile
2045 2050 2055

Phe Thr Phe Thr Pro Gln Asn Asn Glu Phe Gln Leu Gln Leu Ser
2060 2065 2070

Pro Lys Thr Phe Ala Ser Lys Thr Tyr Gly Leu Cys Gly Ile Cys
2075 2080 2085

Asp Glu Asn Gly Ala Asn Asp Phe Met Leu Arg Asp Gly Thr Val
2090 2095 2100

Thr Thr Asp Trp Lys Thr Leu Val Gln Glu Trp Thr Val Gln Arg
2105 2110 2115

Pro Gly Gln Thr Cys Gln Pro Ile Leu Glu Glu Gln Cys Leu Val
2120 2125 2130

Pro Asp Ser Ser His Cys Gln Val Leu Leu Leu Pro Leu Phe Ala
2135 2140 2145

Glu Cys His Lys Val Leu Ala Pro Ala Thr Phe Tyr Ala Ile Cys
2150 2155 2160

Gln Gln Asp Ser Cys His Gln Glu Gln Val Cys Glu Val Ile Ala
2165 2170 2175

Ser Tyr Ala His Leu Cys Arg Thr Asn Gly Val Cys Val Asp Trp
2180 2185 2190

Arg Thr Pro Asp Phe Cys Ala Met Ser Cys Pro Pro Ser Leu Val
2195 2200 2205

Tyr Asn His Cys Glu His Gly Cys Pro Arg His Cys Asp Gly Asn
2210 2215 2220

Val Ser Ser Cys Gly Asp His Pro Ser Glu Gly Cys Phe Cys Pro
2225 2230 2235

Pro Asp Lys Val Met Leu Glu Gly Ser Cys Val Pro Glu Glu Ala
2240 2245 2250

Cys Thr Gln Cys Ile Gly Glu Asp Gly Val Gln His Gln Phe Leu
2255 2260 2265

Glu Ala Trp Val Pro Asp His Gln Pro Cys Gln Ile Cys Thr Cys
2270 2275 2280

Leu Ser Gly Arg Lys Val Asn Cys Thr Thr Gln Pro Cys Pro Thr
2285 2290 2295

Ala Lys Ala Pro Thr Cys Gly Leu Cys Glu Val Ala Arg Leu Arg
2300 2305 2310

Gln Asn Ala Asp Gln Cys Cys Pro Glu Tyr Glu Cys Val Cys Asp
2315 2320 2325

Pro Val Ser Cys Asp Leu Pro Pro Val Pro His Cys Glu Arg Gly
2330 2335 2340

Leu Gln Pro Thr Leu Thr Asn Pro Gly Glu Cys Arg Pro Asn Phe
2345 2350 2355

Thr Cys Ala Cys Arg Lys Glu Glu Cys Lys Arg Val Ser Pro Pro
2360 2365 2370

Ser Cys Pro Pro His Arg Leu Pro Thr Leu Arg Lys Thr Gln Cys
2375 2380 2385

Cys Asp Glu Tyr Glu Cys Ala Cys Asn Cys Val Asn Ser Thr Val
2390 2395 2400

Ser Cys Pro Leu Gly Tyr Leu Ala Ser Thr Ala Thr Asn Asp Cys
2405 2410 2415

Gly Cys Thr Thr Thr Thr Cys Leu Pro Asp Lys Val Cys Val His
2420 2425 2430

Arg Ser Thr Ile Tyr Pro Val Gly Gln Phe Trp Glu Glu Gly Cys
2435 2440 2445

Asp Val Cys Thr Cys Thr Asp Met Glu Asp Ala Val Met Gly Leu
2450 2455 2460

Arg Val Ala Gln Cys Ser Gln Lys Pro Cys Glu Asp Ser Cys Arg
2465 2470 2475

Ser Gly Phe Thr Tyr Val Leu His Glu Gly Glu Cys Cys Gly Arg
2480 2485 2490

Cys Leu Pro Ser Ala Cys Glu Val Val Thr Gly Ser Pro Arg Gly
2495 2500 2505

Asp Ser Gln Ser Ser Trp Lys Ser Val Gly Ser Gln Trp Ala Ser
2510 2515 2520

Pro Glu Asn Pro Cys Leu Ile Asn Glu Cys Val Arg Val Lys Glu
2525 2530 2535

Glu Val Phe Ile Gln Gln Arg Asn Val Ser Cys Pro Gln Leu Glu
2540 2545 2550

2540	2545	2550
Val Pro	Val Cys Pro Ser Gly	Phe Gln Leu Ser Cys Lys Thr Ser
2555	2560	2565
Ala Cys	Cys Pro Ser Cys Arg	Cys Glu Arg Met Glu Ala Cys Met
2570	2575	2580
Leu Asn	Gly Thr Val Ile Gly	Pro Gly Lys Thr Val Met Ile Asp
2585	2590	2595
Val Cys	Thr Thr Cys Arg Cys	Met Val Gln Val Gly Val Ile Ser
2600	2605	2610
Gly Phe	Lys Leu Glu Cys Arg	Lys Thr Thr Cys Asn Pro Cys Pro
2615	2620	2625
Leu Gly	Tyr Lys Glu Glu Asn	Asn Thr Gly Glu Cys Cys Gly Arg
2630	2635	2640
Cys Leu	Pro Thr Ala Cys Thr	Ile Gln Leu Arg Gly Gly Gln Ile
2645	2650	2655
Met Thr	Leu Lys Arg Asp Glu	Thr Leu Gln Asp Gly Cys Asp Thr
2660	2665	2670
His Phe	Cys Lys Val Asn Glu	Arg Gly Glu Tyr Phe Trp Glu Lys
2675	2680	2685
Arg Val	Thr Gly Cys Pro Pro	Phe Asp Glu His Lys Cys Leu Ala
2690	2695	2700
Glu Gly	Gly Lys Ile Met Lys	Ile Pro Gly Thr Cys Cys Asp Thr
2705	2710	2715
Cys Glu	Glu Pro Glu Cys Asn	Asp Ile Thr Ala Arg Leu Gln Tyr
2720	2725	2730
Val Lys	Val Gly Ser Cys Lys	Ser Glu Val Glu Val Asp Ile His
2735	2740	2745
Tyr Cys	Gln Gly Lys Cys Ala	Ser Lys Ala Met Tyr Ser Ile Asp
2750	2755	2760
Ile Asn	Asp Val Gln Asp Gln	Cys Ser Cys Cys Ser Pro Thr Arg
2765	2770	2775

Thr Glu Pro Met Gln Val Ala Leu His Cys Thr Asn Gly Ser Val
 2780 2785 2790

Val Tyr His Glu Val Leu Asn Ala Met Glu Cys Lys Cys Ser Pro
 2795 2800 2805

Arg Lys Cys Ser Lys
 2810

<210> 5
 <211> 1444
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Single Chain Factor VIII

<400> 5
 Ala Thr Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser Trp Asp Tyr
 1 5 10 15

Met Gln Ser Asp Leu Gly Glu Leu Pro Val Asp Ala Arg Phe Pro Pro
 20 25 30

Arg Val Pro Lys Ser Phe Pro Phe Asn Thr Ser Val Val Tyr Lys Lys
 35 40 45

Thr Leu Phe Val Glu Phe Thr Asp His Leu Phe Asn Ile Ala Lys Pro
 50 55 60

Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile Gln Ala Glu Val
 65 70 75 80

Tyr Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala Ser His Pro Val
 85 90 95

Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser Glu Gly Ala
 100 105 110

Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys Glu Asp Asp Lys Val
 115 120 125

Phe Pro Gly Gly Ser His Thr Tyr Val Trp Gln Val Leu Lys Glu Asn
 130 135 140

Gly Pro Met Ala Ser Asp Pro Leu Cys Leu Thr Tyr Ser Tyr Leu Ser

Gly Phe Met Ala Ser Asp Phe Leu Cys Leu Thr Tyr Ser Tyr Leu Ser
145 150 155 160

His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu Ile Gly Ala Leu
165 170 175

Leu Val Cys Arg Glu Gly Ser Leu Ala Lys Glu Lys Thr Gln Thr Leu
180 185 190

His Lys Phe Ile Leu Leu Phe Ala Val Phe Asp Glu Gly Lys Ser Trp
195 200 205

His Ser Glu Thr Lys Asn Ser Leu Met Gln Asp Arg Asp Ala Ala Ser
210 215 220

Ala Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr Val Asn Arg
225 230 235 240

Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val Tyr Trp His
245 250 255

Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile Phe Leu Glu
260 265 270

Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala Ser Leu Glu Ile
275 280 285

Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu Met Asp Leu Gly
290 295 300

Gln Phe Leu Leu Phe Cys His Ile Ser Ser His Gln His Asp Gly Met
305 310 315 320

Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu Pro Gln Leu Arg
325 330 335

Met Lys Asn Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp Leu Thr Asp
340 345 350

Ser Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn Ser Pro Ser Phe
355 360 365

Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr Trp Val His
370 375 380

Thr Ile Ala Ala Gly Gly Gly Asp Thr Asp Thr Ala Pro Leu Val Leu

Tyr Ile Ala Ala Glu Glu Glu Asp Trp Asp Tyr Ala Pro Leu Val Leu
385 390 395 400

Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr Leu Asn Asn Gly Pro
405 410 415

Gln Arg Ile Gly Arg Lys Tyr Lys Lys Val Arg Phe Met Ala Tyr Thr
420 425 430

Asp Glu Thr Phe Lys Thr Arg Glu Ala Ile Gln His Glu Ser Gly Ile
435 440 445

Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu Leu Ile Ile
450 455 460

Phe Lys Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro His Gly Ile
465 470 475 480

Thr Asp Val Arg Pro Leu Tyr Ser Arg Arg Leu Pro Lys Gly Val Lys
485 490 495

His Leu Lys Asp Phe Pro Ile Leu Pro Gly Glu Ile Phe Lys Tyr Lys
500 505 510

Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp Pro Arg Cys
515 520 525

Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg Asp Leu Ala
530 535 540

Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu Ser Val Asp
545 550 555 560

Gln Arg Gly Asn Gln Ile Met Ser Asp Lys Arg Asn Val Ile Leu Phe
565 570 575

Ser Val Phe Asp Glu Asn Arg Ser Trp Tyr Leu Thr Glu Asn Ile Gln
580 585 590

Arg Phe Leu Pro Asn Pro Ala Gly Val Gln Leu Glu Asp Pro Glu Phe
595 600 605

Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val Phe Asp Ser
610 615 620

Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Trp Trp Ile Leu

625 630 635 640
 Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe Ser Gly Tyr
 645 650 655
 Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr Leu Phe Pro
 660 665 670
 Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro Gly Leu Trp
 675 680 685
 Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn Arg Gly Met Thr Ala
 690 695 700
 Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr Gly Asp Tyr Tyr Glu
 705 710 715 720
 Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu Ser Lys Asn Asn Ala
 725 730 735
 Ile Glu Pro Arg Ser Phe Ser Gln Asn Ser Arg His Pro Ser Thr Arg
 740 745 750
 Gln Lys Gln Phe Asn Ala Thr Thr Ile Pro Glu Asn Thr Thr Leu Gln
 755 760 765
 Ser Asp Gln Glu Glu Ile Asp Tyr Asp Asp Thr Ile Ser Val Glu Met
 770 775 780
 Lys Lys Glu Asp Phe Asp Ile Tyr Asp Glu Asp Glu Asn Gln Ser Pro
 785 790 795 800
 Arg Ser Phe Gln Lys Lys Thr Arg His Tyr Phe Ile Ala Ala Val Glu
 805 810 815
 Arg Leu Trp Asp Tyr Gly Met Ser Ser Ser Pro His Val Leu Arg Asn
 820 825 830
 Arg Ala Gln Ser Gly Ser Val Pro Gln Phe Lys Lys Val Val Phe Gln
 835 840 845
 Glu Phe Thr Asp Gly Ser Phe Thr Gln Pro Leu Tyr Arg Gly Glu Leu
 850 855 860

Asn Glu His Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu
865 870 875 880

Asp Asn Ile Met Val Thr Phe Arg Asn Gln Ala Ser Arg Pro Tyr Ser
885 890 895

Phe Tyr Ser Ser Leu Ile Ser Tyr Glu Glu Asp Gln Arg Gln Gly Ala
900 905 910

Glu Pro Arg Lys Asn Phe Val Lys Pro Asn Glu Thr Lys Thr Tyr Phe
915 920 925

Trp Lys Val Gln His His Met Ala Pro Thr Lys Asp Glu Phe Asp Cys
930 935 940

Lys Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val His
945 950 955 960

Ser Gly Leu Ile Gly Pro Leu Leu Val Cys His Thr Asn Thr Leu Asn
965 970 975

Pro Ala His Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu Phe Phe
980 985 990

Thr Ile Phe Asp Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Met Glu
995 1000 1005

Arg Asn Cys Arg Ala Pro Cys Asn Ile Gln Met Glu Asp Pro Thr
1010 1015 1020

Phe Lys Glu Asn Tyr Arg Phe His Ala Ile Asn Gly Tyr Ile Met
1025 1030 1035

Asp Thr Leu Pro Gly Leu Val Met Ala Gln Asp Gln Arg Ile Arg
1040 1045 1050

Trp Tyr Leu Leu Ser Met Gly Ser Asn Glu Asn Ile His Ser Ile
1055 1060 1065

His Phe Ser Gly His Val Phe Thr Val Arg Lys Lys Glu Glu Tyr
1070 1075 1080

Lys Met Ala Leu Tyr Asn Leu Tyr Pro Gly Val Phe Glu Thr Val
1085 1090 1095

Glu Met Leu Pro Ser Lys Ala Glu Ile Thr Asp Val Glu Gln Leu

Glu Met Leu Pro Ser Lys Ala Gly Ile Trp Arg Val Glu Cys Leu
1100 1105 1110

Ile Gly Glu His Leu His Ala Gly Met Ser Thr Leu Phe Leu Val
1115 1120 1125

Tyr Ser Asn Lys Cys Gln Thr Pro Leu Gly Met Ala Ser Gly His
1130 1135 1140

Ile Arg Asp Phe Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp
1145 1150 1155

Ala Pro Lys Leu Ala Arg Leu His Tyr Ser Gly Ser Ile Asn Ala
1160 1165 1170

Trp Ser Thr Lys Glu Pro Phe Ser Trp Ile Lys Val Asp Leu Leu
1175 1180 1185

Ala Pro Met Ile Ile His Gly Ile Lys Thr Gln Gly Ala Arg Gln
1190 1195 1200

Lys Phe Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met Tyr Ser
1205 1210 1215

Leu Asp Gly Lys Lys Trp Gln Thr Tyr Arg Gly Asn Ser Thr Gly
1220 1225 1230

Thr Leu Met Val Phe Phe Gly Asn Val Asp Ser Ser Gly Ile Lys
1235 1240 1245

His Asn Ile Phe Asn Pro Pro Ile Ile Ala Arg Tyr Ile Arg Leu
1250 1255 1260

His Pro Thr His Tyr Ser Ile Arg Ser Thr Leu Arg Met Glu Leu
1265 1270 1275

Met Gly Cys Asp Leu Asn Ser Cys Ser Met Pro Leu Gly Met Glu
1280 1285 1290

Ser Lys Ala Ile Ser Asp Ala Gln Ile Thr Ala Ser Ser Tyr Phe
1295 1300 1305

Thr Asn Met Phe Ala Thr Trp Ser Pro Ser Lys Ala Arg Leu His
1310 1315 1320

.....

Leu Gln Gly Arg Ser Asn Ala Trp Arg Pro Gln Val Asn Asn Pro
 1325 1330 1335

Lys Glu Trp Leu Gln Val Asp Phe Gln Lys Thr Met Lys Val Thr
 1340 1345 1350

Gly Val Thr Thr Gln Gly Val Lys Ser Leu Leu Thr Ser Met Tyr
 1355 1360 1365

Val Lys Glu Phe Leu Ile Ser Ser Ser Gln Asp Gly His Gln Trp
 1370 1375 1380

Thr Leu Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly Asn
 1385 1390 1395

Gln Asp Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Pro Leu
 1400 1405 1410

Leu Thr Arg Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln
 1415 1420 1425

Ile Ala Leu Arg Met Glu Val Leu Gly Cys Glu Ala Gln Asp Leu
 1430 1435 1440

Tyr

<210> 6

<211> 585

<212> PRT

<213> Homo sapiens

<400> 6

Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
 1 5 10 15

Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
 20 25 30

Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
 35 40 45

Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
 50 55 60

Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
 65 70 75 80

Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
85 90 95

Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
100 105 110

Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
115 120 125

Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
130 135 140

Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
145 150 155 160

Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
165 170 175

Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
180 185 190

Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
195 200 205

Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
210 215 220

Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys
225 230 235 240

Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp
245 250 255

Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser
260 265 270

Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His
275 280 285

Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser
290 295 300

Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala
305 310 315 320

Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg
 325 330 335

Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr
 340 345 350

Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu
 355 360 365

Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro
 370 375 380

Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu
 385 390 395 400

Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro
 405 410 415

Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys
 420 425 430

Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys
 435 440 445

Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His
 450 455 460

Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser
 465 470 475 480

Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
 485 490 495

Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
 500 505 510

Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
 515 520 525

Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
 530 535 540

Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
 545 550 555 560

Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val

565

570

575

Ala Ala Ser Gln Ala Ala Leu Gly Leu

580

585

<210> 7

<211> 519

<212> PRT

<213> Artificial sequence

<220>

<223> His-tagged D'D3

<220>

<221> MISC_FEATURE

<222> (1)..(479)

<223> Amino acid sequence of D'D3 - His8

<220>

<221> MISC_FEATURE

<222> (1)..(479)

<223> VWF D'D3 region (VWF amino acids 764 - 1242)

<220>

<221> MISC_FEATURE

<222> (480)..(511)

<223> glycine / serine linker

<220>

<221> MISC_FEATURE

<222> (512)..(519)

<223> polyhistidine tag

<400> 7

Ser Leu Ser Cys Arg Pro Pro Met Val Lys Leu Val Cys Pro Ala Asp
1 5 10 15

Asn Leu Arg Ala Glu Gly Leu Glu Cys Thr Lys Thr Cys Gln Asn Tyr
20 25 30

Asp Leu Glu Cys Met Ser Met Gly Cys Val Ser Gly Cys Leu Cys Pro
35 40 45

Pro Gly Met Val Arg His Glu Asn Arg Cys Val Ala Leu Glu Arg Cys
50 55 60

Pro Cys Phe His Gln Gly Lys Glu Tyr Ala Pro Gly Glu Thr Val Lys
65 70 75 80

Ile Gly Cys Asn Thr Cys Val Cys Arg Asp Arg Lys Trp Asn Cys Thr
 85 90 95

Asp His Val Cys Asp Ala Thr Cys Ser Thr Ile Gly Met Ala His Tyr
 100 105 110

Leu Thr Phe Asp Gly Leu Lys Tyr Leu Phe Pro Gly Glu Cys Gln Tyr
 115 120 125

Val Leu Val Gln Asp Tyr Cys Gly Ser Asn Pro Gly Thr Phe Arg Ile
 130 135 140

Leu Val Gly Asn Lys Gly Cys Ser His Pro Ser Val Lys Cys Lys Lys
145 150 155 160

Arg Val Thr Ile Leu Val Glu Gly Gly Glu Ile Glu Leu Phe Asp Gly
 165 170 175

Glu Val Asn Val Lys Arg Pro Met Lys Asp Glu Thr His Phe Glu Val
 180 185 190

Val Glu Ser Gly Arg Tyr Ile Ile Leu Leu Leu Gly Lys Ala Leu Ser
 195 200 205

Val Val Trp Asp Arg His Leu Ser Ile Ser Val Val Leu Lys Gln Thr
 210 215 220

Tyr Gln Glu Lys Val Cys Gly Leu Cys Gly Asn Phe Asp Gly Ile Gln
225 230 235 240

Asn Asn Asp Leu Thr Ser Ser Asn Leu Gln Val Glu Glu Asp Pro Val
 245 250 255

Asp Phe Gly Asn Ser Trp Lys Val Ser Ser Gln Cys Ala Asp Thr Arg
 260 265 270

Lys Val Pro Leu Asp Ser Ser Pro Ala Thr Cys His Asn Asn Ile Met
 275 280 285

Lys Gln Thr Met Val Asp Ser Ser Cys Arg Ile Leu Thr Ser Asp Val
 290 295 300

Phe Gln Asp Cys Asn Lys Leu Val Asp Pro Glu Pro Tyr Leu Asp Val
305 310 315 320

Cys Ile Tyr Asp Thr Cys Ser Cys Glu Ser Ile Gly Asp Cys Ala Cys
325 330 335

Phe Cys Asp Thr Ile Ala Ala Tyr Ala His Val Cys Ala Gln His Gly
340 345 350

Lys Val Val Thr Trp Arg Thr Ala Thr Leu Cys Pro Gln Ser Cys Glu
355 360 365

Glu Arg Asn Leu Arg Glu Asn Gly Tyr Glu Cys Glu Trp Arg Tyr Asn
370 375 380

Ser Cys Ala Pro Ala Cys Gln Val Thr Cys Gln His Pro Glu Pro Leu
385 390 395 400

Ala Cys Pro Val Gln Cys Val Glu Gly Cys His Ala His Cys Pro Pro
405 410 415

Gly Lys Ile Leu Asp Glu Leu Leu Gln Thr Cys Val Asp Pro Glu Asp
420 425 430

Cys Pro Val Cys Glu Val Ala Gly Arg Arg Phe Ala Ser Gly Lys Lys
435 440 445

Val Thr Leu Asn Pro Ser Asp Pro Glu His Cys Gln Ile Cys His Cys
450 455 460

Asp Val Val Asn Leu Thr Cys Glu Ala Cys Gln Glu Pro Gly Gly Ser
465 470 475 480

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
485 490 495

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser His
500 505 510

His His His His His His His
515

<210> 8

<211> 584

<212> PRT

<213> Artificial sequence

<220>

<223> His-tagged CTP fusion protein

<220>

<221> MISC_FEATURE

<222> (1)..(479)

<223> VWF D'D3 region (VWF amino acids 764 - 1242)

<220>

<221> MISC_FEATURE

<222> (480)..(511)

<223> glycine / serine linker

<220>

<221> MISC_FEATURE

<222> (512)..(576)

<223> C-terminal peptide of human chorionic gonadotropin beta subunit

<220>

<221> MISC_FEATURE

<222> (577)..(584)

<223> Polyhistidin tag

<400> 8

Ser	Leu	Ser	Cys	Arg	Pro	Pro	Met	Val	Lys	Leu	Val	Cys	Pro	Ala	Asp
1		5			10				15						

Asn	Leu	Arg	Ala	Glu	Gly	Leu	Glu	Cys	Thr	Lys	Thr	Cys	Gln	Asn	Tyr
	20				25				30						

Asp	Leu	Glu	Cys	Met	Ser	Met	Gly	Cys	Val	Ser	Gly	Cys	Leu	Cys	Pro
	35			40			45								

Pro	Gly	Met	Val	Arg	His	Glu	Asn	Arg	Cys	Val	Ala	Leu	Glu	Arg	Cys
	50			55			60								

Pro	Cys	Phe	His	Gln	Gly	Lys	Glu	Tyr	Ala	Pro	Gly	Glu	Thr	Val	Lys
65			70			75			80						

Ile	Gly	Cys	Asn	Thr	Cys	Val	Cys	Arg	Asp	Arg	Lys	Trp	Asn	Cys	Thr
	85				90				95						

Asn	His	Val	Cys	Asn	Ala	Thr	Cys	Ser	Thr	Ile	Gly	Met	Ala	His	Tyr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Asp His Val Cys Asp His Thr Cys Ser Thr Ile Gly Met Ala His Tyr
100 105 110

Leu Thr Phe Asp Gly Leu Lys Tyr Leu Phe Pro Gly Glu Cys Gln Tyr
115 120 125

Val Leu Val Gln Asp Tyr Cys Gly Ser Asn Pro Gly Thr Phe Arg Ile
130 135 140

Leu Val Gly Asn Lys Gly Cys Ser His Pro Ser Val Lys Cys Lys Lys
145 150 155 160

Arg Val Thr Ile Leu Val Glu Gly Gly Glu Ile Glu Leu Phe Asp Gly
165 170 175

Glu Val Asn Val Lys Arg Pro Met Lys Asp Glu Thr His Phe Glu Val
180 185 190

Val Glu Ser Gly Arg Tyr Ile Ile Leu Leu Leu Gly Lys Ala Leu Ser
195 200 205

Val Val Trp Asp Arg His Leu Ser Ile Ser Val Val Leu Lys Gln Thr
210 215 220

Tyr Gln Glu Lys Val Cys Gly Leu Cys Gly Asn Phe Asp Gly Ile Gln
225 230 235 240

Asn Asn Asp Leu Thr Ser Ser Asn Leu Gln Val Glu Glu Asp Pro Val
245 250 255

Asp Phe Gly Asn Ser Trp Lys Val Ser Ser Gln Cys Ala Asp Thr Arg
260 265 270

Lys Val Pro Leu Asp Ser Ser Pro Ala Thr Cys His Asn Asn Ile Met
275 280 285

Lys Gln Thr Met Val Asp Ser Ser Cys Arg Ile Leu Thr Ser Asp Val
290 295 300

Phe Gln Asp Cys Asn Lys Leu Val Asp Pro Glu Pro Tyr Leu Asp Val
305 310 315 320

Cys Ile Tyr Asp Thr Cys Ser Cys Glu Ser Ile Gly Asp Cys Ala Cys
325 330 335

Phe Cys Asp Thr Ile Ala Ala Tyr Ala His Val Cys Ala Gln His Gly
340 345 350

340 345 350
 Lys Val Val Thr Trp Arg Thr Ala Thr Leu Cys Pro Gln Ser Cys Glu
 355 360 365
 Glu Arg Asn Leu Arg Glu Asn Gly Tyr Glu Cys Glu Trp Arg Tyr Asn
 370 375 380
 Ser Cys Ala Pro Ala Cys Gln Val Thr Cys Gln His Pro Glu Pro Leu
 385 390 395 400
 Ala Cys Pro Val Gln Cys Val Glu Gly Cys His Ala His Cys Pro Pro
 405 410 415
 Gly Lys Ile Leu Asp Glu Leu Leu Gln Thr Cys Val Asp Pro Glu Asp
 420 425 430
 Cys Pro Val Cys Glu Val Ala Gly Arg Arg Phe Ala Ser Gly Lys Lys
 435 440 445
 Val Thr Leu Asn Pro Ser Asp Pro Glu His Cys Gln Ile Cys His Cys
 450 455 460
 Asp Val Val Asn Leu Thr Cys Glu Ala Cys Gln Glu Pro Gly Gly Ser
 465 470 475 480
 Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly
 485 490 495
 Gly Ser Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Gly Ser Ser Ala
 500 505 510
 Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg
 515 520 525
 Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln Ala Ser Ser Ser
 530 535 540
 Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly
 545 550 555 560
 Pro Ser Asp Thr Pro Ile Leu Pro Gln Ala Gly Gly Ser Gly Gly Ser
 565 570 575
 His His His His His His His His

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO03093313A2 \[0007\]](#)
- [WO02060951A2 \[0007\]](#)
- [WO9415625A \[0007\]](#)
- [WO9711957A \[0007\]](#)
- [US4970300A \[0007\]](#)
- [WO9955306A \[0007\]](#)
- [WO9703193A \[0007\]](#)
- [WO9740145A \[0007\]](#)
- [WO03087355A \[0007\]](#)
- [WO02103024A2 \[0007\]](#)
- [WO2006108590A \[0007\]](#)
- [WO2007126808A \[0008\]](#)
- [WO2006053299A \[0008\]](#)
- [WO2004075923A \[0008\]](#)
- [WO2006071801A \[0008\]](#)
- [WO2004101740A \[0008\] \[0065\]](#)
- [WO2008077616A \[0008\]](#)
- [WO2009156137A \[0008\]](#)
- [WO2013106787A1 \[0012\] \[0048\]](#)
- [WO2014198699A2 \[0012\] \[0048\]](#)
- [WO2013083858A2 \[0012\]](#)
- [WO2011060242A2 \[0012\] \[0048\]](#)
- [WO2013093760A2 \[0012\] \[0048\]](#)
- [WO2008151817A1 \[0013\] \[0013\]](#)
- [US7256253B \[0051\]](#)
- [WO2007090584A \[0054\] \[0054\]](#)
- [WO2013120939A1 \[0054\] \[0066\] \[0076\]](#)

- [US20040087778A](#) [0065]
- [WO2005001025A](#) [0065]
- [WO2006000448A](#) [0065]
- [WO2005063808A](#) [0065]
- [WO2003076567A](#) [0065]
- [WO2005000892A](#) [0065]
- [US6403077B](#) [0065]
- [EP117060A](#) [0082]
- [EP117058A](#) [0082]
- [US4399216A](#) [0082]
- [WO2004067566A](#) [0101]
- [WO2007144173A](#) [0128]
- [EP15168930](#) [0189]
- [EP16163239](#) [0189]

Non-patent literature cited in the description

- COLLINS et al. Proc. Natl. Acad. Sci. USA, 1987, vol. 84, 4393-4397 [0009]
- FISCHER et al. FEBS Lett., 1994, vol. 351, 345-348 [0009]
- KAUFMAN et al. Mol Cell Biol, 1989, vol. 9, 1233-1242 [0011]
- YEE et al. Blood, 2014, vol. 124, 3445-452 [0012]
- Structure and function of von Willebrand factor HABERICHTER S.L. MONTGOMERY R.R. Hemostasis and Thrombosis Lippincott Williams & Wilkins 2013 0000197-207 [0023]
- ZHOU et al. Blood, 2012, vol. 120, 2449-458 [0035]
- SCHELLENBERGER et al. Nature Biotechnol., 2009, vol. 27, 1186-1190 [0056]
- DUMONT J A et al. BioDrugs, 2006, vol. 20, 151-160 [0065]
- GRAHAM et al. J. Gen Virol., 1977, vol. 36, 59- [0081]
- CHO, URLAUB CHASIN Proc. Natl. Acad. Sci. USA, 1980, vol. 77, 4216- [0081]
- MATHER Biol. Reprod., 1980, vol. 23, 243-251 [0081]
- MATHER et al. Annals NY. Acad. Sci., 1982, vol. 383, 44-68 [0081]
- GETHING et al. Nature, 1981, vol. 293, 620-625 [0082]
- MANTEI et al. Nature, 1979, vol. 281, 40-46 [0082]
- GRAHAM VAN DER ERB Virology, 1978, vol. 52, 456-457 [0082]
- HAWLEY-NELSON Focus, 1993, vol. 15, 73- [0082]
- KEOWN et al. Methods in Enzymology, 1989, [0082]
- KEOWN et al. Methods in Enzymology, 1990, vol. 185, 527-537 [0082]
- MANSOUR et al. Nature, 1988, vol. 336, 348-352 [0082]
- N LEEMARTIN L et al. An Effect of Predilution on Potency Assays of FVIII Concentrates, Thrombosis Research Pergamon Press Ltd. 1983 0000vol. 30, 511-519 [0110]
- Chromogenix-Instrumentation Laboratory SpA V.le Monza 338 - 20128 Milano, [0111]

- Remington's Pharmaceutical Sciences19800000 [0112]

PATENTKRAV

1. Polypeptid omfattende en trunkeret von Willebrand Faktor (VWF) til anvendelse i behandlingen af en blodkoagulationsforstyrrelse, nævnte behandling omfatter administration til et individ med endogent VWF, polypeptidet og en Faktor VIII (FVIII), hvor polypeptidet er i stand til binding til nævnte FVIII, og hvor molforholdet mellem polypeptidet der skal administreres til FVIII, skal administreres er større end 50, hvor polypeptidet omfatter en halveringstidsforlængende del.
2. Polypeptid til anvendelse ifølge krav 1, hvor polypeptidet administreres intravenøst, og derudover er molforholdet mellem polypeptidet der administreres til det endogene VWF større end 0,5, og hvor nævnte molforhold er den molære plasmakoncentration af polypeptidet fra det behandlede individ umiddelbart efter administration af polypeptidet divideret med den molære plasmakoncentration af endogent VWF af det behandlede individ, hvor koncentrationen af det endogene VWF er defineret som koncentrationen i normalt humant plasma (NHP).
3. Polypeptid til anvendelse ifølge krav 1 eller krav 2, hvor individet er et menneske.
4. Polypeptid til anvendelse ifølge krav 1, hvor polypeptidet administreres intravenøst.
5. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den trunkerede VWF omfatter aminosyrer 764 til 1242 i SEQ ID NO:4.
6. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den trunkerede VWF mangler aminosyrer 1243 til 2813 i SEQ ID NO:4.
7. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den trunkerede VWF består af (a) aminosyrer 764 til 1242 i SEQ ID NO:4, (b) en aminosyresekvens med en sekvensidentitet på mindst 90% til aminosyrer 764 til 1242 i SEQ ID NO:4 eller (c) et fragment af (a) eller (b).
8. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den

halveringstidsforlængende del er en heterolog aminosyresekvens fusioneret til den trunkerede VWF.

- 5 9. Polypeptid til anvendelse ifølge krav 8, hvor den heterologe aminosyresekvens omfatter eller består af et polypeptid udvalgt blandt gruppen bestående af immunglobulin-konstante regioner og dele deraf, f.eks. Fc-fragmentet, transferrin og fragmenter deraf, det C-terminale peptid af humant chorionisk gonadotropin, solvatiserede tilfældige kæder med stort hydrodynamisk volumen kendt som XTEN, homo-aminosyregentagelser (HAP), prolin-alanineserin-gentagelser (PAS), albumin, afamin, alfa-fetoprotein, vitamin D-bindende protein, polypeptider, der er i stand til at binde under
- 10 fysiologiske betingelser til albumin- eller immunglobulin-konstante regioner og kombinationer deraf.
- 15 10. Polypeptid til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor halveringstidsforlængende del er konjugeret til polypeptidet.
- 20 11. Polypeptid til anvendelse ifølge krav 10, hvor nævnte halveringstidsforlængende del er udvalgt blandt gruppen bestående af hydroxyethylstivelse (HES), polyethylenglycol (PEG), polysialsyre (PSA'er), elastinlignende polypeptider, heparosan polymerer, hyaluronsyre og albuminbindende ligander, f.eks. fedtsyrekæder og kombinationer deraf.
- 25 12. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor polypeptidet er et glycoprotein omfattende N-glycaner, og hvor mindst 75%, foretrukket mindst 85% af N-glycanerne i gennemsnit omfatter mindst en sialinsyrederel.
13. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor polypeptidet er en dimer.
- 30 14. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den gennemsnitlige opholdstid (MRT) af FVIII forøges ved samtidig administration af polypeptidet sammenlignet med en referencebehandling, hvor nævnte referencebehandling er identisk til nævnte behandling bortset fra at polypeptidet og FVIII administreres i ækvimolære mængder i nævnte referencebehandling.

15. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor administrationsfrekvensen af FVIII er reduceret sammenlignet med en behandling med FVIII alene.

5

16. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor polypeptidets halveringstid er større end den for endogent VWF.

10 17. Polypeptid til anvendelse ifølge krav 16, hvor polypeptidets halveringstid er mindst 25% større end den endogene VWF.

18. Farmaceutisk sammensætning omfattende (i) et FVIII og (ii) et polypeptid som defineret i et hvilket som helst af kravene 1 til 17, hvor molforholdet mellem polypeptidet og FVIII i sammensætningen er større end 50.

15

19. Farmaceutisk sæt omfattende (i) en FVIII og (ii) et polypeptid som defineret i et hvilket som helst af krav 1 til 17 til samtidig, separat eller sekventiel anvendelse i behandling af blodkoagulationsforstyrrelse, hvor nævnte behandling omfattende administration til et individ med endogent VWF, polypeptidet og FVIII, og hvor molforholdet mellem polypeptidet der skal administreres til FVIII, skal administreres er større end 50, hvor polypeptidet omfatter en halveringstidsforlængende del.

20

20. Polypeptid til anvendelse efter et andet som helst af kravene 1 til 17 til forbedring af plasmahalveringstiden for FVIII.

DRAWINGS

Figure 1A




Figure 1B




Figure 1C




Figure 2A




Figure 2B




Figure 2C




Figure 3A




Figure 3B




Figure 3C




Figure 4A




Figure 4B




Figure 4C




Figure 5A




Figure 5B




Figure 5C




Figure 6A




Figure 6B




Figure 6C




Figure 7A




Figure 7B




Figure 7C




Figure 8A




Figure 8B




Figure 8C




Figure 9A




Figure 9B




Figure 9C

